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Abstract 
Abstract 
The a4~2 nicotinic acetylcholine receptor (nAChR) assembles in two alternate 
forms, (a4p2ha4 and (a4~2hP2, which display stoichiometry-specific agonist 
sensitivity. Being heteromeric pentameric ligand-gated ion channels (pLGIC), 
a4p2 receptors are activated by binding of agonist to sites located at the 
a4( + )/P2( -) interfaces. These interfaces are present in both stoichiometries they 
are unlikely to contain structural differences conferring specific properties to 
(a4~2)2a4 and (a4p2)2p2 receptors. In contrast, the auxiliary subunit can be 
either a4 or P2, leading to stoichiometry-specific ~2( + )/P2( -) and a4( + )/a4( -) 
interfaces. Using fully concatenated (a4p2ha4 nAChRs in conjunction with 
structural modelling, chimeric receptors and functional mutagenesis, this study 
identified an additional agonist site at the a4( + )/a4( -) interface that accounts for 
the stoichiometry-specific agonist sensitivity of the (a4p2ha4 receptor. The 
additional agonist site occupies a region that also contains a potentiating 2n2+ 
binding site. However, unlike 2n2+, the agonist binding influences agonist 
responses by directly contributing to channel gating. By engineering a receptor 
with a C226S mutation to provide a free cysteine in loop C in the + side of the 
a4(+)/a4(-) interface, this study found that the acetylcholine (ACh) responses of 
the additional agonist site are modified following modification of the substituted 
cysteine with sulfhydryl reagents. These findings suggested that agonist 
occupation of the site at the a4(+)/a4(-) interface leads to channel gating through 
a coupling mechanism involving a conformational switch in loop C. The 
sulfhydryl reagents had similar effects on substituted cysteines in the a4( + )/P2( -) 
interfaces. Further studies showed that the additional agonist site is less sensitive 
to desensitisation than the sites at the a4( + )/~2( -) interfaces, suggesting that the 
agonist sites are functionally non-equivalent. Non-functional equivalency was 
also indicated by the finding that the agonist selectivity of the site at the 
a4(+)/a4(-) differs from that of the sites at the a4(+)/p2(-) interface. The findings 
may have important consequences for drug discovery programs and the manner 
by which a4p2 receptor signalling in the brain can be modified in brain 
pathologies. 
XIU 
CHAPTER! 
Introduction 
Chapter J 
Introduction 
The spectacular progress in the field of molecular biology in the last 30 years has 
made it possible to identify and clone the genes coding for pentameric Ligand-
gated ion channels (pLGIC). Subsequent expression of pLGIC cDNAs 
(complementary deoxyribose nucleic acids) in artificial expression systems has 
permitted the characterization of the functional properties of these ion channels 
without the ambiguities often encountered in native cells. Heterologous 
expression ofpLGIC has also facilitated assays of the functional consequences of 
single point mutations positioned in various regions of these proteins, giving 
invaluable insights into the architecture and function of the agonist binding site, 
allosteric sites and the ion pore. More recently, the availability of structural data 
at the atomic level has given in sights of how these proteins exert their functions 
at the molecular level. However, as the functional properties of these proteins 
and the mechanisms underlying them are elucidated, more questions arise 
regarding how the different structural and functional components of these 
proteins such as non-agonist binding subunit interfaces or allosteric sites 
contribute to generate global signals. This thesis explores the role of the auxiliary 
subunit in an ACh-gated pLGIC, the (a4~2ha4 nicotinic acetylcholine receptor 
(nAChR). 
1.1 Nicotinic Acetylcholine Receptors 
nAChRs are integral membrane ion channels gated by the neurotransmitter ACh. 
They transmit neuronal signals in the central (CNS) and peripheral (PNS) 
systems, where they broadly contribute to regulate an assortment of 
physiological functions and pathophysiological processes associated with 
cognition, mood, reward, skeletal muscle function, motor control, arousal, 
analgesia and inflammation (Corringer et aI., 2000; Gotti et aI., 2009; Taly et aI., 
2009; HUTSt et aI., 2013 for comprehensive reviews). The nAChRs belong to the 
broader gene superfamily of Cys-loop pLGIC's, which also includes ion 
channels gated by glycine (GlyR), y-aminobutyric acid (GABAA and GABAc), 
serotonin (5-HT3) and in invertebrates glutamate receptors (Lester et aI., 2004). 
2 
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Like all cell-surface pLGIC's, nAChRs regulate the flow of ions across the 
plasma membrane. In the case of nAChRs, the net influx of cations that occurs 
upon receptor gating depolarises the plasma membrane and increases cell 
excitability. Calcium entry through nAChRs such as the homomeric a7 nAChRs 
leads to additional effects on multiple intracellular signaling cascades (Dajas-
Bailador & Wonnacott, 2004). Like all other chemical synapses the nicotinergic 
synapse consists of a pre-synaptic terminal, a post-synaptic terminal and a 
synaptic gap, in between the terminals (Fig. 1.1). The presynaptic terminal 
contains the synaptic vesicles, which store ACh. The transmitter is synthesized in 
the presynaptic terminal from acetyl Coenzyme A and choline in a reaction 
catalyzed by the enzyme choline acetyltransferase. The newly synthesized ACh 
is then transported into the vesicles by vesicular ACh transporters. When the pre-
synaptic terminal is depolarized by the arrival of action potentials synaptic 
vesicles fuse with the pre-synaptic membrane facing the synaptic gap and the 
post-synaptic membrane causing ACh release. This produces a sharp rise in ACh 
concentration at the post-synaptic membrane such that many post-synaptic 
nAChRs become occupied with ACh and then open within a few milliseconds to 
produce synaptic signals. Like all fast ligand-gated ion channels, nAChRs have 
low affinity for agonists, which allows for fast dissociation from the binding site 
and thus a rapid termination of the post-synaptic signals. The transient nature of 
the ACh-postsynaptic signals is further achieved by removal of ACh from the 
synaptic gap by diffusion and, more critically, by hydrolysis into choline and 
acetate in a reaction catalyzed by acetylcholinesterase. Choline is transported 
into the presynaptic terminal by a Na+/choline transporter and once in the 
presynaptic terminal it is used for the synthesis of ACh. Fast synaptic 
nicotinergie transmission occurs at excitatory autonomic ganglia and at the 
neuromuscular junction. 
In the CNS, however, nAChRs are predominantly located in pre-, peri- or extra-
synaptic regions, from where they modulate the release of other 
neurotransmitters such as dopamine, GABA, glutamate, noradrenalin and 5-HT3, 
which makes nAChR-signalling one of the most important modulatory systems 
in the CNS (see reviews by Wonnacott, 1997; Gotti et al., 2009). Some nAChR-
mediated synaptic signalling has been reported in the brain (Dani, 200 I; 
3 
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Mansvelder & McGehee, 2002) but an overwhelming degree of nicotinergic 
transmission in the CNS is extra-synaptic. In this type of transmission, nAChRs 
are exposed to lower concentrations of ACh and for longer periods than at 
synaptic transmission, mainly because the receptors are at a greater distance from 
the source of ACh release than their synaptic counterparts. In addition, because 
non-synaptic regions display lower levels of acetylcholinesterase activity, 
removal of ACh from non-synaptic regions is probably less efficient than at 
synapses. 
4 
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• ACh-receptorli 
• Voltage-gated Ca" channel 
m Voltage-gated 8 ' channels 
Figure. 1.1. Cholinergic synapse. Diagram of the cholinergic synapse 
depicting vesicle fusion, ACh hydrolysis, choline uptake and ACh metaboli m. 
1.2 Classification of nAChR subunits 
So far, 16 genes coding for nAChR ubunits have been identified and cloned 
from vertebrates (Albuquerque et al., 2009). The subunits have been grouped into 
two different classes, the a subunits (ai-aIO) and non-a subunits (~1-~4 y, 0 and 
e). On the basi of their distribution in the body, gene structure and protein 
sequence, a and non-a nAChR subunits have been classified into four 
subfamilies (I-N) (Corringer et al. , 2000; Novere et al., 2002). The subunits of 
the subfamilies I and II are considered ancestral, whereas subfamily IV evolved 
later than the other subfamilies. Subfamily I contains the a9 and a I 0 subunits, 
subunits mostly found in epithelial ti ssues. Subfamily I1 contains the neuronal 
subunits a7, a8, both of which form homomeric nAChRs. So far, subunit a ha 
only been found in avian neurons (Lukas et al., 1999). Homomeric a7 nAChRs 
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are prevalent in the mammalian CNS and are distinguished by their high relative 
permeability to Ca2+ (Fucile, 2004). Subfamily III comprises a2 to a6 and P2 to 
P4 subunits, which form ap heteromeric nAChRs. This group of receptors 
include autonomic and CNS nAChRs. In autonomic neurons, nAChRs 
responsible for synaptic transmission are generated from a3 and P4 subunits, 
with the possible addition of as (hence they are referred to as a3P4*, where * 
indicates the presence of one or more additional types of subunit (Lukas et aI., 
1999). a3P4* nAChRs are also expressed in the CNS to a limited extent, whereas 
the a4 subunit is exclusively expressed in the CNS. In combination with the P2 
subunit, a4J}2 nAChRs are the most abundant and widespread nAChR subtypes 
in the brain, exhibiting high affinity for nicotine (Gotti et aI., 2009). a6-
containing receptors have more restricted distribution in the CNS; they are 
present in the ventral tegmental area (VTA), striatum and retina (Gotti et aI., 
2009). Until recently, it was thought that members of subfamily 11 and III did not 
combine to assemble receptors, however, there is evidence that a7 subunits may 
combine with P2 subunits to assemble functional a7p2 nAChRs. Thus, co-
expression of a7 and P2 subunits mRNAs has been detected in rat brain 
cholinergic neurons (Azam et aI., 2003) and heterologous co-expression of these 
two subunits in oocytes or brain slices yields receptors that display slower 
desensitisation than that of a7 homomers (Khiroug et aI., 2002; Murray et aI., 
2012). Although subunit a9 can form homomeric receptors, it specifically 
assembles with subunit alO to form a9alO nAChRs (Sgard et aI., 2002). These 
receptors display a unique pharmacology, somewhere between that of nicotinic 
and muscarinic receptors (Verbitsky et aI., 2000). They are found in the organ of 
Corti in the inner ear (Elgoyhen et aI., 2001) but also in the pain perception 
pathway, specifically in dorsal root ganglion neurons (Lips et aI., 2002) and in 
epithelial tissue (Kummer et aI., 2008). Subfamily IV comprises a I, PI, 0, y and 
E subunits, which interact only between themselves to assemble the muscle 
alyalopl (fetal muscle) or in the alwlopl (adult skeletal muscle) nAChRs 
(Corringer et aI., 2000). 
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1.3 The Structure of nAChRs 
The functional nAChR is made up of five peptide subunits arranged around a 
central membrane-spanning pore (Fig. 1.2). Like all other members of the Cys-
loop LGIC superfamily, nAChR subunits have a hydrophilic extracellular N-
terminal domain (ECD) largely made of p-sheets followed by a transmembrane 
domain (TMD). TMD is made of 4 hydrophobic segments (TMI to TM4) mostly 
consisting of a-helices. TM3 and TM4 are linked by an intracellular hydrophilic 
loop, whereas TM2 and TM3 are linked by a short extracellular hydrophilic 
segment. The nAChR subunit C-terminus is located extracellularly (Unwin, 
2005). 
A 
Figure 1.2. Ribbon diagrams of the tridimensional structure of the whole 
Torpedo nAChR at a 4A resolution. (A) Anti-clockwise organization viewed 
from the extracellular side. (B) Parallel side view with the membrane plane. 
(Subunits: a brown; ~, green; y, blue B light blue; in red the locations of Trp 149; 
E and I, show the extracellular an intracellular side respectively). (Adapted from 
Unwin, 2005). 
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In the last twelve years, breakthrough structural studies have led to a better 
understanding of the structure of Cys-Ioop LGIC and the events that trigger 
receptor gating following agonist binding in Cys-Ioop LGIC and nAChRs in 
particular. These breakthroughs are as follows. (1) Resolution of the X-ray 
crystal structures of ACh binding protein (AChBP) from various fresh water 
snails, which is a homolog of the nAChR extracellular domain, illuminated how 
an agonist binds to the receptor, and crucially that a peripheral loop, called loop 
C, closes when agonist occupies the binding site (Brejc et aI., 2001; Hansen et 
aI., 2005; Celie et aI., 2004). (2) The 4 A resolution structure of the nAChR has 
provided a picture of the agonist binding site, the pore and intracellular region of 
the nAChR in near-physiological conditions (Unwin, 2005). Currently, this 
structure is accepted as a model of the closed state of the nAChR because agonist 
was not present during the electron microscope sampling. (3) The resolution of 
the crystal structures of related prokaryotic proton-activated channels. The 
channel from the bacterium Erwinia chrysanthemi (ELIC) was solved in the 
inactive state and exhibited a narrow hydrophobic constriction at the upper half 
of the channel (Hilf & Dutzler, 2008), whereas the channel from the 
cyanobacterium Gloeobacter violaceus (GLIC) was solved in the open state and 
showed widening in the upper half of the channel (Bocquet et aI., 2009). 
Together, these experimental data have led to the views on the structure and 
function of Cys-Ioop LGIC and nAChRs in particular that are discussed in the 
next sections. 
1.3.1 The ECD 
ECD ofnAChRs contains the structural elements that form the ACh binding site 
(Fig. 1.3). The ECD contains a hydrophobic ~-sandwich core of 8 (GLIC) or to 
(AChBPs, Torpedo nAChR, ELIC) anti-parallel ~ strands that define the inner 
and the outer sheets of this region. This region also contains loops linking the 
various ~-sheets that are critical for receptor activation (Celie et aI., 2004; 
Hansen et aI., 2005; Unwin, 2005; Dellisanti et aI., 2007; Bocquet et aI., 2009; 
Hilf & Dutzler, 2009). In Q subunits these loops are loops A, B, C, Cys-Ioop and 
the ~1-~2 loop, whereas in non-Q subunits, i.e., ~, 'Y, b, E subunits, the loops are 
D, E, F. The ECD has a short a-helix, also conserved in the AChBPs that 
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contains glycosylation sites and anti genic regions (Dellisanti et aI., 2007; Unwin , 
2005; Hansen et aI., 2005; Celie et aI., 2004). 
ECD 
Cloop 
TMD 
Figure. 1.3. Ribbon diagrams of the Torpedo al-subunit. Regions with a-
helices are shown in brown; the p-strands composing the p-sandwich are in blue 
(inner) and green (outer). (Adapted from Unwin, 2005). 
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1.3.2 The ACh Binding Site 
The ACh binding site is a hydrophobic pocket that lies at the interface between 
the ECD of two adjacent subunits (Corringer et aI., 2000). The two ECD must be 
structurally complementary in order to form a binding site (Corringer et aI., 
2000). In heteromeric nAChRs, the a-subunit contributes what is termed the 
principal component (or positive face), whereas the non a-subunit (~2 and ~ in 
neuronal nAChRs and y, E and 5 in the muscle nAChR) contribute the 
complementary component (or negative face) (Fig. 1.4). The principal 
component comprises loop A, Band C, whereas the complementary face consists 
of loops D, E and F. In the case of homomeric nAChRs (e.g., a7 and a9 
receptors), the subunits contain both positive and negative components so that 
the interface of two adjacent subunits house an agonist site, which means that 
homomeric receptors are endowed with five binding sites (Corringer et aI., 2000; 
Taly et aI., 2009). Both the principal and complementary components lie within 
the so called loops of the ECD mentioned above (e.g. loops A, B, C, D, E, F). It 
is within these loops that highly conserved aromatic residues, that are critical for 
the binding of the neurotransmitter, are located. These loops are not conserved by 
all subunits, " and this largely determines the combination of subunits that can 
form an operational agonist binding site. For example, a4, a3 and a6 subunits 
combine with ~2 or P4 subunits to assemble receptors with agonist binding sites 
at the a(+)/~(-) subunit interfaces (Fig. 1.4). These subunits also conserve loops 
D, E and F but they are not thought to form functional homomeric receptors 
(Corringer et a1. 2000). However, as work carried out for this thesis (Mazzaferro 
et aI., 2011; Chapters 3 to 4) and by other researchers (Harpsee et aI., 2011) 
shows, the interface between this type of subunit can house an operational 
agonist site. 
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Heteropentameric receptors Homopentameric receptors 
a4132 a6132133 a7 a9 
Figure. 1.4. nAChR subunit combinations Triangles and semi-circles 
represent the principal and the complementary component of the binding site 
respectively. 
A number of biochemical and mutagenesis tudies have identified key residue 
that are involved in both agonist and antagonist binding (see Corringer et aI., 
2000 for a comprehensive review). These are: Y93 (loop A), W 149 (loop B), 
Y190 and Y198 (loop C), W55 and W57 (loop D). Interestingly, sub titution of 
an aspartic acid residue for Y 198 in nAChR al subunit underlies the inability of 
this subunit to bind agonists. In addition, a couple of cysteine residues, Cl92 and 
C 193 that are signature features of a subuni ts and L112 and M 114 on the 
complementary face were also identified. (Numbering of re idues correspond to 
that of the Torpedo nAChR) . 
Generally, the identity of the hydrophobic re idues on the principal component 
defines ligand affmity, wherea the residues contributed by the complementary 
face appear to determine ligand selectivity. Typically, nicotinic agonist carry a 
positively charged nitrogen moiety that is stabilized by electronegative 
interactions with the conserved aromatic residues of the ligand binding site 
(Srinivasan et aI., 2012). Thus, the positive charged nitrogen moiety of A hand 
nicotine (Nic) are stabi lised by 1t-cation interactions with the electron rich 
aromatic side chains of the conserved amino acids, specifically WI49 (Xiu et al., 
2009). In addition, analysis of AChBP (Hansen et aI., 2005) or a7-AChBP 
chimera (Li et al., 2011) crystal structures in complex with agoni t and studie 
of the interaction of agonists with nAChRs by nuclear magnetic re onance 
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(NMR) (Williamson et aI., 2007) or unnatural amino acid mutagenesis (Zhong et 
aI., 1998), suggest that agonists interact with other residues within the binding 
site through a number of electronegative and hydrophobic interactions such as 
hydrogen bonding and Van der Waals interactions. 
1.3.3 The TMD 
The TMD is composed of four a-helical segments named TMI-TM4 (al-a4 in 
ELIC). These hydrophobic regions are organized as a four-helix bundle (see 
Figs. 1.2 and 1.3). The first region, TMI, links the outer sheet of the ECD to the 
TMD. The other segments follow TM I and cross the plasma membrane in 
opposite directions ending with TM4. TM I, TM2 and TM3 are linked by the 
important loops MI-M2 and M2-M3. Interactions between loop M2-M3 and 
segment PI-P2 and the Cys-Ioop of the ECD play a key role in the transduction 
of agonist binding into gating of the ion channel; this region is critically 
important for coupling agonist binding with ion pore gating (Unwin, 2005; Hilf 
& Dutzler, 2008; Bocquet et aI., 2009). 
1.3.4 The ion Channel 
In Torpedo nAChR the four segments that make the TMD of each subunit are 
packed around a hydrophilic central pore that is lined by residues of TM2 of each 
subunit. TM2 is surrounded by TM I, TM3 and TM4, with TM4 being farthest 
from the pore. TM4 of all the TMs is the one that has the highest interaction with 
the lipid bi-Iayer. TM I and TM3 make several contacts with TM2 and these 
appear to be essential for the stabilization of TM2 (Miyazawa et aI., 2003). 
Electron micrographs of the Torpedo nAChR have shown that TM2 has different 
dimensions across the membrane (Miyazawa et aI., 2003). The upper part of 
TM2, which faces the extracellular compartment, is wider than the rest of the 
pore, whilst the narrowest part of M2 is found towards the middle of the region. 
The pore is lined by conserved residues that form concentric rings; these residues 
determine the ion selectivity of the pore and influence other functional properties 
such as conductance and receptor desensitisation (Yakel, 20 I 0). By convention, 
the concentric rings are numbered from the cytoplasmic end of the pore, where a 
first positively-charged ring is defined as 0', whilst the last ring, at the 
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extracellular end of M2 represents ring 20'. Above this region there is an outer 
vestibule facing the extracellular milieu, whereas below there is an intracellular 
vestibule that faces the cytoplasmic compartment. 
Electron micrographs of the Torpedo nAChR, which as mentioned previously 
represent the receptor in the close state, suggest that the gate of the pore lies 
within rings 9' and 14' (Unwin, 2005). Leucine residues forming ring 9' and 
valine residues forming ring 13' form a hydrophobic constriction of 6 A in 
diameter that is small enough to block the hydrated Na + and K+ ion fluxes (about 
8 A in diameter) (White & Cohen, 1992; Miyazawa et al., 2003; Arevalo et al., 
2005; Unwin, 2005; reviewed by Miller & Smart, 2010). Comparisons of the 
pore region of Torpedo nAChR and ELIC reveal interesting differences. Unlike 
the pore in the Torpedo nAChR, the extracellular entrance in ELIC is occluded 
by bulky hydrophobic side chains. This occlusion is what has led to the view that 
ELIC was crystalized in a closed conformation. The hydrophobic occlusion 
could represent a physical gate that stops diffusion of ions in the closed 
conformation of ELIC (Hilf & Dutzler, 2008). 
1.3.5 The Extracellular and Intracellular Vestibules of TM2 
The vestibules of TM2 seem to play an important role in the ion selectivity and 
conductance of pLGIC. For instance, altering the charge of this region by single 
point mutations changes ion conductance in Torpedo nAChR (lmoto et al., 1988) 
or the ionic selectivity of the channel (Galzi et al., 1992). Both vestibules contain 
negatively charged residues (aspartate and glutamate) and it may be that this 
creates a negative electrostatic environment required for efficient cation-selective 
transport by pLGIC (Fig. 1.5) (Unwin, 2005; Hilf & Dutzler, 2008). Consistently 
with this view, in anion-selective LGIC such as GABAA receptors, GlyR or 
glutamate-gated chloride channels (GluCI) receptors these regions are 
electropositive, which provide an attractive environment for negatively charged 
cr ions (Hibbs & Gouaux, 2011). 
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Figure 1.5. Central section of the whole (A) extracellular (8) and 
intracellular (C) vestibules of Torpedo nAChR. Aspartate and glutamate 
residues are present in the vestibules of the ion pore as shown. Colour diffe rences 
show the variation in the electrostatic potenti al surface. (Adapted from Unwin , 
2005). 
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1.4 nAChR Activation 
Structural insights obtained from the superposition of crystal structures of 
AChBP with agonists or antagonists (Hansen et aI., 2005; Dutertre & Lewis, 
2006; Ulens et aI., 2006) in conjunction with single channel studies of the 
activation of wild type and mutant pLGIC, particularly the muscle nAChR, have 
provided an overall view of the sequence of structural and energy changes 
triggered by agonist binding that lead to gating. These views are discussed next. 
1.4.1 Functional States of the nAChR 
In addition to the closed (resting), bound-active and bound-inactive 
(desensitised) states, a recent study with comparisons of the effects of partial and 
full agonists on channel gating has proposed a new functional state for the GlyR 
and muscle nAChR (Lape et aI., 2008). This new state has been termed the flip 
state. The new state (a closed state) immediately precedes channel opening and 
displays a higher affinity for agonist than the closed receptors (Fig.l.6). 
Interestingly, the ability to reach fully the flipped state determines the efficacy of 
the agonist. 
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Open 
Figure. 1.6. The flipped state. (A) The receptor at the resting state binds the 
agonist, then changes confonnation to reach a flipped state. The flipped state has 
high affinity for the agonist but the channel is still closed. Next the flipped 
receptor transits to the open confonnation. (8) The flip mechanism in muscle 
nAChR activated by tetramethylammonium (TMA). The agonist is represented 
by A while, Rand R * are the receptor at the rest and activated states 
respectively. F represents the flipped confonnation. (Adapted from Lape et al. , 
2008). 
16 
Chapter 1 
More recently, Sine and his team identified another two intennediate close states 
in muscle nAChRs that precede the transition to the open state (Mukhtasimova et 
aI., 2009). These close states have been tenned primed states and are comparable 
to the flipped state. The first priming leads the receptors to brief openings, 
whereas the second priming elicits long-lived openings of the receptor (Fig. 1.7). 
By covalently locking the loop C in the closed confonnation, which mimics the 
confonnation of the bound binding site, has been found that priming of only one 
site elicits brief openings, whereas the priming of two sites triggers long 
openings (Mukhtasimova et aI., 2009). 
Binding 
Figure. 1.7. Multiple states of the muscle nAChR. Agoni t binding, priming 
and channel gating step are showed. C, C' and C" are closed states, whereas 0 ' 
and 0" represent open states. For the wild type nAChR in the ab ence of ACh, 
the C' and C" states are negligible, suggesting that the first step in the activation 
process generates AC, from which there are three possible paths towards A2C " . 
Only the red pathway has been fitted to agoni t-dependent dwell times, obtaining 
the rate constants. (Adapted from Mukhta imova et aI. , 2009). 
1.4.2 Energy Transitions in Gating 
Measurements of the rate-equilibrium free energy relation hip (REFER) in 
conjunction with single point mutations in the agonist binding and ion channel 
regions (Zhou et aI., 2005) have given insights into how muscle nAChRs tran it 
from the closed to the open, conducting state. Such studies have suggested that 
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agonist binding triggers blocks of coordinated motions starting with the P4-P5 
linker, the p7 -P8 linker, loop C, through the Cys-Ioop and the p I-P2 linker, to 
TM2 and gating of the ion channel (Grosman et aI., 2000; Chakrapani et aI., 
2004; Purohit & Auerbach, 2008). This confonnational wave propagates 
throughout the nAChR via Brownian motion in 1 Jls (Grosman et aI., 2000; 
Chakrapani & Auerbach, 2005). An interesting issue raised by these studies is 
that the receptor confonnational transitions leading to gating are more complex 
and numerous than previously speculated from the classical view of receptor 
isomerisation (i.e., closed and open confonnations corresponding to closed, 
open-bound receptor states). Such confonnational complexity is in accord with 
the currently updated view of the functional states of pLGIC (see section 1.4.1). 
1.4.3 Mechanisms of Receptor Activation 
Current models for how ligand binding is converted into motion to activate the 
nAChR have been suggested through mutagenesis studies, comparisons of 
available liganded and unliganded AChBP, REFER analysis and computer 
stimulation. The emerging model indicates that when an agonist occupies the 
binding site, there is a significant rearrangement of hydrogen bonds among 
conserved amino acid residues located near the binding pocket, including E45, 
polar groups of the main chain and trapped molecules of water (Unwin, 2005; 
Lee & Sine, 2005; Price et aI., 2007; Absalom et aI., 2003; Xiu et aI., 2005). The 
side chains of conserved amino acid residues from the primary and 
complementary subunits appear to converge towards the ligand, which interact 
via Van der Waals interactions. Loop C moves about 11 A towards the receptor 
core, allowing the bridged cysteines in loop C (Cys 190-Cys 198) to interact with 
the ligand and loop F of the complementary subunit. This movement, termed 
loop C capping, perturbs an arginine residue (R209) located at the base of strands 
p9 and plO and its salt bridge with loop 2 residue E45 (Lee & Sine, 2005). 
Studies using REFER analysis have suggested that the cascade of confonnational 
transitions starts when a 1 W 148 and the a 1 Y 120 change position, providing 
binding energy to the ligand. This energy is then propagated along the interfaces, 
down to the coupling region and then to the M2 (Auerbach, 2010). 
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Capping of the binding site by loop C appears to trap the agonist within the 
binding site (Celie et al., 2004; Hansen et al., 2005; Billen et al., 2012; Rucktooa 
et al., 2012). Capping of the agonist site by loop C appears to be a universal 
event among pLGICs. For example, loop C appears contracted in crystals of the 
invertebrate GluCI receptor-glutamate complex (Hibbs & Gouaux, 2011) and P9-
plO loop in crystals of the proton activated GLIC appears in a capping 
conformation (Bocquet et al., 2009). In contrast uncapped loop C, which 
orientates away from the binding site, is typically observed in the presence of 
antagonists or in the absence of agonists (Celie et al., 2004; Hansen et al., 2005). 
In addition, comparisons of the binding site region of the Torpedo nAChR a 
subunit at 4A resolution in its agonist-unbound conformations with the 
corresponding region of agonist bound AChBP have suggested that loop B also 
moves, most likely in synergy with the capping movement of loop C, towards 
bound ACh (Unwin, 2005). 
When loop C capping occurs sufficient force is generated through the receptor 
via changes in the relative position of the p-barrel-like loops, to twist the 
extracellular surface (Fig. 1.8), and in turn, alters the relative position of residues 
near the extracellular segment of TM2 and relocate residues critical to channel 
gating (Unwin, 2005). A key region involved in the changes in the extracellular 
segment of TM2 is the coupling region, which comprises the Cys-Loop, P 1-2 
loop and the M2-3100p (Kash et al., 2003; Bouzat et al., 2004; Xiu et al., 2005; 
Lee & Sine, 2005) (Fig. 1.9). Studies of a chimera made of the AChBP and the 
TMD of the 5-HT3 receptor (5-HT3R) have suggested key conformational events 
that occur in the coupling region, in particular side-chain interactions have been 
observed between the Pl- P2 loop and the Cys-Ioop of the ECD with the M2-M3 
loop of the TMD (Unwin 2005; Lee & Sine 2005; Purohit & Auerbach 2008). 
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Figure. 1.8. Top view of the AChBP. AChBP pentamers in presence of 
agonist (Jeft) and antagonist (right). Note the distinctive confonnations for the 
antagonist (a-conotoxin ImI) and agonist (Epibatidine) complexes. The C-Ioop 
remains open in presence of antagonist (in red) and close with agonist (in blue). 
(Adapted from Hansen at aI., 2005). 
The interactions between residues at the ECD-TMD are mainly hydrophobic and 
electrostatic (Unwin, 2005; Lee & Sine, 2005; Price et aI., 2007; Absalom et aI., 
2003; Xiu et aI., 2005). The hydrophobic residues are highly conserved in the 
Cys-Loop family, whereas the charged residues can be in different positions. 
Rather than specific contact points it seems that the overall electrostatic 
environment is important in the interaction between ECD and TMD. In support 
of this view, findings from studies of the GABAA receptor have suggested that 
charged residues fonn salt bridges between them and that inverting their 
positions appears to have no impact on receptor function (Kash et aI., 2003). 
Furthennore in 5-HT3 receptors a trans to cis side-chain isomerisation of a 
proline (P303) in the M2-M3 loop appears to be critically involved in channel 
opening (Lummis et aI., 2005). lnterestingly, more recent mutagenesis studies of 
5-HT3A receptors have suggested that cis-trans isomerization of P303 is not 
involved in gating (Paulsen et aI., 2009). Studies of the murine muscle nAChR 
using REFER approaches demonstrated that the M2 of a-subunits move before 
the non-a subunits, suggesting that the confonnation change on M2 of alpha 
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subunits, act as a hub that allows gating isomerization (Purohit & Auerbach 
2007). 
Cys-Ioop 
Figure. 1.9. ECD-TMD interfaces of nAChR at 4 A resolutions and 
contact residues between Cys-Loop, Pl-2 Loop and M2-3 Loop. Non-
conserved hydrophobic residues are black and bold, conserved hydrophobic 
residues are red. The green box shows the proline 303 supposed to be implicated 
in the cis- trans isomerization during the activation of 5-HT3A receptor 
(Adapted from Miller & Smart, 2010). 
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1.4.4 Opening of the channel gate 
The consensus view on how the ion channel pore opens up is that the 
transduction process triggered following agonist binding leads to a sideways 
rotation of the M2 a-helices. The TM region, albeit inserted within the plasma 
membrane and made of a-helices, is quite flexible due to the presence of 
conserved glycine residues in the MI-M2 and M2-M3 loops. In addition, limited 
interaction between TM2 and the other two alpha-helices TM I and TM4, confers 
movement flexibility to TM2 (Miyazawa et aI., 2003; Miller & Smart, 2010). 
The upper region of TM2 moves outwards, which produces a separation of the 
hydrophobic barrier at the midpoint of the gate (Cymes et aI., 2005; Paas et aI., 
2005; Unwin, 2005). Recently, studies of muscle nAChRs using REFER analysis 
have suggested that TM3 and TM4 move as a rigid body as they appear to have 
identical energy levels. TM2 has higher energy levels values than TM3/TM4, 
which has led to the suggestion that TM2 is the first helix of the TMD that moves 
as a consequence of the wave conformation transitions coming from the ECD 
(Auerbach,201O). 
More recently, electron microscopy studies of ACh-sprayed and freeze-trapped 
Torpedo post-synaptic membranes have suggested that gating is asymmetric 
(Unwin &Fujiyoshi, 2012). Binding of ACh to the a subunit in the agonist site 
located at the air interface induces an outward displacement of the ~ subunit. 
Propagation of the outward movement down the protein structure perturbs the 
symmetrical side-to-side interactions within the ion pore, which leads to a more 
relaxed ion pore conformation typical of an open pore. The agonist site at the aI[) 
interface is also implicated in gating but conformational transitions in this 
agonist site are not associated with displacement of the ~ subunit conformational. 
It is likely that this agonist site influences break up and reassembly of the gate-
forming ring found in the ion pore. 
1.5 «4112 nAChRs 
a4p2 nAChRs are the most abundant nAChR subtype in the brain where they 
form the high-affinity binding sites for nicotine (Picciotto et aI., 200 I). 
Pharmacological, immunocytochemical and molecular biological studies indicate 
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that the a4 and P2 can also combine with a5 subunits to fonn a4p2a5 nAChRs 
(Brown et aI., 2007; Tapia et aI., 2007; Kuryatov et aI., 2008; Grady et aI., 2010). 
Henceforth, receptors made of only a4 and P2 subunits will be referred as a4p2 
nAChRs, whilst those made of a4, P2 and a5 subunits will be referred to as 
a4p2a5 nAChRs. Both a4p2 and a4p2a5 receptors are expressed in the brain, 
however as yet there are no phannacological tools available that can separate 
them reliably, hence when it is not clear whether a4p2a5 receptors are also 
present in neurones, the a4p2-containing receptors will be referred to as a4p2* 
nAChRs. In addition, a4 and P2 subunits also combine with a6 and p3 subunits 
to generate a4a6p2p3 or a6p2p3 nAChRs (Gotti et aI., 2009). These and other 
receptors containing a6 subunits will be referred to as a6-containing nAChRs. 
The latter are sufficiently different from a4p2 or a4p2a5 nAChRs in terms of 
their phannacology and distribution in the CNS to justify a separate a6-
containing receptor group. 
Like most brain nAChRs, a4p2* nAChRs appear to be primarily localized 
presynaptically where they facilitate the release of various neurotransmitters 
(Dani, 2001; Wonnacott, 1997). Depending on the brain region, a4p2 nAChRs 
account for 90 to 60% of total presynaptic a4p2* nAChR present (Brown et aI., 
2007; Mao et aI., 2008). a4p2* nAChRs have been implicated in learning and 
memory, nociception and nicotine dependence (Picciotto et aI., 2001; Tapper et 
aI., 2004; Maskos et aI., 2005). Mutations in both the a4 (CHRNA4) and P2 
(CHRNB2) subunit genes cause autosomal nocturnal frontal lobe epilepsy 
(ADNFLE) (Weiland et aI., 2000). Losses in numbers of a4p2* nAChRs have 
been documented in age-related degenerative diseases such as Alzheimer's, 
suggesting possible pathological involvement (Zanardi et aI., 2002) and a single-
nucleotide polymorphism (D398N) in the a5 nAChR subunit gene, rs16969968, 
has been repeatedly associated with both susceptibility to nicotine addiction and 
respiratory health phenotypes (Berrettini et aI., 2008; Grucza et aI., 2008; Spitz et 
aI., 2008; Weiss et aI., 2008). 
23 
Chapter 1 
1.5.1 Recombinant «4112 and «4112«5 nAChRs 
Phannacological studies of functional a4~2 nAChRs expressed heterologously in 
Xenopus oocytes or Human Embryonic Kidney (HEK) 293 cells after 
transfection with equal amounts of a4 or ~2 cDNA or cRNA show biphasic 
sensitivity to activation by ACh (Buisson & D Bertrand, 2001; Houlihan et aI., 
2001; Nelson et aI., 2003). Typically, the ACh concentration response curve 
(CRC) comprises a high sensitivity component (EC50 1 - 4 J,lM) that accounts for 
10-20% of the max response. The second component displays approx. lOO-fold 
lower sensitivity for ACh (EC 50 90 - 120 J,lM) and accounts for 80 - 90% of the 
CRe. Subsequent studies that used extreme transfection ratios of a4 and ~2 
subunits to obtain monophasic high- or low-sensitivity ACh CRC showed that 
the components of biphasic ACh CRC reflected the presence of two different 
types of a4~2 nAChR (Nelson et aI., 2003; Moroni et aI., 2006). Since then the 
two receptor types have been referred to as HS (high sensitivity a4~2 nAChR) or 
LS (low sensitivity a4~2 nAChR) (Moroni et al. 2006). Subsequent studies that 
used either biochemical (Nelson et aI., 2003) or electrophysiological (Moroni et 
al. 2(06) approaches to detennine the stoichiometry of a4~2 nAChRs inferred 
that the stoichiometry of HS receptors is (a4~2h~2, whereas LS receptors are 
(a4~2)2a4. To avoid confusion with the various tenns used to refer to the a4~2 
nAChRs, the tenns HS and LS will not be used in this thesis. Although the 
stoichiometry of a4~2 nAChRs in neurones is not known, the phannacological 
similarities between native and recombinant a4~2· nAChRs are remarkably 
pronounced to confidently assume that the stoichiometry of native a4~2 nAChRs 
is identical to that inferred for their recombinant counterparts. 
a4 and ~2 subunits when assembled with a5 subunits in cell expression systems 
generate a4~2a5 receptors (Tapia et al. 2007; Kuryatov 2008). Studies of avian 
as-containing nAChR have shown that the subunit stoichiometry of this receptor 
type is (a4~2)2aS (Ramirez-Latorre et aI., 1996). This subunit composition is 
likely replicated in mammalian as-containing nAChRs, as suggested from the 
findings of phannacological studies that have expressed tethered ~2 and a4 
subunits together with loose a5 subunits in artificial expression systems (Tapia et 
al. 2007; Kuryatov 2008). 
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1.5.2 Expression of a4p2* nAChRs in Neurones 
Functional evidence from studies carried out on thalamic and cortical 
preparations suggest that both (a4~2)2~2 and (a4~2)2a4 nAChRs co-exist in the 
brain. Thus, functional studies have shown biphasic agonist CRCs for stimulation 
of putative a4~2 nAChR function in mice thalamic and cortical preparations 
(Marks et al. 1999; Marks et al. 2008; Marks et aI., 20 I 0). Such function is not 
present in the thalamus or cortex of a4-/- or ~2-/- knockout mice, which also lack 
high affinity binding sites for the agonists epibatidine (Epi) and Nic both of 
which are a signature property of a4~2 nAChRs (Picciotto et aI., 1999; Picciotto 
et aI., 2001). Furthermore, immunocytochemical studies show changes in high-
and low-sensitivity function with partial deletion of the genes coding for either of 
the a4 or ~2 subunits (Gotti et aI., 2008). More recently, the use of 3-[3-(3-
pyridyl)-1,2,4-oxadiazol-5-yl]benzonitrile (NS9283), a novel allosteric 
modulator selective for (a4~2)2a4 nAChRs, on rodent brain neuronal 
preparations has confirmed that thalamo-cortical neurones express both 
(a4~2h~2 and (a4~2ha4 nAChRs and that striatal neurones express solely a4~2 
receptors of the high-sensitivity type (Timmermann et aI., 2012; Rode et aI., 
2012). Thus, together, functional and immunocytochemical studies strongly 
support the presence of (a4~2)2~2 and (a4~2ha4 nAChRs in neurones. Although 
(a4~2h~2 and (a4~2)2a4 nAChRs can be distinguished with available 
pharmacological probes, (a4~2h~2 nAChRs cannot be so easily separated from 
(a4~2ha5 nAChRs as they have remarkably similar pharmacological profiles 
(Kuryatov, 2008). This problem is exacerbated by the fact that the a5 subunit is 
found in the presence of a4 and ~2 subunits (Gotti et al. 2006; Brown et al. 2007) 
in the brain, where it contributes about 10 - 40%, depending of the brain region, 
of all a4~2* nAChR activity (Brown et al. 2007; Grady et al. 2007). Thus, a 
question that needs to be answered if we are to elucidate a4~2* nAChR functions 
in the brain is whether the high- sensitivity a4~2* nAChR activity detected in 
areas such as the thalamus is due to signals generated by (a4~2)z~2 or (a4~2ha5, 
or a mixture of both receptor types. So far, the availability of stoichiometry-
specific compounds such as NS9283 suggests a scenario in which some a4~2-
modulated brain functions may be preferentially influenced by a particular a4~2 
nAChR isoform, while others may be modulated by a mixture of two or three 
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a4~2 nAChR types (Rode et al., 2012; Timmermann et al., 2012). In this 
scenario, changes in the relative proportion of the a4~2 or a4~2* nAChRs may 
have important consequences for the physiological/therapeutic effects of a4~2-
selective compounds. 
It is well documented that chronic exposure to competitive ligands alters the 
expression and activity of nAChRs in neurones, particularly those of a4~2 
nAChRs (Nelson et a1. 2003; Moroni et al. 2006; Kuryatov et al. 2005; Sallette et 
al. 2005; Srinivasan et al. 2011). There is also evidence that chronic exposure to 
competitive ligands preferentially enhances assembly of (a4~2h~2 nAChRs 
(Kuryatov et al. 2005; Sallette et al. 2005; Srinivasan et al. 2011). This 
selectivity is so strong that mammalian cell lines heterologously expressing 
mostly (a4~2)2a4 nAChRs shift expression to (a4~2)2~2 nAChR following 
chronic exposure to nicotine (Kuryatov et al. 2005; Moroni et al., 2006). Other 
factors that also influence the type of a4~2 nAChR expressed include an absolute 
or relative increase in ~2 subunit levels (Nelson et al., 2003), lower incubation 
temperatures (Nelson et al., 2003), phospho-kinase A driven phosphorylation of 
a4 subunits (Exley et al., 2006) and ADNFLE epilepsy mutations (Son et al., 
2009). The relevance of this plasticity for a4~2-driven behaviours or their 
potential use as therapeutic targets is not known, but it is noteworthy that a 
mouse a4 A529T polymorphism increases the (a4~2)2~2/( a4~2)2a4 strain-
specific differences in measures of a4~2 nAChR function such as sensitivity to 
and, effects of nicotine on V-maze activity, respiration rate and body temperature 
(Kim et al., 2003). Further work is needed to determine the neuroanatomical 
distribution of a4~2 nAChRs as well as the contribution of each stoichiometry to 
brain behaviours modulated by a4~2 nAChRs. The success of such studies 
largely rests on the availability of a4~2 stoichiometry-specific compounds. So 
far, a number of agonists have been developed that show preference for 
(a4~2h~2 nAChRs such as 4-( 5-ethoxy-3-pyridinyl)-N-methyl-(3E)-3-buten-l-
amine difumarate (TC-2559) (Moroni et al. 2006; Carbone et a1. 2009) and TC-
1734 (Gatto et al., 2004). Higher stoichiometry-selectivity has been achieved 
with allosteric modulators such as NS9283. This compound has been shown to 
increase agonist-evoked current responses at a4- and a2-containing nAChRs of 
stoichiometry (aPha (Timmermann et al., 2012). It has no effects on receptors 
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with high sensitivity (a~)2~ stoichiometry or a3-containing nAChR, and it cannot 
distinguish ~2 from ~4-containing receptors (Timmermann et al., 2012). 
Nonetheless, since NS9283 appears to be highly selective for the (a~)2a, the 
compound shows promise both as a prototypic research tool and potential 
therapeutic drug. 
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1.6 a4p2* nAChRs in Brain Pathoiogies 
a4~2· nAChRs are considered as valid targets for therapeutic intervention in 
diverse diseases such as Nic addiction, depression, ADNFLE, central or 
peripheral pain management and cognitive diseases. The evidence supporting the 
involvement of a4~2 nAChR in these diseases is discussed next. 
1.6.1 a4p2* nAChR and Nic Addiction 
Nic is one of the most widely used addictive drugs. Over three million smoking-
related deaths occur per year in the world. In Western countries, it is believed 
that 20% of all deaths are caused by illnesses related to smoking (Peto et aI., 
1996; Laviolette & van der Kooy, 2004). Thus, an understanding of the 
mechanisms that cause addiction to Nic remains an important focus of medical 
research and drug discovery. 
Addiction to Nic involves activation of the reward pathway in the brain. Here, 
several lines of evidence suggest that Nic mediates its addictive property via the 
regulation on the action of dopamine (DA) and non-DA neuronal substrates in 
the ventral tegmental area (VTA) (De Biasi & Dani, 2011). DA neurons from the 
VTA send projections to the nucleus accumbens (NAc) and the prefrontal cortex 
(PFC). The rewarding and aversive psychological properties of Nic are believed 
to involve the activation of these DA pathways in the VT A. Non-DA neuronal 
substrates comprise GABAergic neurones in the VT A and the tegmental 
pedunculopontine nucleus (TPP). In this system, VT A GABAergic neurones 
send descending projections to the TPP, which through ascending cholinergic 
and glutamatergic projections to the VT A also regulate the activity of DA 
neurons in the VT A. 
a4~2 nAChRs were thought to be involved in Nic addiction since it was shown 
that these receptors form the high-affinity binding site for Nic in the brain 
(Picciotto et aI., 2001). Later studies have shown that Nic does not modulate DA 
release in the VT A or in the NAc in ~2 knock out (Picciotto et aI., 1999) and this 
is accompanied by lack ofNic self-administration (Picciotto et aI., 1999). Further 
support for the involvement of a receptor containing ~2 subunits comes from 
studies in which the ~2 subunit was reintroduced in ~2 knock-out mice. Whilst 
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P2 knock in mIce do not self-administrate Nic, reintroducing P2 usmg the 
lentivirus expression system, restores not only Nic self-administration behaviour 
but also Nic-induced DA release in the NAc (Maskos et aI., 2005). Other studies 
have provided evidence in support of 0.4 subunit involvement in Nic addiction. 
Knock-in mice for the 0.4L9' A subunit shows Nic reinforcement behaviour at a 
concentration 50-fold lower than the concentration needed to induce the same 
response in wild type mice. 0.4L9'A is a 0.4 subunit that carries a mutation in 
position 9' of TM2 that markedly increases sensitivity to activation by Nic. The 
increased sensitivity is used to distinguish responses of 0.4-containing receptors 
from other nAChRs as the latter are not activated at concentrations of Nic 
eliciting full responses at receptors carrying 0.4L9' A mutant subunit (Tapper et 
aI., 2004). Together, the studies with 0.4L9' and f32 knock in mice strongly 
support the involvement of 0.4f32 nAChRs in Nic addiction. As mentioned before, 
recent studies have shown an association between vulnerability to smoking 
addiction and a single-nucleotide polymorphism in the gene coding for the 0.5 
subunit (CHRNAS)(rsI6969968) (Berrettini & Doyle, 2012), although it is not 
known how this polymorphism may affect the pathways leading to smoking 
addiction. 
A long standing question in the nAChR field is whether Nic exerts its addictive 
effect via activation or desensitisation of a4f32 nAChRs. 0.4f32 nAChRs are prone 
to long-term desensitisation when exposed chronically to agonists, which is the 
case during smoking. Thus, it is thought that the most likely scenario is that 
initially nicotine activates 0.4p2 nAChR on DA presynaptic terminals in NAc and 
the VT A, which leads to increased reward signals. However, continued exposure 
to nicotine desensitises 0.4P2 nAChR. Because 0.4f32 nAChRs control release of 
GABA from VT A GABAergic neurones that inhibit release of DA from 
dopaminergic neurones in the NAc, desensitisation of 0.4f32 nAChRs also 
increases DA release in NAc (Mansvelder et aI., 2002). The current view is that 
the acute activation of DA neurons in VTA represents the basis for Nic 
reinforcing and rewarding, whilst the long lasting desensitisation of 0.4f32 nAChR 
in the VT A might represent nicotine tolerance (Mansvelder & McGehee, 2002). 
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Other nAChRs present in the VT A and NAc are likely to contribute to Nic 
addiction but as yet it is not clear how. Thus, a7 nAChRs are present in 
glutamatergic neurones in the VTA and, importantly, a7 nAChRs are not prone 
to desensitisation by low or non-activating concentrations of agonist as a4~2 
nAChR, which suggest they may be activatable when a4~2 nAChR are 
desensitised. a6-containing nAChRs are also present in the VT A and NAc, 
particularly in the posterior VT A subnuclei, which project to the NAc (lkemoto, 
2007) as compared to the anterior subnuclei (Zhao-Shea et aI., 20 11). 
Interestingly, at Nic concentrations close to the plasma concentration found in 
smokers, a6-containing nAChRs are activated (Liu et aI., 2012; Grady et aI., 
2012) and contribute to Nic-dependent activation of mesolimbic DA neurons 
(Zhao-Shea et aI., 2011). 
1.6.2 04P2* nAChRs in depression 
Both clinical and preclinical data support a potential therapeutic benefit of 
modulating the activity of CNS a4~2* nAChRs to treat mood and anxiety 
disorders. For instance, smoking is more prevalent in depressed subjects than in 
non-depressed patients (Covey et aI., 1998). Panic disorder patients have higher 
rates of smoking than the general population (Ziedonis et aI., 2008). 
Additionally, smokers report anxiety relief as a key reason for continued 
smoking and relapse from abstinence (McKee et aI., 2011), and chronic exposure 
to Nic results in increased response to antidepressants (Andreasen et aI., 2009). 
a4~2* nAChRs are expressed in neuroanatomic regions known to be involved in 
reward, mood and stress such as the VTA, NAc, locus coerelus, dorsal raphe 
nucleus, PFC, amygdala and hippocampus (Mineur & Picciotto, 20 10; Maskos, 
2010; Wonnacott et aI., 2006). In these regions, a4~2* nAChRs are 
predominantly located presynaptically or preterminally, from where they 
modulate the release of ACh and other important neurotransmitters involved in 
mood, for example GABA and DA (Wonnacott et aI., 2006). Furthennore, a 
number of established antidepressants, such as fluoxetine, sertraline and 
ibupropion, inhibit neuronal a4p2 nAChRs at relevant therapeutic drug 
concentrations (Mineur & Picciotto, 2010). nAChRs are also found in the 
hypothalamicpituitary-adrenal (HPA) axis, which is dysregulated in mood 
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disorders. Here, nAChRs under certain conditions play a part in modulating the 
release of corticotropin from the hypothalamus (Raber et aI., 1995) and 
corticosterone from the adrenal gland (Wonnacott et aI., 2006). Nic increases 
levels of circulating corticosteroids in both animal models and human smokers 
(Caggiula et aI., 1991) while mecamylamine (Mec), a blocker of nAChRs, 
decreases circulating corticosteroids (Wilkins et aI., 1982; Newman et aI., 2001). 
Interestingly, aging knockout mice lacking the ~2 subunit have elevated 
circulating levels of corticosteroids (Mineur & Picciotto, 20 I 0). 
The nAChRs receiving most attention for their potential therapeutic use in mood 
disorders are the a4~2* nAChR. Studies with a4~2* nAChR-preferring 
competitive antagonists, such as dihydro-~-erythroidine (Dh~E), have 
demonstrated antidepressant-like effects in mice (Mineur & Picciotto, 2010; 
Rabenstein et aI., 2006). Point mutant mice with hypersensitive a4 subunit 
display altered basal levels of anxiety (Labarca et aI., 200 I). Targeted genetic 
deletion of the a4 subunit from dopaminergic neurones has shown that the 
presence of a4-containing nAChRs are necessary for the anxiolytic effects of 
nicotine (Mineur & Picciotto, 20 10). Also, a polymorphism in the a4 subunit 
gene (CHRNA4, rs1044396) is associated with negative emotionality (Markett et 
aI., 201l). Interestingly, a4~2* nAChRs are highly expressed in midbrain 
dopamine pathways known to be involved in reward and mood disorders while 
pharmacological studies of knock-out ~2-/- mice suggest that a4~2 receptors are 
essential for dopamine release (Mineur & Pieciotto, 2010). a4~2 nAChRs 
directly enhance the release of the neurotransmitter dopamine. However, they 
may also modulate it indirectly through their effects on the release of GABA. 
Such modulatory effects would be of relevance for the targeting of a4~2 nAChRs 
for depression therapies. nAChRs receptors on GABAergic neurones have been 
implicated in the anxiolytic effects of nicotine, which are reversed by blocking 
GABA transmission (Paterson & Nordberg, 2000). Furthermore, there is 
increasing evidence that a central GABAergic dysfunction may be primarily 
related to the physiopathology of affective disorders. 
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1.6.3 a4(J2 nAChR and ADNFLE 
ADNFLE is a rare familial focal epilepsy characterized by brief nocturnal 
seizures that originate in the frontal lobe (Scheffer et aI., 1995) and occur mainly 
during stage 11 of non-rapid-eye-movement sleep. ADNFLE is monogenic 
epilepsy linked, with high penetrance, to mutations in the a4~2 nAChR. So far, 
four a4 and five ~2 mutations have been linked to ADNFLE (see Steinlein et aI., 
2012 for a comprehensive review). Among these, six mutations are located 
within or at the C-terminal end of the TM2 domain of the a4 (a4S248F; 
a4776insL; a4S252L; a4T265I) or the P2 (P2V287L; P2V287M) nAChR 
subunits. Studies on TM2 ADNFLE mutant a4~2 nAChRs expressed 
heterologously in surrogate cells have shown that these mutations affect 
sensitivity to activation by agonists, desensitisation and Ca2+ permeability 
(Steinlein et aI., 2012). 
Little is known about the mechanisms that may induce seizures in ADFNLE 
patients. One hypothesis suggests that the increased ACh sensitivity displayed by 
ADNFLE mutant a4~2 receptors could lead to seizures (Bertrand et aI., 2002). 
An alternative hypothesis postulates that the reduced Ca2+ permeability of 
ADNFLE mutant a4~2 receptors decreases the influx of Ca2+ into GABAergic 
presynaptic terminals. This would decrease the release of the inhibitory 
neurotransmitter GABA, which would shift the brain excitation-inhibition 
equilibrium towards excitation (Rodrigues-Pinguet et aI., 2005). 
1.6.4 a4(J2* nAChRs and analgesia 
One of the most promising therapeutic applications of nicotinic agonists is in the 
control of pain. The analgesic effect of Nic was described 70 years ago but, 
because of its short-lived effect, it has been overlooked, and the development of 
nicotinic agonists as analgesics started only after the description of the 
antinociceptive effects of Epi, which exceed those of morphine (Daly et aI., 
2000). Reduced nociception in mice lacking a4 or P2 nAChR subunits suggests a 
key role for a4p2 nAChRs in analgesia, but (a4p2ha5 may also be involved. The 
role of (a4p2)2a5 in analgesia is supported by studies showing an increase in 
spinal a5 expression in response to the spinal nerve ligation (VincJer & Eisenach, 
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2004) and lack of effect of nicotinic analgesics in mice lacking as subunit 
(Jackson et aI., 2010). In addition to the a4~2* nAChRs, a9alO located in 
sensory dorsal root ganglion neurones may also contribute to cholinergic-
analgesic effects (Gotti et aI., 2009). 
As with Nic addiction, there is controversy as to whether activation or 
desensitisation of a4p2* nAChRs produces analgesia. Studies by Gao et aI., 
(2010) on various in vivo and in vitro models have found that activation of a4~2 
nAChRs was necessary but not sufficient to produce analgesia. More recent 
studies have shown that compounds that are more potent at desensitisation of 
a4p2* nAChRs are more effective at producing analgesia, which suggests that 
desensitisation contributes to the efficacy of nicotinic analgesics (Zhang et aI., 
2012). Thus, it seems that both activation and desensitisation may play a part in 
analgesia. 
1.6.5 a4p2* nAChRs and cognition 
Both muscarinic and nicotinergic signalling play a well-established role in 
cognitive processes including attention and working memory (Sarter et aI., 
2005). Analysis of the ability of nAChR stimulation to improve cognitive 
function has identified attention performance as the most likely component to be 
positively influenced by a4~2* nAChR activation. These effects are more readily 
seen in individuals with pathological disease states, rather than normal 
individuals (Levin & Simon, 1998). In animal models, nicotinic agonists improve 
learning, memory (Levin & Simon, 1998) and attention (Hahn et aI., 2003). 
1.7 Thc Pharmacological profile of a4p2 nAChRs 
The section that follows will describe well-established competitive and non-
competitive compounds of a4p2* nAChRs. Where possible from available 
information, the effects of the compounds described below on (a4p2ha4, 
(a4p2hP2 and (a4p2ha5 will be noted. A summary of the pharmacological 
profile of these receptors built over the years by Bermudez and her team is 
shown in Table 1.1. Some of the data shown for u4P2 nAChRs have been 
published (i.e., Moroni et aI., 2006; Moroni et aI., 2008; Carbone et aI., 2009; 
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Mantione et al,. 2012) but the profile of (a4p2ha5 nAChRs is unpublished (I 
Bermudez, personal communication). 
Table 1.1. Pharmacological profIle of «4P2* nAChRs. 
All values are means ± S.E.M. from 5-10 cells. Key: dFBr, 
desformylflustrabromine; 5-Br-Cys, 5-Br-cytisine; NE, no effects; ND, not 
determined. Note that for dFBr only parameters estimated for positive allosterism 
are shown. Maximal response (lmax), and apparent potency of stimulation (ECso) 
or inhibition (ICso), were estimated from CRCs fit to the Hill equation as 
previously published (Moroni et al. 2006; Carbone et al. 2009). Data for ACh, 
A85380, 5I-A5380, Cyt, 5-Br-Cys, Epi, TC-2559 and Saz-A are adapted from 
Moroni et al. 2006; Zwart et al. 2006 and Carbone et aI., 2009. Data for dFBr, 
estradiol, progesterone are from Mantione et al. 2012 and Zn2+ from Moroni et 
al. 2008. Data for (a4p2)2a5 nAChR are unpublished and are from a personal 
communication from I Bermudez. 
(a4j32hj32 (a4j32ha4 (a4j32huS 
lma/I ACh _ max ECso (IlM) Ima/IACh_max ECso (IlM ) Ima/IACh_max ECso (IlM ) 
ACh I 2.4±O.5 I III±IS I 2iO.4 
A8S380 1.86iO.1 0.3iO.07 1.32iO.06 2.7iO.OS I.liO.3 0.O8±O.O07 
SI-A8S380 2.4iO.1 0.14iO.01 0.99iO.06 28.20± 5 
Cyt NE 0.27iO.04 55±8 O.07iO.OOOI O.OO8iO.OOOI 
S-Br-Cyt NE 0.28iO.05 11±3 
Epi 0.6iO.014 O.16iO.02 2.7iO.01 0.30±0.03 O.46±0.05 O.OO5iO.OOOI 
Nic O.S2±O.04 O.4±O.06 
TC-2SS9 4.18iO.1 2iO.05 0.13±0.1 0.91±0.OS O.83±0.03 1.5±O.02 
Saz-A 1.01iO.0I 0.007 0.OO8iO.0004 ND liO.005 0.OO6±O.000S 
± 
0.0009 
Progesterone 7iO.04 11 ±4 (ICso) 1.8±O.1 
(IC so) 
Estradiol 3iO.9 18±8 1.8 iO.6 18±6 1.29±0.04 2.8iO.7 
dFBr 2.6iO.8 16±5 3.9iO.4 0.SiO.03 
Zn'+ 17±2 (ICso) l.5iO.2 49±5 (ECso) 4iO.1 (ICso) 
881±43 
(ICso) 
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1.7.1 Agonists 
Agonists bind the orthosteric sites of the nAChRs, leading to receptor activation. 
Typically, nicotinic agonists are endowed with at least one quaternary 
ammonium group or a protonated tertiary ammonium group. As mentioned 
previously, the ammonium group seems to interact via 1t-cation interactions with 
the side chains of the aromatic residues of the binding site. Established a4p2 
nAChR-preferring agonists include Nic, TC-2559, cytisine (Cyt), varenicline 
(Var), Epi, 3-[(2S)-2-Azetidinylmethoxy pyridine dihydrochloride (A-85380), 5-
iodo-A-8S380 and sazetidine-A (Saz-A). 
Nic is an alkaloid found in the Solanaceae family, particularly in tobacco plants. 
Nic acts on all nAChRs as an agonist but has higher-affinity for a4p2* nAChRs; 
reported binding affinity (K j) and functional potency (EC50) are at the nanomolar 
level (Table 1.1) (Jensen et aI., 2005). In contrast, Nic displays moderate 
nanomolar binding and functional affinity for a7 nAChRs (Kj 400-15000 nM and 
EC50 49-113 JlM). Intermediate binding affinity and functional potency have 
been reported for a3p4 nAChRs (K j 290-476 nM; EC50 8.1-110 JlM) (Jensen et 
aI., 2005). In the case of a9 or a9al0 nAChRs, Nic behaves as an antagonist 
(Verbitsky et aI., 2000). 
TC-2559 is a selective agonist of the a4p2* nAChRs (Chen et aI., 2003), 
interestingly, TC-2559 showing different efficacy at a4J32* nAChRs (Table 1.1). 
TC-2559 is a supcr agonist at (a4p2hP2, full agonist at (a4p2)2a5 nAChRs and a 
partial agonist at (a4p2ha4 nAChR (Table 1.1) (Zwart et aI., 2006; Carbone et 
al.,2009). 
Cyt is an alkaloid with a strongly restricted conformation and well-established 
nicotinic agonist pharmacology, exhibiting low nano-molar affinity at a4p2* 
nAChRs and low micro-molar affinity at the a7 subtype (Slater et aI., 2003). Cyt 
has almost no efficacy at (u4P2hP2 or (a4p2ha5 nAChRs but at (a4p2ha4 
displays higher efficacy (Table 1.1) (Moroni et aI., 2006; Carbone et aI., 2009). 
The potency and the efficacy of Cyt increases following halogenation at the 3-
position of the pyridine ring (Houlihan et aI., 2001; Slater et aI., 2003). Cyt is 
35 
Chapter 1 
used in Eastern European countries as an aid for smoking cessation and also has 
anti-depressant effects in animal models of depression (Mineur & Picciotto, 
2010). 
Varenicline (V ar) marketed as Chantix ™ or Chanpix ™ is used as an aid for 
smoking cessation (Coe et aI., 2005). It also produces antidepressant-like effects 
in animal models of depression but only at reduced doses (Rollema et aI., 2010). 
Var is a partial agonist at a4~2* nAChRs displaying lower efficacy at (a4~2h~2 
and (a4~2)2a5 nAChRs than at (a4p2ha4 nAChRs (Table 1.1). 
Epi was isolated from the skin of the Amazonian frog Epidobates Tric%ris 
(Badio & Daly, 1994). Epi is a potent agonist at all nAChRs, although its binding 
affinity and potency are highest at a4p2* nAChRs. The high potency of Epi at all 
nChRs leads to side effects, particularly of the autonomic type, making it 
impossible to use Epi as a therapeutic compound. However, the structure of Epi 
has been widely used as a template in drug discovery efforts (Arneric et aI., 
2007). 
A-85380 displays high affinity for a~ heteromeric nAChRs (SuJlivan et aI., 
1996). Introducing an iodine atom into the pyridine ring of A-85380, results in 
the more potent a4~2-preferring compound 5-iodo-A-85380. This compound 
however also activates a6-containing nAChRs (Mogg et aI., 2004; Mukhin et aI., 
2000) at concentrations slightly higher than those activating a4~2 nAChRs. 
Saz-A has low nanomolar binding affinity for a4~2 nAChRs. Studies that 
showed no functional efficacy at a4p2 nAChRs led to the view that Saz-A is a 
highly desensitising a4~2 nAChR agonist, driving a4~2 nAChRs into a 
desensitised state without first activating them, a mechanism termed silent 
desensitisation (Xiao et aI., 2006). However, other studies established that Saz-A 
is a stoichiometry-specific a4~2 nAChR agonist; thus, Saz-A is a full agonist at 
(a4J32)2J32 and (a4~2)2a5, but has very low efficacy (5%) at (a4p2ha4 
stoichiometry (Table 1.1) (Zwart et aI., 2008). As shown in Chapter 3 and S 
(Mazzaferro et aI., 2011), the efficacy of Saz-A seems to be determined by its 
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inability to recognise an ACh binding site located at the a4( + )/a4( -) interface of 
(a4~2)2a4 nAChRs (Mazzaferro et al., 2011). 
1.7.2 Antagonist of a4~2 nAChRs 
Antagonists recognise specific sites in receptors and upon occupancy of those 
sites they reduce in a concentration dependent manner the responses elicited by 
agonists. Antagonists that recognise the agonist binding site are competitive 
ligands, whereas those that occupy other sites are non-competitive antagonists. 
The latter can be allosteric modulators or ion channel blockers. 
Dh~E, isolated from Erythrina americana seeds, is a reversible competitive 
antagonist of neuronal nAChRs. Dh~E preferentially blocks ~2-containing 
. nAChRs; thus Dh~E displays high potency at human and rat a4~2 and a3~2 
nAChRs, whereas the potency at a7 and at a3~4 nAChRs is considerably 
decreased (l0-50 fold less) (Jensen et aI., 2005; Chavez-Noriega et aI., 1997; 
Harvey et aI., 1996). In hippocampal neurones sub-micromolar concentrations of 
DhpE blocks specifically a4p2*-mediated currents whereas a7 currents are 
insensitive at micromolar concentrations (Alkondon & Albuquerque, 1993). In 
animal models, DhPE has antidepressant-like effects in mice (Andreasen et aI. 
2009; Mineur and Picciotto, 2010) and has been used to dissect non-a7 nAChRs 
mechanisms in Nic addiction studies (Kenny & Markou, 2006). DhPE is more 
potent at (a4p2h~2 and (a4~2)za5 nAChRs than at (a4p2)za4 nAChRs (Table 
1.1) (Moroni et aI., 2006; Carbone et aI., 2009) but the difference in sensitivity is 
not sufficient to discriminate a4~2* nAChR subtypes (Moroni et aI., 2006). 
Recent studies have shown that Dh~E interacts with a ~2D 169 in loop E, an 
interaction that homology models of the a4~2 nAChRs suggests acts to keep loop 
C in an un capped position (lturriaga-V asquez et aI., 2010). 
Mec is a non-competitive antagonist of nAChRs. Mee inhibits alP heteromeric 
nAChRs at low micromolar concentrations (lCso values between 0.1-10 IlM), 
whereas it is less potent at homomeric a7 nAChRs (Jensen et aI., 2005; Chavez-
Noriega et aI., 1997). At low concentrations Mec shows antidepressant like 
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effects in mice (Rabenstein et al., 2006) and these effects appear to be exerted 
through a4f32 nAChRs. Mec is a racemate of S-( +)- and S-( -)-enantiomers. 
MK-801 (dizocilpine), developed as a channel blocker of N-methyl-D-aspartate 
receptors (NMDA), also blocks, as an open channel blocker, a7 and a4f32 
nAChRs (Briggs & McKenna, 1996; Buisson & Bertrand, 1998b) . 
Buproprion (Zyban TM), a compound used as antidepressant and to aid smoking 
cessation, behaves as an inhibitor of noradrenaline and dopamine transporters. 
However, it also non-competitively inhibits a4f32, a3f32 and a7 nAChRs (Jensen 
et al., 2005). This cholinergic effect of bupropion adds to the body of evidence 
suggesting involvement of a4f32 nAChRs in depression. 
1.7.3 Allosteric modulators 
Binding of ligands to allosteric sites located elsewhere from the orthosteric sites 
can modulate nAChR signalling via an effect on the equilibrium between the 
resting, active or inactive states (Mantione et al., 2012). Positive allosteric 
modulators (PAMs) have been shown to Increase agonist potency (e.g., 
benzodiazepine effects in GABAA receptors) and/or increase efficacy (e.g., 
barbiturate effects on GABAA receptors) (Mantione et al., 2012). PAMs can 
increase agonist potency by enhancing agonist binding to the receptor resting 
state. They can also increase agonist efficacy by reducing the energy of the 
transition between the closed and open states and/or increasing the energy tariff 
of the transition from the active to the desensitised states. In contrast, negative 
allosteric modulators (NAMs) can increase the energy barrier for activation and 
thus decrease or inhibit the effect of agonists. Alternatively, allosteric modulators 
can decrease the energy barrier to enter desensitisation, which leads to 
physiological inactivation. 
A diverse group of allosteric modulators have been identified to interact with 
«4132* nAChRs, However, with the exception of Zn2+ (Moroni et al., 2008) or 
Bipbenyl-2-carboxylic acid 1-(3-pbenyl-propyl)-piperidin-3-ylmethyl ester 
(KAB-18) (Henderson et al., 2010; Pavlovicz et al., 2011), there is limited 
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knowledge of the binding sites or transduction mechanisms associated with this 
family of a4p2* nAChR ligands. 
Zn2+ effects on a4p2 nAChRs are stoichiometry selective. Zn2+ is a NAM of 
(a4p2)2p2 receptors, whereas it potentiates or inhibits, depending on its 
concentration, the function of (a4p2)2a4 nAChRs (Table 1.1) (Moroni et aI., 
2008). Znz+potentiation of (a4p2)za4 nAChRs is determined by a site located at 
this receptor type stoichiometry-specific a4( + )/a4( -) subunit interface, whereas 
Znz+ inhibits both receptor types by binding a site located at the p2(+)/a4(-) 
interfaces, which are present in both receptor stoichiometries. The effects of Zn2+ 
on nAChRs are likely to be not physiologically relevant since the concentrations 
at which Zn2+ exerts its effect on a4p2 nAChRs are above the levels found in the 
external medium or at synapses. Nevertheless, the identification of Zn2+ binding 
sites represents an important advance for a4p2 nAChR research because it 
demonstrated for the first time the potential of stoichiometry-specific subunit 
interfaces as targets for drug discovery. 
Steroid hormones estradiol (Paradiso et aI., 2001) and progesterone (Buisson & 
Bertrand 1998a) have been found to modulate a4p2 nAChRs. Progesterone 
exerts allosteric inhibition on a4p2 nAChRs, whereas estradiol behaves as a 
PAM. Estradiol displays higher efficacy at (a4p2)zp2 nAChRs than at (a4p2ha4 
nAChRs. It is likely that this is due to the presence of three estradiol binding sites 
on the (a4p2hPz nAChRs. The binding sites for estradiol are located in the C-
terminus of the p2 subunit (Paradiso et aI., 2001), hence, there are three of these 
sites on (a4p2hP2 nAChRs. Interestingly, unlike the effects of progesterone and 
other modulators, the allosteric effects of estradiol are species specific. Human 
a4p2 nAChRs are positively modulated by estradiol, whereas rat a4p2 nAChRs 
are inhibited (Paradiso et aI., 2001). Rat a4p2 nAChRs lack the sequence 
segment in the C-terminus of the P2 subunit that contributes the binding site for 
cstradiol in human a4p2 nAChRs (Paradiso et aI., 2001). 
Desformylflustrabromine (dFBr), a tryptamine derivative, which is a mctabolite 
of the marine bryozoan Flustrafoliacea, potentiates, in the micromolar range, 
a4p2 nAChRs by increasing both the potency and efficacy of ACh (Weltzin & 
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Schulte, 2010). At concentrations higher than those exerting potentiation, dFBr 
inhibits a4~2 nAChRs, possibly by ion channel blockade (Weltzin & Schulte, 
2010). dFBr shows higher affinity and efficacy at (a4~2)2a4 nAChRs. Similar to 
(a4~2)2~2, dFBr also enhances the function of other heteromeric nAChRs such 
as a2P2 and a3~2 nAChRs (Pandya & Yakel, 2011). 
Galantamine and physostigmine are acetylcholine-esterase inhibitors that are 
believed to act as PAMs of nAChRs, including a4~2 nAChRs (Samochocki et 
aI., 2003). However, there is a degree of controversy as to whether they are 
PAMs of a4~2· nAChRs. Galantamine has been reported to increase the potency 
of ACh responses of a4~2· nAChRs expressed heterologously in HEK cells 
(Samochocki et aI., 2003). However, this effect is not reproduced on a4p2 
nAChRs expressed in Xenopus oocytes (Kuryatov et aI., 2008). In oocytes, 
galantamine inhibits at moderate micromolar concentrations the agonist-induced 
responses of heterologously expressed a4~2 nAChRs. Further work needs to be 
carried out to resolve this discrepancy. However, the lack of nAChR specificity 
and its moderate potency makes galantamine less promising as a template for the 
development of a4~2-specific compounds. 
NS9283 developed by NeuroSearch is a novel compound that enhances the 
agonist- evoked responses of (a4p2ha4, (a2p2)a2 and (a4p4)2a4 receptors 
(Timmermann et aI., 2012) but not those of nAChRs with the stoichiometry 
(a~)2p2 or containing a3 subunits. The use of NS9283 in diverse in vivo and in 
vitro tests has shown that this compound is precognitive and enhances the effects 
of a4~2 nAChRs in nociception (Rode et aI., 2012). Furthermore, when co-
administered with agonists, NS9283 enhances the analgesic efficacy of the 
agonists at well-tolerated clinical doses (Lee et aI., 20 11). The latter finding is of 
great interest for therapeutic strategies because it supports the view that allosteric 
modulators could be used as add-on therapies to either orthosteric agonists of 
a4~2 nAChRs or other established drugs to decrease side effects and/or increase 
clinical efficacy. The identification of the binding site for NS9283 on (a4p2ha4 
nAChRs has not been reported; however, as mentioned above, given the 
selectivity profile of the compound, it is possible that NS9283 binds the signature 
a4(+)/a4(-) interface of(a4~2ha4 receptors. 
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[N-( 1 ,2,3,4-tetrahydro-l-naphthyl)-4-nitroaniline] (UCI-30002) is a compound 
that is a4p2* nAChR preferring. UCI-30002 is reported to reduce nicotine self-
administration in rats (Y oshimura et aI., 2007). 
KAB-18 is another compound reported to be a selective a4p2* nAChR NAM 
(Henderson et aI., 2010; Pavlovicz et aI., 2011). KAB-18 inhibits a4p2 nAChRs 
in the low micromolar range and its binding site is located in the aJP interface 
approximately loA away from the agonist-binding pocket; with the key 
contributing amino residues on the P2 subunit (Pavlovicz et aI., 2011). 
The anthelmintic compound oxantel also behaves as a selective a4p2 nAChR 
NAM and may binds a site in the pia subunit interfaces (Cesa et aI., 2012). To 
the author's knowledge, a4p2 nAChR stoichiometry-specific effects of NAMs 
have not been reported. There is evidence that a4p2 nAChR-preferring NAMs 
interact with either the aJP (Pavlovicz et aI., 2011) or the pia (Cesa et aI., 2012) 
subunit interfaces present in both a4p2 nAChR forms, suggesting that these 
compounds are unable to discriminate a4p2 nAChR stoichiometries. 
1.8 Funciional differences between a4p2* nAChRs 
(a4p2ha4 and (a4p2hB2 nAChRs differ approximately lOO-fold in sensitivity to 
activation by ACh (Covernton & Connolly, 2000; Buisson & Bertrand, 2001; 
Houlihan et aI., 2001; Nelson et aI., 2003). As summarised in Table 1.1, these 
reccptors also differ in sensitivity to activation by other agonists, including Epi, 
Cyt, halo- and nitro-Cyt, A-85380 I, 5-J-A85380 I, (Houlihan et aI., 2001; Slater 
et aI., 2003; Moroni et aI., 2006; Zwart et aI., 2006) Saz-A (Zwart et aI., 2008), 
while competitive antagonists such as d-tubocurarine (d-TC) and DhPE inhibit 
them with different potencies (Moroni et aI., 2006). Interestingly, agonists 
activate currents at (a4p2hP2 and (a4p2ha4 nAChRs with strikingly different 
efficacies (Moroni et aI., 2006; Zwart et aI., 2008) (Table 1.1). Also, (a4p2hP2 
and (a4p2ha4 nAChRs display different desensitisation kinetics (Nelson et aI., 
2003), unitary conductance (Nelson et aI., 2003) and, Ca2+ permeability (Tapia et 
aI., 2007). They also differ in sensitivity to modulation by Zn2+ (Moroni et aI., 
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2008), steroid honnones, dFBr and up-regulation by chronic exposure to nicotine 
(Nelson et al., 2003; Kuryatov et al., 2005; Moroni et al., 2006). 
The sensitivity of (a4/32)2a5 nAChRs to activation by agonists is higher than 
that of (a4/32ha4 nAChR but lower than that of (a4/32hI32 receptors (Kuryatov 
et al., 2008) (Table 1.1). (a4/32)2a5 receptors desensitise more rapidly than a4132 
nAChRs, and display the highest Ca2+ penneability of the a4/32* nAChRs (Tapia 
et al., 2007). In addition, the a5 subunit confers sensitivity to positive allosteric 
modulation by galanthamine, which (a4/32hI32 and (a4/32ha4 receptors lack 
(Kuryatov et al., 2008). 
1.9 Subunit interfaces and stoichiometry-specific properties of 
a4p2 nAChRs 
Work on the effects of Zn2+ on a4/32 nAChRs (Moroni et al., 2008) has given 
insight into how the auxiliary subunit may confer functional signatures to a4132 
nAChRs and it is described here. In one set of studies the effects of Zn2+ on the 
function of both (a4132)2132 and (a4/32ha4 nAChRs were studied because work 
on the related GABAA receptor and GlyR had shown that the effects of Zn2+ 
varies according to subunit composition (Miller et al., 2005; Bloomenthal et al., 
1994; Smart et al., 1994). As mentioned previously, work on a4132 nAChR 
showed that Zn2+ exerts an inhibitory modulatory effect on (a4/32h/32 receptors, 
whilst it potentiates or inhibits, depending upon its concentration, the function of 
(a4/32ha4 receptors. On the basis of homology modelling with the AChBP from 
several snail species (Brejc et al., 2001; Celie et al., 2004; Hansen et al., 2005) 
and the 4 A resolution structural model of the Torpedo nAChR (Unwin, 2005), 
residues in the a4 and /32 subunits that could contribute to Zn2+ coordination were 
systematically selected and mutated and then tested for effects on sensitivity to 
Zn2+. This strategy led to the identification of two distinct sets of residues that 
may coordinate Zn2+. One of these sites is inhibitory and is located at the 
interface between the (+) side of the /32 subunit and the (-) side of an ACh-
binding a4 subunit. The site is present on both stoichiometries and key 
contributors are a4H 195 (loop F), and /32D218 (loop C). The other site is 
potentiating and is present only on the (a4/32ha4 nAChR. This site resides on 
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the a4(-)/a4(+) interface of the (a4p2)2a4 nAChR, within a regIOn that is 
homologous to the Zn2+ inhibiting site located on the p2(+)la4(-) interface. 
a4H195 on the (-) face of an ACh-binding a4 subunit and a4E224 on the (+) 
side of non-ACh binding a4 subunit critically contribute to this site. Thus, the 
Zn2+ inhibiting and Zn2+ potentiating sites are located at equivalent positions, 
arising from subunit homology. Similar phenomena have been observed in other 
pseudo-symmetric proteins such as the GABAA receptor where the residues 
contributing to the benzodiazepine site are homologous to residues implicated in 
agonist binding (Sigel, 2005). 
From the above discussion, it is clear that the non-agonist binding subunit in 
a4p2 nAChRs confers functional and pharmacological signatures to these 
receptors. How could these subunit interfaces impact a4p2 nAChRs properties? 
By analogy to the muscle alya18~1 nAChR (Unwin, 2005), it is presumed that 
in the a4~2 nAChR the subunit order around the channel is a4p2a4~2( a4/p2). 
Since the agonist binding sites are formed by conserved aromatic residues in the 
+ face of the a4 subunit and the - face of the P2 subunit (Brejc et aI., 2001; 
Unwin, 2005), the binding sites at the a4( + )/P2( -) interfaces are structurally 
idcntical, and thus unlikely to confer receptor subtype-specific functional 
signatures. However, the fact that the auxiliary subunit can be a4 or ~2, leads to a 
different composition of non-agonist binding interfaces. In the (a4~2)2~2 
receptor there will be two ~2( + )/a4( -) interfaces and a ~2( + )/~2( -) interface, 
whereas in the (a4~2)2a4 reccptor there will be two p2(+)/a4(-) interfaces and an 
a4( + )/a4( -) interface. As the P2( + )/P2( -) and a4( + )/a4( -), interfaces are receptor 
subtype-specific, they are likely candidates for conferring functional signatures 
to a4p2 nAChRs. Similarly, the receptor-specific a4(-)/a5(+) and p2(+)/a5(-) in 
a4~2a4~2(a5) rcceptors are likely to play a key role in shaping the functional 
propertics of this a4p2* nAChR subtype. 
Thc hypothcsis driving this thcsis is that the auxiliary subunit confers receptor 
subtypc functional signaturcs to the a4p2* nAChRs. Thcse signatures could be 
(i) allostcric modulatory sitcs that form because of subunit homology, and/or (ii) 
receptor activation or inactivation characteristics that could arise from 
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interactions between closely apposed residues of the auxiliary and ligand-binding 
subunits, as suggested by the most recent structural data from Unwin (2005). The 
focus of this thesis is to examine the role of the a4(+)/a4(-) interface in the 
signature agonist profile of (a4p2)2a4 nAChRs. Chapter 3, 4 and 5 will present 
data that shows that this interface is largely responsible for the signature ligand 
sensitivity of (a4p2ha4 receptors. 
1.10 Concatenated 04P2 nAChRs as tools to dissect the 
contribution of subunit interfaces to receptor function 
Functional data from studies of a4p2 nAChRs assembled from loose a4 and P2 
subunits are particularly difficult to interpret because of the concurrent 
expression of multiple stoichiometric arrangements, even after 
transfection/injection of drastic ratios of a4 and P2 subunits (Zwart et aI., 2006; 
Carhone et aI., 2009). This problem is particularly exacerbated by the fact that 
the a4 and ~2 subunits are homologous and fairly conserved, which in practice 
makes the identification of ligand binding sites or down-stream pathways 
difficult (e.g., Moroni et aI., 2008). This problem has been circumvented by 
concatenating the subunits covalently at the DNA level to create receptors with a 
defined subunit composition and subunit order. Carbone et aI., (2009) have 
shown that covalently linking a4 and P2 subunits into pentameric concatamers 
with a subunit order of ~2 _ a4 _P2 _ a4 _~2 or ~2 _ a4 _~2 _ a4 _ a4 produce receptors 
that express well in Xenopus oocytes (Fig. 1.10). These concatenated receptors 
recapitulate the functional properties of non-linked (a4~2)2~2 or (a4~2ha4 
receptors. In addition, the functional expression of both ~2_a4_~2_a4_p2 or 
~2_a4J32_a4_a4 receptors is up-regulated by co-expression with chaperone 
protein 14-3-3 and in this thesis it is shown that their pattern of desensitisation by 
chronic exposure to agonist is also maintained (see Chapter 4). Thus, subunit 
concatenation does not impair the functional properties of a4p2 nAChRs, 
making concatameric a4~2 nAChRs excellent tools to analyse the role of 
individual subunit interfaces on receptor function. 
In addition to their ability to recapitulate the functional properties of a4~2 
nAChRs, fully concatenated a4~2 nAChRs permit the introduction of mutations 
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in defined subunits. This in turn offers the unique possibility of studying the 
contribution of individual subunit interfaces to receptor function. Full subunit 
concatenation has contributed to the localization of a novel binding site for 
benzodiazepines in the GABAA receptor and has shown differences in the 
functional properties of the two agonist sites of the GABAA receptor (for a 
review see Sigel et aI., 2009). The studies that are next described have been 
carried out on fully con catenated a4p2 nAChRs. 
Figure 1.10. a4p2 concatenated receptors. (A) (a4p2)2a4; (B) (a4p2)2p2 
receptor . The auxiliary ubunit is outlined by dashed black lines. 
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Aims of the thesis 
The overall goal of this study was to unveil the role of the a4( + )/a4( -) subunit 
interface on the functional signatures of the a4~2 nAChR. The use of 
concatameric a4~2 nAChRs led during the early stages of this study to the 
identification of an additional fully operational ACh binding site at the a4( + )/a( -) 
interface of the (a4~2ha4 nAChR. This finding led to the following specific 
aims. 
I To reveal how occupancy of the additional agonist site at the a4(+)/a4(-) 
interface affects receptor function. 
11 To determine whether the additional agonist site contributes to receptor 
desensitisation. 
III Application of the SCAM method to fully concatenated (a4~2ha4 
nAChRs, to reveal the pharmacology of the a4( + )/a4( -) ACh binding site. 
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Materials and Methods 
Chapter 2 
2.1 Reagents 
Standard laboratory chemicals were of Analar grade. Collagenase Type lA, ACh, 
Epi and Dh~E were purchased from Sigma-Aldrich (UK). Cyt, Nic and Saz-
were purchased from Tocris Chemicals (UK). TC-2559 was a gift from 
Targacept Inc. (Winston-Salem, NC, USA) and Var was a gift from Pfizer 
(USA). Methenosulphate reagents (MTS) aminoethyl methanethiosulfonate 
(MTSEA) and [2-(Trimethylammonium)ethyl]methanethiosulfonate (MTSET) 
were purchased from Toronto Chemicals (Canada). 
2.2 Animals 
Xenopus laevis (X laevis) were purchased from Portsmouth University. Xenopus 
care and experimental procedures were in accordance with the Home Office 
regulations and were approved by the Animal Use Committee of Oxford Brookes 
University. Briefly, X laevis were housed in black tanks filled with dechlorinated 
water (> 15 L per toad) that was kept in a temperature-controlled room (18 CO). 
The animals were kept under a fixed 12 h light/dark cycle. Frogs were fed twice 
a week with worms purchased from Willy Worms (Yorkshire. UK). The water 
was refreshed twice a week. 
2.3 Molecular Biology 
DNA ligations, maintenance and growth of Escherichia coli bacterial strains and 
the use of restriction enzymes were carried out following the procedures 
described by Sambrook et aI., (1989). Plasmid isolation and DNA gel 
purification were carried out using commercially available kits (Promega, UK). 
Capped cRNA coding for wild type and mutant concatameric receptors was 
synthesized by in vitro transcription from SwaI-linearized cDNA template using 
the mMessage mMachine T7 kit (Ambion, UK.). The integrity and size of the 
cRNA transcripts was confirmed using RNA gel electrophoresis. 
2.3.1 Single Point Mutations 
Point mutations were carried out using the QuikChange ™ Site-Directed 
Mutagenesis Kit (Stratagene, The Netherlands). Oligonucleotides for PCR 
(Polymerase chain reaction) reactions were purchased from Eurofins (UK). The 
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full-length sequence of wild type and mutated subunit cDNAs were verified by 
DNA sequencing (BiosourceScience, Oxford). In order to increase the number of 
positive transformants, the protocol used was slightly modified from the 
manufacturer's instructions, as described below. 
1) OligonucIeotides primers (35 to 45 long, Melting TO > 80 CO) were 
synthesised carrying the desired mutations in the middle. 
2) The synthesised primers were diluted to a final concentration of 125 ngllll 
and used in the subsequent peR reaction. 
3) The peR mix consisted of the following: 
5 III Pfu Buffer 10X 
I III DNA template (stock 50 ng/lll) 
1 III of sense primer (125 ng) 
1 III of anti sense primer (125 ng) 
3 III dimethyl sulphoxide 
5 III dNTPs (from 2 mM stocks) 
1 III High Fidelity Pfu enzyme 
33 III Nuclease free water 
4) The parameters for the peR run were as follows: 
Segment Number ofCyclcs Holding Temperature (C) Time (minutes) 
I I 95 1 
95 0.5 
2 16 55 1 
68 I min per kbp 
3 1 68 1 min per kbp 
5) I III of the enzyme Dpnl was added to the peR mixture in order to 
degrade the parental methylated DNA, which corresponds to the template (non-
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mutated DNA), and to leave intact only the newly formed DNA (non-methylated 
and likely containing the desired mutation). 
6) X-Gold Competent cells were transformed with 30 J.lI of the digestion 
product. After overnight incubation at 37 CO, 3 colonies were picked and 
amplified by growing them in 10 ml of CircleGrow medium (Anachem, UK) at 
37 CO. After overnight growth, the plasmid was isolated from the bacteria using 
commercially available DNA purification kits (Promega, UK), and fully 
sequenced to confirm the presence of the desired mutation and verified the 
sequence of the non-mutated regions. 
The residue numbering used throughout this thesis includes the signal sequence. 
To obtain the position in the mature form, subtract 28 for a4 and 26 for ~2. 
2.3.2 Concatameric (a4112)2a4 and (a4112)2112 receptors 
The fully concatenated form of the (a4~2)za4 and (a4~2)z~2 isoforms, constructs 
~2_a4_~2_a4_a4 and ~2_a4_~2_a4_~2 were engineered as previously described 
by Carbone et al. (2009). Briefly, the signal peptide and start codon were 
removed from all the subunits but the first (a ~2 subunit) and the subunits were 
bridged by AGS (alanine, glycine, serine) tinkers. The number of AGS triplets 
was 6 between ~2 and a4 subunits, and 9 between a4 and ~2 subunits or between 
a4 subunits. Only the last subunit in the construct (an a4 subunit) contained a 
stop codon. The subunits were subcloned into a modified pCI plasmid vector 
(Promega, UK) using unique restriction enzyme sites flanking the N - and C-
terminals of each subunit. Wild type or mutant concatenated receptors were 
assayed for integrity by determining the ACh sensitivity of con catenated 
receptors co-expressed with an excess of ~2 or a4 monomers carrying the LT 
reporter mutation (L9'T in the second transmembrane domain). No changes were 
observed in comparison to constructs expressed alone. This indicates that the 
constructs used in this study did not degrade into lower-order concatamers or 
monomers as such degradation products would incorporate the P2L T or a4 LT 
monomers into receptors of higher sensitivity to ACh than the intact 
concatenated (a4~2)2a4 receptors (Groot-Kormelink et aI., 2004). Henceforth, 
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concatenated receptors will be referred to as ~2_a4_~2_a4_a4 whereas 
(a4~2)2a4 or (a4~2h~2 will be used to denote receptors assembled from loose a4 
and ~2 subunits when a4 subunits are respectively, in excess or shortage over ~2 
subunits. 
To introduce mutations into specific regions of ~2_a4_~2_a4_a4 receptors, the 
mutation was first introduced into the appropriate individual subunit subcloned 
into a modified pCI plasmid as described in section 2.3. After confirming the 
presence of the desired mutation and verifying the sequence of the non-mutated 
regions, the subunit cDNA was digested with appropriate unique flanking 
restriction enzymes and then ligated into the desired position in the concatamer 
using standard cDNA ligation protocols with T4 ligase (New England Biolabs, 
UK). The presence of the mutated subunit was also confirmed by DNA 
sequencing. Following ligation and DNA amplification, the appropriate subunit 
was cut by enzyme restriction digestion from the concatamer and sequenced by 
standard DNA sequencing. For clarity, mutations in the concatameric receptors 
are shown as superscript positioned in the (+) or (-) face of the mutated subunit 
(e.g., in ~2_ WI82Aa4_~2_a4_a4 the mutation Wl82A is located in the (+) face of 
the a4 subunit occupying the second position of the linear sequence of the 
concatamer, (see Chapter 3 for experimental evidence showing the spatial 
orientation of the subunits in the concatamer). 
2.3.4 Chimeric P2_u4_P2_u4_P2/u4 receptor 
A subunit made of the N-terminal of the ~2 subunit and the remaining part of the 
a4 subunit was ligated to ~2_a4_~2_a4 to construct chimera 
~2_a4_~2_a4_~2/a4. ~2_a4_~2_a4_~2/a4 was constructed by ligating a chimera 
p2/a4 subunit into the 5th position of the wild type p2_a4_~2_a4_a4 receptor. 
Chimeric p2/a4 subunit was constructed by first adding to both the a4 and P2 
subunits a BspEI restriction enzyme site at the end of the ECD within a region, 
IRR, that is conserved in the nAChR family. The site was used to cut the 
subunits into two portions, the ECD-IR and the remaining subunit containing the 
four TMDs and the C-terminus (R-TMD-C-terminus). After digestion of the 
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subunits with BspEI and after gel purification, the restricted sites are ligated 
using standard DNA ligation procedures to fonn ~2/a4 chimera. Thus, chimera 
~2/a4 comprises the N-tenninal of ~2 (1 to R231) and the remaining part of the 
a4 subunit (R241 to 1628) to its stop codon. 
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2.4 Xenopus laevis oocytes preparation 
Xenopus oocytes were collected from adult female Xenopus laevis, anaesthetised 
and sacrificed according to Home Office guidelines. A visceral incision was 
made through the skin and body wall. The ovaries were removed and stored in 
OR2 solution (82mM NaCl, 2mM KCl, 2mM MgCl 2.5mM HEPES (N-2-
hydroxyethylpiperazine-N' -2-ethansulphonic acid) adjusted to pH 7.6 with 
NaOH). Only oocytes at the stage V and VI of maturation were isolated. The 
theca and epithelial layers were removed enzymatically by incubating the 
oocytes for about 2 h in Type lA collagenase (2 mg/ml) dissolved in OR2 and 
placed on a rotating platform at room temperature. Oocytes were maintained at 
18°C in an incubator in a modified Barth's medium (88 mM NaCl, 1 mM KCl, 
2.4 mM NaHC03, 0.3 mM Ca(N03)2, 0.41 mM CaCI2, 0.82 mM MgS04, 15 mM 
HEPES supplemented with streptomycin 1 /lg/ml, 1 U/ml penicillin, 50 /lg/ml 
neomycin and 5% horse scrum, pH 7.6 (adjusted with NaOH). 
2.5 l\1icroinjection of cRNA 
Needles for microinjection were prepared from Drummond glass capillaries 
(Sartorius, UK), which were pulled in one stage using a horizontal 
microelectrode puller (Campden Instruments-Model 753). Prior to use, the tip of 
a selected needle was broken using fine forceps to give a narrow tip length of 
approximately 3 mm with an external ranging from 1.0 to 1.5 /lm. The needle 
was back-filled with light mineral oil and loaded on to a Nanoject 11 
microinjector (Drummond, USA). Wild type or mutant concatamcric receptor 
cRNA were injected into the oocyte cytoplasm (50.6 nl at 0.1 ng/nl) as illustrated 
in Fig.2.1. Injected oocytes were transferred to 96 well sterile dish (onc oocyte 
per well) containing modified Barth's solution and incubated at 18 Co for a 
maximum of 5 days. 
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Figure.2.1. Diagram showing P2_u4_P2_u4_u4 cRNA injection into 
Xenopus oocytes. Afte r 2-3 days post-injection currents were recorded uSing 
two-electrode voltage clamp technique. 
2.6 Electropbysiological Recordings 
After 2-3 days post-injection oocytes were se lected according to their 
appearance. Only oocyte with integral membrane and no igns of degradation 
were cho en for electrophysiol ogical recordings. Oocytes were placed in a 3 0~1 
recording chamber (Digitimer Ltd, UK) and bathed with a modified Ringer 
olution (in mM: NaCI 150, KCI 2.8, HEPES 10, BaCI2 1.8; pH 7.2, adjusted 
with NaOH). A gravity driven perfus ion y tern was u ed for all the experiments. 
All solution were fre hly made prior to recordings. 
Oocytes were impaled by two electrode connected to a Geneclamp 500B 
(Molecular Device, USA) for tandard vo ltage clamp recording as illustrated in 
Fig. 2.1 . Briefl y, electrodes were made from boro ilicate capillary gla (Harvard 
Apparatu , GC 150 TF) u ing a vertical two tage electrode puller (Nari hige PP-
83) to give a top diameter of 1 -2~m . Prior to recordings electrode were fill ed 
with 3 M KCI and onl y electrode with a re i tance between 0.5 and 2 MO were 
used for voltage clamping. Oocyte were continuall y perfused with fre h Ringer 
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solution at a rate of 10ml/min switching between different solutions occurred 
through manually activated valves. 
2.7 CRC for agonists and antagonists 
CRC for agonists were obtained by nonnalizing agonist-induced responses to the 
control responses induced by a near-maximum effective agonist concentration, as 
previously described (Moroni et aI., 2006; Mazzaferro et aI., 2011; Carbone et 
aI., 2009). A minimum interval of 5 min was allowed between agonist 
applications to ensure reproducible recordings. Agonist CRC data were first 
fitted to the one-component Hill equation: 
Where EC50 represents the concentration of agonist inducing 50% of the 
maximal response (Imax), x is the agonist concentration and nH the Hill 
coefficient. When agonists induced biphasic receptor activation, agonist CRC 
were fitted with the sum of two Hill equations, (two-component Hill equation). 
Data were fit to the following equation from Prism v 5 (GraphPad 5 software): 
Y=Top - Bottom + Span * Frac/(l + lO"((logEC50_I-X)*nHI» + Span 
* (I-Frac)/(l + 10"«LogEC50_2-X) * nH2» 
where Top and Bottom are the plateaus at the right and left ends of the curve in 
the same units as Y; logEC50_1 and logEC50_2 are the concentrations that give 
half-maximal high sensitivity or Iow sensitivity stimulatory effects respectively; 
nil I and nll2 are the unitless slope factors or Hill coefficients; Frae is the 
proportion of maximal response due to the higher sensitivity component; and 
Span is a fitted coefficient between 0 and I that gives the weight of the first 
component. 
To detcnninc the effects of the a4~2-selective competitive antagonist Dh~E on 
the ACh responses of wild type or mutant reccptors, the antagonist was included 
in the ACh and perfusing (Ringer) solution. The responses to ACh obtained in 
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the presence of the antagonists were normalised to control ACh responses 
(responses to ACh evoked in the absence of the antagonist). The ACh responses 
used were elicited by concentrations close to the EC50 concentration. 
2.8 Desensitisation protocol 
Desensitisation of a4~2 nAChRs was assessed by determining the degree of 
functional inhibition caused by prolonged exposure to ACh as measured under 
equilibrium conditions. The protocol used was based on that designed by 
Corringer aI., (1998) to measure desensitisation of a7-5-HT3 chimeric receptors. 
Oocytes injected with nAChR cRNAs were challenged approximately every 90 s 
by short pulses (2 s) of ACh at a concentration near the ACh EC50 (test pulses), 
first in the absence and then during a prolonged perfusion with Ringer solution 
containing low concentrations of ACh (prepulse). Prepulses were applied until 
the amplitude of the test pulses were constant. Although the extent and rate of 
inhibition varied depending on the ACh concentration of the prepulse and the 
nature of the receptor under study, a 10 min prepulse period was sufficient to 
reach steady-state level of desensitisation for all ACh concentrations used. 
Desensitisation data were fitted using non-linear regression to the one component 
Hill equation: I = Imin + (Imax-1min)/(1+10A«LogIC50-X)*nH» where IC50 is the 
concentration of drug that inhibits 50% of maximum response. The amplitude of 
current at steady state conditions was used for data analysis. 
2.9 Substituted cysteine accessibility method (SeAM) 
The substituted cysteine accessibility method (SCAM) was used to both assess 
the impact of loop C of the auxiliary subunit (fifth subunit) of ~2_a4_~2_a4_a4 
receptors on receptor activation and the nicotinic ligand selectivity of ACh 
binding sites at a4(+)/~2(-) and a4(+)/a4(-) interfaces. SCAM was first applied 
to pLGIC to identify the amino acid residues lining the ion channel of the muscle 
nAChR (Karlin & Akabas, 1998). Since then, SCAM has become a powerful 
experimental strategy that has been successfully applied to gain invaluable 
insights into diverse aspects of pLGIC such as amino acid residues contributing 
to competitive or allosteric ligands bindings, structure of (e.g., Boileau et aI., 
1999; Holden & Czajkowski, 2002), conformational changes induced by agonist 
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or allosteric modulators, and secondary structure of functional domains. SeAM 
involves the introduction of cysteines, one at a time, into a protein region and the 
subsequent application of thiol-specific reagents to the engineered residues to 
determine whether they are modified by the thiol reagents (Karlin & Akabas, 
1998). Modification of the introduced cysteine is monitored using 
electrophysiological or biochemical assays. 
2.9.1 l"fodification ofIoop C by SCAM 
MTSEA and MTSET were used to modify covalently a free cysteine residue in 
loop C. The free cysteine residue was created by dismantling the disulphide bond 
between vicinal C225 and C226 at the tip of loop C, through serine substitution 
of C226. The effect of the MTS reagents was assessed as illustrated in Fig. 2.2. 
Oocytes expressing receptors with cysteine substituted loop C or wild type 
receptors were first challenged with control ACh pulses (ECso x 5) every 5 
minutes until a stable response was obtained. Oocytes were then perfused with 
Ringer solution containing MTSEA (2.5 mM) or MTSET (1 mM) for 180 
seconds, after which time the impaled cells were washed with Ringer solution for 
60 seconds. After washing, ACh was applied every 5 min until the amplitude of 
the responses was constant. The average of the current amplitudes prior to 
application of MTS reagents was the control response current (Iinitial), and the 
average of current amplitudes after rinsing was the average response after MTS 
application (lafter MTS). The effect of the MTS reagents was estimated using the 
equation, % Change = ((Iafter MTS/linitial) - 1) x 100. The covalent effects of MTS 
were confirmed by exposing the oocytes to the reducing reagent dithiothreitol 
(DTT) (5mM) for 60 s (MTSET-treated oocytes) or I mM for 180 s (MTSEA-
treated oocytes). In all cells tested the response after DTT treatment was 
comparable to the one prior to the MTSET or MTSEA application, confirming 
that the functional changes observed were due to the covalent modification of 
C225 by the MTS reagents. 
2.9.2 l\lodification of ACh binding sites using SCAl\l 
MTSET was used to modify covalently a cysteine residue introduced at the 
agonist site at a4( + )/P2( -) and a4( + )/a4( -) interfaces. The amino acids mutated, 
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one at a time, to cysteine were ~2L146 and a4T152. Previous studies have shown 
that ~2L146 in loop E at a4( + )/~2( -) is suited for cysteine substitution studies: 
~2L146C has little impact on receptor activation but in the presence of MTS 
reagents produces a profound decrease in the responses of a4~2 receptors to ACh 
(Papke et aI., 2011). Structural modelling of the agonist site at the a4(+)/a4(-) 
interface showed that a4T152 occupies a position homologous to that to ~2L146 
in the agonist site at the a4( + )/~2( -) interfaces. Therefore, ~2 _ a4 _~2 _ a4 T152C _ a4 
and ~2L146C _a4~2_a4_a4 receptors were engineered to characterise the 
pharmacology of agonist sites at, respectively the a4(+)/a4(-) and a4(+)/~2(-) 
interfaces. Mutant and wild type concatamers were expressed in Xenopus 
oocytes, and characterised using two electrode voltage clamping procedures, as 
described above. 
2.9.3 Covalent modification of introduced cysteines by MTSET 
reagent 
The effect of the MTSET reagent on agonist responses was assessed as shown in 
Fig. 2.3. Briefly, oocytes expressing receptors with a free cysteine or wild type 
receptors were first challenged with a control agonist (ACh, Cyt, Var, TC-2959) 
concentration every 5 min until a stable response was obtained. Oocytes were 
then perfused with Ringer's solution containing MTSET (l mM) for 120 s after 
which time the impaled cells were washed with Ringer's solution for 90 s. After 
washing, the agonist was applied again every 5 min until the amplitude of the 
responses was constant to determine accessibility to the modified cysteine 
residue by the MTS reagent. The average of the current amplitudes prior to 
application of MTS was the control response current (Iinitial), and the average of 
current amplitudes after rinsing was the average response after MTSET 
application (Iafter MTS). The effect of the MTS reagents was estimated using the 
following equation: % Change = «(Iafter MTsl1initial) - I) x 100. For both mutants, 
(p2_a4~2_a4T152C_a4 and p2L146C_a4_~2_a4_a4 and wild type 
(p2_a4~2_a4_a4) receptors, the concentration of MTSET used was ImM (the 
optimal concentration for MTSET; Zhang & Karlin 1997). All mutants were also 
tested for the specificity of the MTSET reaction by treating the oocytes with 
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DTT (1 mM, 120 s), which reversed the inhibition caused by covalent 
modi fication. 
A 
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Figure 2.2. Covalent MTS modification of substituted cysteine in an 
identified subunit interface. The figure shows the effect of MTSET treatment 
on the ACh responses of the ~2_a4_~2_u4TI 52C_a4 mutant. (A) Using 
concatenated (a4~2)2a4 nAChRs it is possible to introduce single point mutations 
at an identified subunit interface. The diagram shows the reaction of MTSET 
with a cysteine introduced in the complementary face of the agonist site at the 
a4(+)/a4(-) interface. The first reaction is between the thiolic group of the 
cysteine and MTSET whereas the second reaction shows the reversibility of the 
disulphide bond (cys-MTSET) by using DTT. (B) Representative traces that 
shows max inhibition of ACh current (blue arrows) after maximal MTSET 
concentration (lmM) treatment. MTSET is applied for 120 s (red arrow). The 
reaction is fully reversible after treatment with ImM DTT (green arrow), as a 
consequence the level of ACh current, is completely re-established as prior the 
MTSET application. 
2.9.4 MTSET reaction rates 
To determine whether nicotinic ligands recognIze the agonist site at the 
u4(+)/a4(-) interface, we assayed the effect of nicotinic ligands on the rate of 
MTSET modification of C 152. If reversible ligands reduce MTSET reaction 
rates, it was inferred that the reversible ligands bind the site, thus impeding, 
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likely by steric hindrance, the modification of the introduced cysteine residue by 
MTSET. The rate of MTSET covalent modification of introduced cysteines was 
first determined by measuring the effect of sequential applications of sub-
saturating concentrations of MTSET on IAch responses. The concentrations of 
MTSET reagent used were 1 JlM. Preliminary experiments established that these 
concentrations of MTSET were optimal to describe adequately the early and 
plateau phases of the MTSET reaction rate data. Responses to ACh prior to 
MTSET reagent application were first stabilised as follows: ACh (EC 5o x 5) 
pulses were applied for 5 s, followed by a recovery time of 70 s. The protectant 
(EC5o x 5) was then applied for 10 s followed by a washing period of 3 min and 
40 s with ringer solution. The cycle was repeated until the responses to ACh 
were stable «5% on four successive applications of EC50 x 5 ACh). MTS 
reagent was then applied using the following sequence of reactions: at time 0, 
ACh (ECso x 5) was applied for 5 s, followed by a period of recovery of 70 s; 
MTSET was then applied for lOs, followed by a recovery period of 10 s. 
Immediately after the recovery time, the protectant (EC5o x 5) was applied for 10 
s, after which time the cell was washed with Ringer's solution for 3 min and 40s. 
This cycle was repeated until MTSET applications produced no further changes 
in IAch. Because a4~2 nAChRs are highly prone to long-term desensitisation 
when exposed to agonists, the protectant was applied in the control experiments 
prior to the MTS reagent to correct for any process of desensitisation that could 
develop during the protection assays, when the protectant is added together with 
the MTSET reagent. To confirm that any observed decrease in IAch was due to 
the effects of MTSET and not to receptor desensitisation, ACh and protectant 
pulses (following the same scheme used to stabilize the ACh responses prior the 
MTSET application) were applied at the end of the protocol as illustrated in Fig. 
2.3. 
2.9.5 Protection assays with agonist/antagonists 
The effects of agonists and antagonists on the rate of MTSET modification were 
tested by co-applying MTSET with agonist (5 x ECso) or antagonist (5 x IC50). 
The protocol used was identical to the one used to determine the rate of MTSET 
reaction, except that the reversible ligand (protectant) was co-applied with 
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MTSET reagent. The sequence of steps illustrated in Fig. 2.3 was as follows: 
IAch was stabilised by applying 5 x EC50 pulses of ACh for 5 s, followed by a 70 
s period of recovery, the protectant was then applied for lOs, followed by a 
recovery period of 3 min and 40s. This cycle was repeated until stability was 
achieved. (i.e., <5% on four successive applications of 5 x EC50 ACh). The 
sequence of MTSET reactions was as follows: at time 0, ACh (5 x EC50) is 
applied (5 s), followed by a brief period of recovery (70 s); MTSET and the 
protectant (5 x EC50 for the agonists and 5 x ICso for the antagonist) were then 
co-applied for lOs, followed by a recovery period of 3 min and 40 s. This cycle 
was repeated until the application of MTSET produced no further changes in 
IAch. To exclude receptor desensitisation as responsible for decreases in IAch, 
ACh and protectant pulses (following the same scheme used to stabilize the ACh 
responses prior the MTSET application) were applied at the end of the protocol 
as a control. (Fig.2.3) The change in current was plotted versus cumulative time 
of MTSET exposure. A pseudo-fIrst-order rate constant was calculated from the 
change in IAch. Peak values at each time point were normalized to the initial peak 
at time 0 s, and a pseudo-first-order rate constant (k 1) was determined by fitting 
the data with a single exponential decay equation: y = span x e-kl + plateau using 
Prism v.5.0 (GraphPad Software). Because the data are normalized to values at 
time 0, span = 1 - plateau. The second order rate constant (k2) for MTSET 
reaction was determined by dividing the calculated pseudo-first-order rate 
constant by the concentration of MTSET reagent used. The drug concentrations 
used to monitor changes in MTSET reactions were as follows: receptor 
p2_a4_p2_a4TI52C_a4: MTSET 1 JlM, ACh 1mM, Cyt 70 JlM, Var 12 JlM, 
TC2559 12 J.lM, Saz-A 1 JlM; receptor p2L146C_a4_p2_a4_a4: MTSET 10 J.1M, 
ACh 1.6 mM. 
2.10 Statistical analysis 
Data analyses were performed using GraphPAD-Prism software (GraphPAD, 
CA. USA). Data were pooled from at least three different batches of oocytes. An 
F-test determined whether the one-site or biphasie model best fit the data; the 
simpler one-component model was preferred unless the extra sum-of-squares F 
test had a value of p less than 0.05. Log EC50 values for ACh or ACh plus DhPE, 
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changes in current amplitudes in response to mutations or MTS application were 
analysed using one-way ANOVA (analysis of variance) with a Dunnett or 
Bonferroni post hoc correction for the comparison of all mutated receptors, to 
determine significance between wild type and mutant receptors. Significance 
levels between mutant receptors were determined using unpaired t tests. Data are 
plotted as mean ± Standard error of the mean (SEM). Fit parameter values are the 
best fitting values with the SEM values estimated from the fit. 
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Figure 2.3. Protection assay experiment for the partial agonist Cyt at the 
a4(+)/a4(-) interface of the p2_a4_p2_a4T152C_a4 mutant. (A) Representative 
traces of ACh responses prior, during and after cumulative MTSET application 
to determine the kl for the exponential decay of IAch (azure arrows) in presence 
of the partial agonist Cyt (blue arrows). MTSET (red arrows) was applied prior 
to Cyt. From the left to the right, the dashed lines, show respectively I Ach 
stabilization prior the MTSET application (black dashed line), the exponential 
IAch decay due to MTSET reaction with the cysteine free (red dashed line) and 
the final control (black dashed line). (B) When Cyt and MTSET were co-applied 
(protected reaction), MISEI did not impair the I Ach currents. (C) General 
scheme of the protection assay experiment. After cumulative MISEI 
application, the reaction is complete (C, 1) and the result is a decrease of the JACh 
current. However when MISET is co-applied with a ligand that competes or 
impedes the MTSET reaction with the free cysteine introduced in the agonist site 
at the u4( + )/u4( -) interface, the reaction rate is slower (C, 2). 
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2.11 Structure Homology Modelling and Docking 
Sequences of the human a4 and ~2 nAChR subunits were obtained from the 
ExP ASy proteomics server with accession numbers P43681 (a4) and P 17787 
(~2). The homopentameric Lymnaea stagnalis AChBP structure (Protein Data 
Bank code: I UW6) was used to generate models of the extracellular domain of 
the (a4~2)2a4 receptor as previously described (Moroni et aI., 2008; Mazzaferro 
et aI., 2011). 
Molecular docking was kindly carried out by Or Patricio Iturriaga-Vasquez 
(University of Chile, Chile). Molecular docking of nicotinergic ligands at the 
agonist binding sites of the a4~2 homology models was investigated using the 
Lamarckian genetic algorithm search method as implemented in AutoDock v4.0 
(Morris et aI., 1998). The receptors were kept rigid, while full flexibility was 
allowed for the Iigands to translate/rotate. Polar hydrogens were added to the 
receptors and Kollman-united atom partial charges along with atomic solvation 
parameters were assigned to the individual protein atoms. The three-dimensional 
structures of each ligand were generated using spartan'08 software (Software 
Solutions International, USA). Ligands were then energy minimized using the 
spartan '08 software. For each ligand, a rigid root and rotatable bonds were 
assigned automatically. The non-polar hydrogens were removed and the partial 
charges from these were added to the carbons (Gasteiger charges). The atom type 
for aromatic carbons was reassigned in order to use the AutoDock 4.0 aromatic 
carbon grid map. Docking was carried out using 60 x 60 x 60 grid points with a 
default spacing of 0.375 A. The grid was positioned to include the full ligand 
binding pocket in the central part of the a4/~2 or a4/a4 subunit interfaces so as to 
allow extensive sampling around residue a4W182 (W143 in mature AChBP). 
Within this grid, the Lamarckian genetic search algorithm was used with a 
population size of 150 individuals, calculated using 200 different runs (i.e. 200 
dockings). Each run had two stop criteria, a maximum of 1.5 x 106 energy 
evaluations or a maximum of 50,000 generations, starting from a random 
position and conformation; default parameters were used for the Lamarckian 
genetic algorithm search. 
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An additional ACh binding site at the 
a4(+)/a4(-) interface of the (a4B2)2a4 
nicotinic receptor influences agonist 
sensitivity 
Chapter 3 
3.1 Introduction 
The structural determinants that bestow isoform-specific agonist sensitivity to the 
alternate a4p2 nAChRs have not been fully elucidated. Nonetheless, work on the 
effect of Zn2+ on o.4p2 nAChRs has highlighted the auxiliary subunit as a key 
determinant of stoichiometry-specific properties. Thus, it has been shown that the 
a,4( -)/a,4( +) interface contains a Zn2+ potentiating site within a region that is 
homologous to a Zn2+ inhibiting site located on P2( + )/a,4( -) interfaces in both 
receptor forms (Moroni et aI., 2008). Furthermore, crystal structures of the 
AChBP lacking vicinal cysteines in loop C bound to allosteric ligands have 
suggested that interactions between modulators and heteromeric nAChRs may 
occur at non-o.4 interfaces through interactions with conserved aromatic residues 
(Hansen & Taylor, 2007). Therefore, because of subunit homology, it is plausible 
to speculate that additional agonist binding sites may be present at the P2( + )/P2( -
) and a4(+)/o.4(-) interfaces that are responsible for the isoform-specific agonist 
sensitivity of the alternate forms of the 0.4/32 nAChR. 
In this chapter, the possible impact of the 0.4(+ )/o.4( -) interface on the agonist 
sensitivity of the (a4p2)2o.4 nAChR was investigated. Using fully concatenated 
(o.4p2ho.4 nAChRs containing a chimera /32/0.4 auxiliary subunit, it was found 
that the o.4(+)/a4(-) interface appears to define the agonist sensitivity of 
(o.4/32ho.4 receptors. Mutagenesis studies in conjunction with functional assays 
led to the identification of an additional ACh binding site at the 0.4(+ )/o.4( -) 
interface. The site is capable of binding ACh, as suggested by functional assays 
of mutant receptors engineered by alanine substitution of conserved aromatic 
residues contributing to the consensus agonist sites located at a4( + )/P2( -) subunit 
interfaces. Subsequently, using mutated receptors with a free cysteine residue in 
loop C, together with covalent modifications with MTS reagents, it was 
demonstrated that the additional site contributes directly to channel gating. 
Overall, the studies described in this chapter strongly suggest that the additional 
site at the 0.4(+ )/o.4( -) is operational and that its contribution to receptor 
activation defines the agonist sensitivity of the (a4/32ho.4 nAChR isoform. 
66 
Chapter 3 
3.2 Results 
3.2.1 Position of the auxiliary subunit and agonist sites in 
~2_a4_~2_a4_a4 nAChRs 
The conservation of aromatic residues contributing to the agonist binding site in 
nAChR subunits, together with homology modelling of the extracellular domain 
of the (a4~2ha4 nAChR, suggested a putative ACh site at the a4(+)/a4(-) 
interface (Figs. 3.1 B, C). The primary (+) face of this putative agonist site would 
be contributed by the auxiliary a4 subunit, whilst the complementary (-) face 
would be contributed by an a4 subunit that simultaneously provides the primary 
face of the consensus agonist site at an a4( +)/~2( -) interface. The putative site is 
homologous to the agonist site at the a4(+)/~2(-) interfaces, having the conserved 
residues a4Yl26 (loop A), a4Wl82 (loop B), a4Y223 and a4Y230 (loop C), on 
the primary face of the binding site. On its complementary side, a4W88 (loop D) 
is in homologous position to ~2W82 in the agonist sites at a4(+)/~2(-) interfaces 
(Fig. 3.1 C). The homologous residues in Torpedo and muscle nAChR are 
a1Y93, a1W149, alYl90 and a1Y198, and residues W55 and W57 located in 
the complementary Ely or 5 subunits of the binding site (Corringer et aI., 2000). 
To obviate uncertainties about subunit assembly, stoichiometry and positions, 
especially concerning placement of mutant or chimeric subunits in the additional 
as opposed to the consensus agonist binding positions when engaging 
heterologous expression from loose subunits, the studies described in this chapter 
were conducted using, as a template, a fully con catenated fonn of the (a4~2ha4 
nAChR. Functional studies of ~2_a4_~2_a4_a4 receptors expressed 
heterologously in Xenopus oocytes have shown that they replicate the functional 
properties of (a4~2ha4 nAChRs (Carbone et aI. 2009). It has been shown 
previously that the a4 subunit is involved either in inhibitory effects of Zn2+ (due 
to ion binding at ~2( + )/a4( -) interfaces) or in potentiating effects of Zn2+ (due to 
ion binding at the a4(+)/a4(-) interfaces) (Moroni et aI., 2008). To detennine 
which a4 subunit contributes to the Zn2+ potentiating site in p2_a4_~2_a4_a4 
nAChRs, alanine substitution of a4H 195 was carried out individually in the three 
a4 positions of the concatenated receptor (Fig. 3.2). When the mutation was 
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incorporated into the u4 subunit in either the second or fifth position of the 
concatamer, the sensitivity to potentiation by Zn2+ was enhanced. However, 
when the mutation was introduced into the fourth position of the receptor, the 
potentiating effect of Zn2+ was almost abolished. The explanation for this result 
is that H 195 in the u4 subunits at the second or fifth positions contributed to the 
inhibitory Zn2+ binding site that resides at the ~2( + )/u4( -) interfaces of the 
receptor. Therefore, the potentiating site is located in the interface between the 
u4 subunit in the fourth and fifth positions of the ~2_u4_~2_u4_u4 nAChR; u4 
in the fourth position contributes H 195, whereas the u4 subunit in the fifth 
position contributes the plus face of the Zn2+ binding site. From these findings, it 
was inferred that the consensus agonist sites at aI~ interfaces are located at the 
interface between the first ~2 and second u4 subunits and between the third ~2 
and fourth u4 subunits of the con catenated receptor (Fig.3.2). 
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YI26 WI 2 Y223 Y230 
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Figur 3.1. A h binding ite at the (a4p2)2a4 nAChR. (A) Schematic 
r pr cntati n h wing the ubunit arrangement and interfaces on the (a4p2ha4 
nA hR (I ft pan I) and a4~2)2p2 nA hR . In both receptor , the a4(+)/p2(-) 
interface c ntain ag ni t itc. (B) Alignment of con erved aromatic re idues 
ntributing t ag ni t binding In human (h) a4p2 nA hRs and Torpedo (tc) al 
and nA hR ubunit . ( ) The left-hand panel i a ide-on view of the 
a4(+)/a4 - int rfa c h wing the location of conserved aromatic residues and 
I p ntri uting t a putati e agoni t ite. The right-hand panel i aide-on 
iew h wing the a4(+)/p2(-) ag ni t ite. (D) chematic representation of the 
linear qu n f th n at nated (a4p2)2a4 nA hR i hown howing the 
ori ntati n fth ( ) and - fa e of the ubunits. 
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Figure 3.2. Position of the potentiating Zn 2+ binding site in the 
con catenated (a4p2)2a4 nAChR. (A) CRC for the effect of Zn2+ in wild type 
and receptors carrying the a4H 195A mutation on either of the a4 subunits 
present in ~2_a4_~2_a4_a4 nAChRs. When the mutation was incorporated into 
the a4 subunit in either the second or fifth position of the concatamer, the 
sensitivity to potentiation by 2n2+ was enhanced, whereas the same mutation on 
the fourth position of the receptor almost abolishes the potentiating effect of 
Zn2+. (B) It is inferred therefore that the a4 subunits at the second or fifth 
positions contributed with the H 195 residue to the inhibitory 2n2+ binding site 
that resides at the ~2( + )/a4( -) interfaces of the receptor. Therefore, the 
potentiating site resides in the interface between the a4 subunit in the fourth and 
fifth positions of the ~2_a4J32_a4_a4 nAChR; a4 in the fourth position 
contributes H 195, whereas the a4 subunit in the fifth position contributes the plus 
face of the Zn2+ binding site. 
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3.2.2 Functional consequences of incorporating a P2/u4 chimeric 
subunit into the auxiliary subunit position 
To detennine whether the a4(+)/a4(-) interface influences the agonist sensitivity 
of the (a4p2)2a4 nAChR, the a4 subunit located in the fifth position (the 
auxiliary subunit position) of the concatenated p2_a4_p2_a4_a4 receptor was 
replaced by a chimera subunit consisting of the N-tenninal of the P2 subunit and 
the TM 1-4 domains, extracellular and intracellular loops and C-tenninal of the 
a4 subunit (Fig. 3.3.A). 
Oocytes expressing chimeric p2_a4_p2_a4_p2/a4 or wild type receptors were 
functionally characterised using two-electrode voltage clamp. In oocytes 
expressing chimeric p2_a4_p2_a4_p2/a4 nAChRs, ACh activated current 
responses in a concentration-dependent manner but with a potency that was 
about 10-folder greater than for ACh action at wild type receptors (chimeric 
. receptor ACh EC50 = 8.2 ±0.5 J.l.M, n = 4; wild type ACh EC50 78±8 J.l.M (n = 6; p 
< 0.001) (Fig. 3.38; Table 3.1). Interestingly, the ACh sensitivity of the 
chimeric receptor was not statistically different from that for the (a4p2hP2 
isofonn (3.4 ± 1; Table 3.2) (Moroni et al. 2006; Carbone et al. 2009) or for its 
concatenated version p2_a4_p2_a4_p2 (EC50 = 3.2 ± lJ.l.M, n = 4; Fig. 3.38; 
Table 3.1) (Carb~me et aI., 2009). This finding suggested that ablation of the 
putative agonist site at the a4( + )/a4( -) interface by substitution with an 
extracellular p2(+)/a4(-) interface produces an assembly with ACh sensitivity 
approaching that of (a4p2)2p2 nAChRs. This possibility was examined by testing 
the functional effects of Cyt and Saz-A on p2_a4_p2_a4_p2/a4 nAChRs. As 
mentioncd in Chapter 1, Cyt is a partial agonist at (a4p2)2a4 nAChRs or its 
concatcnated tcmplate but it has negligible agonist efficacy at non-linked or 
concatcnatcd (a4p2)2p2 nAChRs (Moroni et aI., 2006; Carbone et aI., 2006). In 
contrast, Saz-A displays poor efficacy at loose or concatenated (a4p2ha4 
reccptors (less than 0.05%) (Zwart et aI., 2006; Carbone et aI., 2009) but is a 
potent, full agonist at non-linked or concatenatcd (a4p2hp2 nAChRs (Zwart et 
aI., 2006; Carbone et aI., 2009). Cyt failed to elicit currents at 
p2_a4_p2_a4_p2/a4 nAChRs, even at 100 J.l.M, a concentration producing 
maximal effects at p2_a4_p2_a4_a4 nAChRs (Figs. 3.3C) (Carbone et aI., 
2009). Saz-A behaved as a full agonist at p2_a4_p2_a4_p2/a4 nAChRs and 
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displayed a potency (ECso = 16 ± 9 nM; n = 3) that was comparable to that at 
loose or concatenated (a4~2h~2 nAChR (ECso = 7 ± 1 nM; (Carbone et aI., 
2009) (Figs. 3.3C, D). These findings show that removal of the a4(+)/a4(-) 
interface produces a (a4~2h~2 nAChR-like agonist sensitivity and are thus 
consistent with the suggestion that the a4(+)/a4(-) interface in (a4~2)2a4 nAChR 
may underlie the agonist sensitivity signature of the isoform (a4~2)2a4 receptor. 
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Figure 3.3. Agonist sensitivity of a chimeric p2_a4_p2_a4_p2/a4 nAChR. 
(A) Cartoon of the chimeri c ~2_a4_~2_a4_~2/a4 nAChR. (B) ACh C RC at 
~2_a4_~2_a4_~2/a4 nAC hRs. The ACh C RC for w ild type nAC hRs are shown 
for com pari son. Data were fit by nonlinear regression analys is as described in 
Materials and Methods. (C) Representa tive traces of the responses of chimeric 
p2_a4_p2_a4_p2/a4 nAChRs to ECloo ACh ( I mM), Cyt (100 IlM ) and Saz-A 
(I IlM) . (D) The C RC for Saz-A. The mean of the Imax ± SEM for 4- 10 
experiments for each receptor we re as follow : p2_a4_p2_a4_p2/a4 (ACh, 115 ± 
28 nA), (Saz-A 142 ± 34 nA); ~2_a4_p2_a4_a4 (ACh, 386 ± 77 nA); 
~2_a4_p2_a4_p2 (ACh, 223 ± 70 nA) The data were anal ysed as described in 
C hapter 2. 
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Table 3.1. Summary of ACh effects on wild type and mutant 
p2_a4j12_a4_a4 nAChRs. Data are the mean ± SEM for 4-10 experiments. 
ACh EC50 values, Hill coefficients, and high sensitivity fractions (HF) are 
indicated. *Values are significantly different from wild type, p < 0.05 (one way 
ANOVA). 
Receplor Type ACh nH ACh nHI ACh nH2 HF 
EC,o EC",_I EC",_2 
IlM IlM IlM 
~2_a4_~2_a4_~2 3.2±1 1.2±0.5 
~2_a4_p2_a4_a4 78±8 0.72±O.02 
~2_a4_p2_a4_~2/a4 8.2±0.5 I.I±O.I 
~2_ w"zAa4_~2_ w,"zAa4_ WI>zAa4 684±63 * 1.37±0.1 
~2_WIH2Aa4_~2_a4_a4 1.51±0.02* 0.55±0.1 566±62* 2.5±O.7 0.63±0.1 
p2_a4_p2_ " "'''a4_a4 1.23±0.03* 0.70±0.2 668±63* 2±0.7 0.64±0.07 
p2_a4~2_a4_w""Aa4 28±2* 1.4±0.2 3483±25* 3.8±1.2 0.66±0.06 
P2_WIH2Aa4_p2_w"'Aa4_a4 38±18* 0.32 ± 0.1 679±78* 1.4±0.5 0.32±0.09 
P2_" "'"a4_p2_a4_""'"a4 10±4* 1.9±0.9 724±S4* 3.8±O.8 OJ4±0.02 
p2_a4~2_w"ZAa4_w"ZAa4 5.1±2* IJ±0.2 441±6S* 1.8±OJ 0.11±0.07 
P2_ ZJOAa4_p2_a4_a4 3.10±0.6* 0.76±0.2 540±43* 3.9±2 0.3S±0.07 
p2_a4_p2_ mOAa4_a4 3.29±0.3* 0.63±0.OS S38+51* 3.7±O.8 0.37±O.1 
P2 _ a4 ~2 _ a4 _ ,,,uAa4 1.64±O.07* 1.1±O.6 2SI±61 2.0 ±0.8 0.15±0.06 
p2_czz·'a4_p2_a4_a4 2.19±0.5* 1.6 ±O.3 352±43* 1.3±0.2 0.17±0.O6 
p2_a4_p2_czz·'a4_a4 1.61±0.1* 1.4±O.2 S27±6S* 1.1 ±O.3 O.16±O.06 
p2_a4_p2_a4_czz·'a4 1.12±O.S* I. I ±0.4 38S±79* 1.2±0.6 0.13±0.09 
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Table 3.2. CRC data for ACh activation of wild type and mutant a4~2 
nAChR isoforms. The maximal current of the mutant receptors was normalised 
to that of wild type receptors to estimate the relative maximal ACh responses of 
mutant receptors. Data represent the mean ± SEM for 7-9 experiments. NO, not 
determined. NR, no functional responses elicited by ACh. 
(a4p2)2a4 (a4p2hP2 
Ihmax JlA EC50 JlM nH l/Imax JlA EC50 nH 
Wild type 1 81±14 O.72±O.O7 1 3.4±1 O.68±0.07 
a4Y126A O.OS6±O.OO4 ND ND O.O63±O.OO8 ND ND 
a4Wl82A O.87±O.O8 634±78 l.3±O.S O.76±O.OS 500±78 1.6±O.4 
a4Y223A NR - - NR 
a4Y230A O.23±0.04 478±99 1.3± 0.15±0.O7 504±112 1.5±0.5 
P2W82A O.46±O.12 256±67 l±OA NR - -
3.2.3 Mutant agonist sites produce biphasic ACh effects 
Given that the putative site at the a4(+)/a4(-) interface is homologous to the 
agonist binding sites at the a4( + )/~2( -) interfaces, it may be possible that the site 
at the a4( + )/a4( -) interface influences receptor function possibly by binding 
agonists. Therefore, conserved aromatic residue a4W182 in the a4(+)/a4( -) 
interface was substituted with alanine aiming to demonstrate that ACh binds this 
site. a4W182 is equivalent to muscle a4W149 and establishes cation-1t 
interactions with the quaternary ammonium group of ACh (Xiu et aI., 2009) and 
affects binding affinity as well as gating (Akk, 200 I; Akk & Auerbach, 1999). 
As shown in Table 3.2, alanine substitution of a4W182 on loose subunit 
(a4~2ha4 nAChRs reduces sensitivity to activation by ACh without impacting 
functional expression. 
Introducing a4W182A into the (+) face of the putative agonist site at the 
a4(+)/a4(-) interface produced mutant ~2_a4_~2_a4_ Wl82Aa4 nAChRs 
responding to ACh with a biphasic CRC (p < 0.003; n = 10), including a 
component that comprised about 65% of the curve, and had an ACh EC50 value 
that was about 3-fold lower than that for wild type (Fig. 3.4A; Table 3.1). 
75 
Chapter 3 
A 1.2 • p1-a4~1-a .... WII1-'a 4 
1.0 0 p1-a4~1-a .... Q4 .. ; 
!- 0.8 .. 
Cl: 
" 0.6 ~ r T r ! 0.4 0 Z 0.2 r 
0.0 
-.1100 nA -10 -8 -6 .... -2 
LoglAChl M SOs 
B 
P1- WII1"aJ1-a .... a 4 
C 
1.2 • J.2 • P1-a4 _P1-WII1"a .... a4 
I. 0 P1-a 4_p1-a .... a 4 1.0 0 P1-a 4 ~1-Q .... a4 .. .. 
I E 
~ 0.8 8. r; 0.8 
Cl: Cl: 
l 0.6 " 0.6 11 
~ 0.4 1 0.4 
0 0 
Z z 
0.2 0.2 
0.0 0.0 
-10 -8 -6 .... -2 -10 -8 -6 .... -2 
LoglAChl M LoglAChl M 
D 
1.2. P1-Will" aJ1-WII1"a4_ WIIl"a4 
1.0 p1-a4~1-a .... a4 0 .. , 
11 . , 
~ 0.8 • ; 
Cl: 
, , 
l 0.6 
, , 
~ , 
~ 0.4 
, ., . 
0 f1 z 
0.2 
, .. . 
p' 
0.0 " 
-10 -8 -6 .... -2 
Log IAChl M 
Figure. 3.4. Effect of u4W182A subunit on the ACh sensitivity of 
P2_u4_P2_u4_u4 nAChR. When the W182A mutation was introduced into a4 
in the fifth (A), second (8) or fourth (C) positions of the concatenated receptor 
biphasic ACh CRCs were obtained; whereas introducing the W182A mutation in 
all the a4 subunits (D) the CRC were monophasic. The mean of the Imax ± SEM 
for 4-10 experiments for each receptor were as follow: p2_a4_p2_a4_a4 (386 ± 
77 nA). P2_ WI82Aa4_p2_a4_a4 (404 ± 55 nA); p2_a4.J32_ W182Aa4_a4 (425 ± 82 
nA); p2_a4_p2_a4_WI82Aa4 (347 ± 55 nA); P2_ W182Aa4_P2_ W182Aa4_ W182Aa4 
(250 ± 30 nA). Data were fit by nonlinear regression analysis as described in 
Chapter 2. 
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The second CRC component became evident at ACh concentrations higher than 
500 JlM and displayed an ACh sensitivity that was 45-fold lower than that for 
wild type ~2_a4_~2_a4_a4 receptors (p < 0.0001, n =10) (Table 3.1). When the 
mutation was simultaneously introduced into the a4( + )/a4( -) and the two 
a4( + )/~2( -) interfaces (triple mutant receptor) in the ~2 _ a4 _~2 _ a4 _ a4 receptor 
the ACh CRC was monophasic (p < 0.001; n = 10) and with an ACh EC50 value 
that was no different from that obtained for non-linked (a4WI82A~2)2a4wI82A 
nAChRs (Fig. 3.4B; Tables 3.1, 3.2). This finding suggested that the biphasic 
ACh CRC for ~2_a4_~2_a4_ Wl82Aa4 receptors reflects the presence of unaltered 
agonist sites at the a4( + )/~2( -) interfaces and the mutated site at the a4( + )/a4( -) 
interface. To test this possibility, a4W182A was introduced into the (+) face of 
either of the agonist binding sites at the a4( + )/~2( -) receptor interfaces to 
produce mutant ~2_ WI82Aa4_~ 2_a4_a4 or ~2_a4_~2_ Wl82Aa4 _a4 receptors. As 
shown in Figs. 3.4C, D, the effects of ACh on ~2_ WI82Aa4_~2_a4_a4 or 
~2_a4_~2_ W182Aa4_a4 receptors were biphasic (p < 0.001; n = 6). The relative 
abundance of the CRC component with the highest sensitivity for ACh was 
similar for all three mutant receptors. However, the ACh sensitivity of this 
component in the CRC for ~2_ WI82Aa4_~2_a4_a4 or ~2_a4_~ 2_WI82Aa4_a4 
receptors was -60-fold greater than wild type, making it comparable to the ACh 
sensitivity of (a4~2)2~2 or chimeric ~2_a4_~2_a4_~2/a4 receptors, both of 
which lack the a4(+)/a4(-) interface (Table 3.1). In contrast, in the case of 
~2_a4_~ 2_a4_ Wl82Aa4 receptors, the ACh sensitivity for the equivalent CRC 
component was increased by only 3-fold, relative to wild type (Table 3.1). The 
ACh CRC component with the lowest ACh sensitivity also differed in both types 
of mutant receptors. For receptors with mutant a4(+)/~2(-) interfaces, the ACh 
sensitivity of this component was 8-fold lower than wild type (Table 3.1), 
whereas for ~2_a4_~ 2_a4_ Wl82Aa4 nAChRs it was 45-fold lower than wild type 
(Table 3.1). For all three mutant receptors, the Hill coefficient of the component 
with lowest ACh sensitivity increased to 2-3 relative to wild type, whereas 
changes in the Hill coefficient of the CRC component with the highest ACh 
sensitivity were not significant, in comparison to wild type. 
Next, a4W 182A was introduced simultaneously into the (+) face of two subunit 
interfaces to create mutant 
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P2_ WI82Aa4_p2_a4_ WI82Aa4, or P2_ WI82Aa4_P2_ WI82Aa4_a4 receptors. As shown 
in Fig. 3.5, introducing W182A simultaneously into two a4 subunits of 
p2_a4J32_a4_a4 receptors produced biphasic ACh CRC. 
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Figure 3.5. Activation of Jl2_a4J2_a4_a4 receptors containing two 
a4W182A mutant subunits. Simultaneous introduction of a4W182 into two 
sites to produce P2_ WI82Aa4_P2_ W182Aa4_a4 (A), P2_ WI82Aa4_p2_a4_ WI82Aa4 
(8) or p2_a4J32_ W182Aa4_ WI82Aa4 (C) led to biphasic ACh CRC. The mean of 
the Imax ± SEM for 4-10 experiments for each receptor were as follow: 
p2_a4_p2_a4_a4 (386 ± 77 nA). P2_ WI82Aa4_P2_ WI82Aa4_a4 (473 ± 106 nA); 
P2_ WI82Aa4_p2_a4_ WI82Aa4 (555 ± 112 nA); p2_a4_p2_ WI82Aa4_ WI82Aa4 (296 ± 
58 nA). Data were fit by nonlinear regression analysis as described in Chapter 2. 
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In comparison to single mutant receptors, the relative abundance of the CRC 
component with higher sensitivity to ACh was reduced in all three mutants (p < 
0.001; n = 6-12) (Figs. 3.4 & 3.5, Table 3.1). For all three mutant receptors, the 
ACh sensitivity of this component was enhanced, as compared to wild type, but 
decreased as compared to the equivalent ACh EC50 for single mutant receptors (p 
< 0.01; n = 6-8) (Table 1). The relative abundance of the CRC fraction with the 
highest ACh sensitivity was influenced by the position of the mutated a4 subunit 
within the receptor (Fig. 3.5, Table 3.1). The ACh EC50 estimated for the 
component with the lowest ACh sensitivity was similar for all three double 
mutant receptors and was not different from the ACh EC50 for (a4WI82Ap2)2P2 
receptors (EC50 = 500 ± 78 flM; Table 3.2). Overall, these findings, together 
with the effects of a4W182A on non-linked a4p2 nAChR function (Table 3.2), 
indicate that the ACh CRC component with the highest sensitivity for ACh is 
contributed predominantly by unaltered binding sites, whereas the mutated sites 
contribute predominantly to the CRC component with the lowest sensitivity for 
ACh. Because introducing W182 into the auxiliary subunit produced a CRC 
fraction with diminished sensitivity for ACh, the findings are consistent with the 
possibility that the a4(+)/a4(-) interface is capable of binding agonist. 
3.2.4 Dh~E inhIbits the a4(+)/a4(-) site 
DhPE displays high affinity (low nM Ki values) competitive antagonism for 
a4/32 nAChRs (Table 1.1) (Moroni et aI., 2006; Carbone et aI., 2009). 
Demonstrating that the site at the u4( + )/u4( -) interface is inhibited by DhPE 
would further support the suggestion that the site is capable of binding agonist. 
This possibility was assessed by determining the ACh sensitivity of mutant 
p2_u4_P2_u4_ WI82AU4 in the presence and absence of 1 JlM DhpE. Because 
a4 W 182 contributes to inhibition of u4P2 nAChR by DhPE (lturriaga-Vasquez et 
aI., 2009) and, as suggested by the present studies, binds agonist in the putative 
site at the u4(+)/u4(-) interface, it was anticipated that DhPE would decrease the 
sensitivity of both mutant u4(+)/u4(-) and unaltered u4(+)//32(-) sites, albeit with 
different potency. As shown in Figs. 3.6A, B, inhibition of the ACh responses of 
P2_u4_P2_u4_ WI82AU4 nAChRs by DhPE reached a plateau at ACh 
concentrations higher than 800 flM, producing monophasic ACh CRC lacking 
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the component with the lowest ACh sensitivity detected in the absence of the 
antagonist. As shown in Figs. 3.6C-E, the ACh CRC for receptors with mutant 
u4(+)/P2(-) binding sites (i.e., P2_ WI82AU4_P2_u4_u4 or P2_u4.J32_ W182AU4_u4 
nAChRs) also became monophasic in the presence of DhpE. However, by 
comparison to P2_u4.J32_u4_ Wl82AU4 receptors, DhPE inhibited more potently 
the responses elicited by concentrations of ACh lower than 10 JlM, a 
concentration range activating non-mutated agonist sites. 
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Figure 3.6. Effects of the antagonist DhPE on mutant P2_Cl4_p2_a4_a4 
nAChRs. (A) Typical trace showing the effects of ACh on ~2_u4_~2_u4_ 
WI 82Aa4 nA hR in the ab ence (black) and presence of 1 llM Dh~E (red). (B) 
R for the effect of Dh~E on the ACh re ponses of ~2_u4 _~2_u4_ Wl82AU4 
nA hR . Data were fit by nonlinear regres ion analysis as described in Chapter 
2. (C) Repre entative trace showing the effect of I flM Dh~E (in red) on the 
A h re pon e (in black) of P2_u4_P2_ W182AU4_u4 nAChRs. (D, E) ACh CRC 
in ab ence or pre ence of I flM Dh~E obtained at P2_u4 _P2_u4_ Wl82AU4 or 
P2_ WI 82AU4_P2_u4_u4 nA hR respectively. Data were fit by nonlinear 
rcgre i n analy i a de cribed in Chapter 2. 
3.2.5 Loop in the au i1iary subunit affects receptor function 
A di cu ed in haptcr 1, agonist binding in ys-Ioop LGICs elicits loop C 
apping, and thi con idered to lead to channel gating via molecular 
intcracti n in th upling interface. To a e the ignificance of loop C on the 
function of the putative ite at the u4(+)/u4(-) interface, u4Y230 was introduced 
int the (+) fa ite and then a ayed it effect on the function of 
P2_u4_P2_u4_u4 r ept r were a ayed. u4Y230 i equivalent to muscle 
ul Y 19 in th -terminal f loop . It ha been hown to affect gating but not 
agoni t binding affin ity in mu cle nA hR and in the (u4P2hu4 receptors 
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decreases the sensitivity to ACh and functional expression (Table 3.2). If the site 
at the u4( + )/u4( -) interface had the capability of contributing to receptor 
activation, alanine substitutions of Y230 should impair channel gating leading to 
biphasic ACh CRC, comprising a fraction contributed by agonist sites with 
unaltered loop C and a component contributed by mutant loop C. As shown in 
Fig. 3.7 and Table 3.1, ~2_u4~2_u4_Y230AU4 nAChRs produced biphasic ACh 
CRC, comprising a component with an ACh EC50 comparable to the ACh ECso 
of the (u4P2)2P2 nAChRs and a component with reduced ACh sensitivity, as 
compared to the high sensitivity fraction. The high sensitivity component 
represented approximately 15% of the CRC (Table 3.1). u4Y230A into either of 
the u4( + )/P2( -) ACh binding sites produced comparatively similar effects, except 
that the high sensitivity fraction was twice greater (p < 0.001; n = 10) (Figs. 
3.7A-C; Table 3.1). 
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Figure 3.7. Functional effects of loop C mutation on fJ2_a4_fJ2_a4_a4 
nAChR function. ACh produced biphasic CRC in oocytes expressing 
p2_Y230Aa4_p2Y~3~Aa4 receptors (A), p2_a4_p2_Y230Aa4_a4 (B) or 
p2_a4_p2_a4_ a4 receptors (C). Data were fit to the monophasic or biphasic 
equations described in the Materials and Methods. Introducing C226S into the 
second (D), fourth (E) or fifth (F) positions of the p2_a4_p2_a4_a4 nAChR 
produced biphasic ACh responses. The mean of the Imax ± SEM for 4-10 
experiments for eac;h receptor were as follow: p2_a4 P2 a4_a4 (386 ± 77 nA). 
p2_Y230Aa4_p2 a4 a4 (46 ± 14 nA); P2 a4 P2_ "V"230Aa4_a4 (28 ± 6 nA); 
P2 a4 P2 a4 Y230Aa4 (84 ± 20 nA); P2 "C226S"a4 P2 a4 a4 (283 ± 81 nA); 
p2=a4=p2=C21bSa4_a4 (367 ± 149 nA); p2_a4_p2=a4=C21OSa4 (213 ± 48 nA). 
Averaged parameters of best fits to CRC are given in Table 3.1. 
3.2.6 Modification of loop C with MTS Reagents 
Demonstrating that conformational changes in loop C in the auxiliary a4 subunit 
alter the ACh responses of the p2_a4_p2_a4_a4 nAChR would strengthen the 
conclusion that the putative agonist binding site in the a4(+)/a4(-) interface 
contributes directly to channel gating. Loop C conformational transitions can be 
inferred from changes in the agonist responses of receptors brought about by 
covalent modification of substituted (Venkatachalan & Czajkowski, 2008) or free 
(Wang et aI., 2009) cysteine residues in loop C by MTS reagents. Accordingly, 
serine was substituted for C226 at the tip of loop C to dismantle the disulphide 
bond between C22S and C226 in order to make C22S accessible to MTS reagents 
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(MTSET or MTSEA; Fig. 3.8A). Substitution of serine for C226 in any of the 
three u4 subunits of the P2_u4_P2_u4_u4 nAChR yielded biphasic ACh CRC 
that were comparable to those produced by the u4Y230A mutation (Figs. 3.70-
F;3.8B; Table 3.1). These findings are in accord with recent studies of muscle 
nAChR showing that removal of the cysteine bridge in loop C decreases agonist 
sensitivity without abolishing loop C function (Mukhtasimova et aI., 2009). To 
assess the effects of MTS reagents on the function of intact and mutated sites, we 
performed the experiments using 800 JlM or 3 JlM ACh. 800 JlM ACh produces 
near maximal activation of the ACh CRC fraction with the lowest ACh 
sensitivity, whereas 3 JlM ACh produces almost maximal activation of the ACh 
CRC fraction with the highest ACh sensitivity (Figs. 3.70-F; Table 3.1). We 
have shown above that ACh produces biphasic CRC at P2_u4_P2_u4_u4 
receptors with one mutant agonist site and that the CRC component with the 
lowest ACh sensitivity is contributed predominantly by the mutated site, whereas 
the component with the highest sensitivity component reflects predominantly the 
activation of intact binding sites. As shown in Fig. 3.8C, when the current 
responses of P2_u4_P2_u4_ C226Su4 nAChRs were activated by 800 JlM ACh, 
MTSET decreased the amplitude of the ACh responses by -30%. In accord with 
a covalent interaction between u4C225 and MTSET, exposure to DTT reversed 
the effects of MTSET (Fig. 3.8e). By comparison, MTSET had no effects on the 
amplitude of the responses evoked by 3 JlM ACh (Fig. 3.8C). These results were 
expected because 3 JlM ACh activates predominantly intact agonist sites, 
MTSET produced similar effects on the ACh responses of p2_C226Su4_P2_u4_u4 
or P2_u4_P 2_C226Su4 _u4 mutant nAChRs (Fig. 3.8E). Exposure to MTSEA did 
not have any apparent effect on the current responses elicited by 800 JlM ACh in 
P2_u4_P2_u4_C226Su4 nAChRs (Fig. 3.80). However, when the responses were 
elicited by lower concentrations of ACh (3 JlM) after MTSEA treatment, the 
amplitude of the ACh responses was enhanced markedly and this effect was 
reversed by DTT (Fig. 3.8D). This result demonstrated that MTSEA enhanced 
the ACh responses of the mutant receptor by covalentIy modifying C225. 
Comparable effects were observed when P2_ C226Su4 _P2_u4_u4 or p2_u4_P2_ 
C226Su4_u4 were exposed to MTSEA (Fig. 3.SE). Although we observed 
differences in the effects of MTS at each agonist site, the differences were not 
significant. 
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Figure 3.8. Effects of MTS reagents on mutant P2_1l4_P2_1l4_1l4 nAChRs. 
(A) Structure of MTS reagents used to eova lentl y modify free C225 in loop C. 
(8) p2_a4_p2_a4_ C226Sa4 reeeptors di splayed biphasie ACh responses. For 
compari son, the ACh CRC at wild type is also shown. Data were analysed by 
nonlinear regress ion as described in Chapter 2. (C) Representati ve current traces 
of the responses to ACh (800 ~M or 3 ~LM) from two diffe rent ooeytes 
express ing p2_a4_p2_a4_C226Sa4 reeeptors before and after modifi cation by 
MTS ET. DTT was applied at the end of the experiments to confirm that the 
effects observed were due to the covalent modifi cation of C22S. (0) 
Representati ve current traces of the responses to ACh (800 ~M or 3 ~M ) from 
two different oocytes expressing p2_a4_p2_a4_C226Sa4 receptors before and 
after modifi ca ti on by MTSEA. DTT reversed the effects of MTSEA. (E) Bar 
graph summary of the percentage of change (mean ± SEM) in the ampli tude of 
the ACh currents after MTS treatment on wild type and mutant receptors. *, 
values are signifi cantl y different from amplitudes of the ACh responses prior to 
MTS treatment (p< 0.001 onc-way ANOVA). 
85 
Chapter 3 
3.3 Discussion 
The a4 and P2 subunits of the nAChR assemble into alternate fonns that differ 
markedly in sensitivity to activation by agonists. Because a4p2 nAChRs contain 
two identical agonist binding sites at the a(+)/p(-) interfaces, a long-standing 
question has been what structural features confer agonist sensitivity to the 
alternate fonns of the a4p2 nAChR. Here, we provide evidence that an additional 
site at the a4(+)la4(-) interface in the (a4p2)za4 nAChR underlies the agonist 
sensitivity signature of the isofonn (a4p2)za4. The additional site binds ACh and 
when engaged by ACh, contributes to channel gating through a coupling pathway 
that includes loop C. The findings have important structural and functional 
implications about the role of subunit composition on the structural-functional 
properties of the a4p2 nAChR and the manner by which agonists activate 
heteromeric pLGIC. 
The agonist site at the a4( + )la4( -) is a major detenninant of the agonist 
sensitivity of the (a4p2)za4 nAChR. Its removal increases ACh sensitivity and 
Saz-A efficacy and obliterates Cyt efficacy, all of which are signatures of the 
isofonn (a4p2)2p2 nAChR. Moreover, the agonist binding at the a4(+)la4(-) site 
was weakened by a4W182A where ACh produced biphasic agonist responses, in 
accord with the functional behaviour of a receptor containing unaltered and 
mutated agonist sites. The high sensitivity component of the curve represented 
the contribution of unaltered agonist sites at the a4( + )/P2( -) interfaces, whereas 
the low sensitivity component was contributed by the mutated agonist site, as 
demonstrated by the differential sensitivity of these components to ACh or the 
antagonist DhpE. The site clearly impacts the activation of the receptor by 
agonist in a manner comparable to the effect of the consensus agonist site located 
at the a4(+)/p2(-) interfaces. When loop C in the primary face of the a4(+)la4(-) 
was impaired, through alanine substitution of Y230 or serine substitution of 
C226 or by covalent modification of a free C22S by MTS reagents, the amplitude 
of the ACh responses was reduced (alanine substitution, MTSET) or enhanced 
(MTSEA). Although this site resides in the same interface where the signature 
potentiating Zn2+ site of the (a4p2)2a4 isofonn is located (Moroni et aI., 2008) or 
analogous to that of the benzodiazepine site in GABAA receptors (Galzi & 
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Changeux 1994), it is not a classic allosteric site. Neither Zn2+ nor 
benzodiazepines is capable of channel gating but appear to enhance receptor 
responses to agonist by increasing channel opening frequency [benzodiazepines; 
(Rogers et al., 1994)] or by increasing burst duration [Zn2+; (Hsiao et al., 2008)]. 
Instead, the site is comparable to the agonist sites in homomeric LGICs (Beato et 
al., 2004; Rayes et al., 2009). 
MTS-modification of a free cysteine engineered at the tip of loop C in the 
auxiliary 0.4 subunit provided strong support for the idea that the putative site at 
the 0.4(+)/0.4(-) interface contributes to channel gating. Interestingly, MTSET and 
MTSEA affected loop C function differentially. It is possible that MTS reagents 
lock loop C into different conformations depending on how the Cys-MTS moiety 
orientates within the binding pocket. MTSET could attenuate ACh responses by 
stabilising the mutated loop C into an extended, antagonist-bound like 
conformation, thus reducing ACh efficacy. By comparison, MTSEA could 
enhance ACh responses by locking the mutated loop C into a capped, agonist-
bound-like conformation, which would increase agonist efficacy leading to the 
activation of the mutated sites at submaximal ACh concentrations. High 
resolution X-ray crystal structures ofa MTS-Y53C mutant of the AChBP support 
this view (Brams et al., 2011). Loop C in MTSET-Y53C AChBP is in an 
extended, antagonist-bound conformation, which is consistent with the finding 
that 0.7 W55C-MTSET nAChRs are unresponsive to ACh (Brams et al., 2011). 
Another reagent, Methyl methanesulfonothioate (MMTS), enhances the ACh 
responses of 0.7 Y53C nAChR and locks loop C in MMTS-Y53C AChBP into a 
close, agonist-bound-like conformation (Brams et al., 2011). Although MTSET 
and MTSEA may affect the contribution of loop C to receptor activation 
diffcrentially, it is clear from their effects on the ACh responses of the mutant 
agonist sites that all three sites contribute to activation of (a.4~2ha.4 nAChRs. 
This additional contribution appears to increase the efficacy of ACh because the 
maximal current responses of single mutants were markedly greater than those 
obtained by maximal activation of the non-mutated agonist sites. 
The sites at the 0.4 ( + )/~2( -) and 0.4(+ )/0.4 ( -) interfaces respond differentially to 
alanine substitutions in respect of sensitivity to ACh or Dh~E and the relative 
87 
Chapter 3 
proportions of the components of the ACh CRC. This could anse from 
differences in the overall architecture of the agonist sites. Unlike the primary 
face of the agonist sites, the complementary face is not identical. In the case of 
the agonist site at the a4( + )/a4( -) interface, the complementary face is 
contributed by an a4 subunit, providing a likely structural determinant for 
differential agonist-binding site interactions. Moreover, the coupling pathway 
leading to gating is also different in both types of agonist sites and this could 
affect the type of interfacial interactions implicated in coupling and gating. In 
accord with this idea, it has been reported that some conserved residues in the 
agonist site of a4p2 nAChR differentially regulate receptor activation by 
agonists, whereas other equally well conserved residucs do not (Williams et aI., 
2009). 
Sensitivity to activation by ACh increased through either ablation of the 
a4(+)/a4(-) interface or through alanine substitution in the a4(+)/a4(-) or either 
of a4( + )/P2( -) sites. Moreover, the pattern of agonist sensitivity of the single or 
double agonist binding mutants, as observed in terms of relative abundance of 
the ACh CRC components, sensitivity to ACh and changes in the nH coefficient, 
suggest a complex, likely allosteric, interaction between the agonist sites. 
Because macroscopic ECso values are composites of binding, gating 
desensitisation as well as ion channel blockade, interpretation of the data in terms 
of molecular mechanisms is limited. However, considering that in homomeric 
LGIC agonist sites contribute interdependently and asymmetrically to channel 
gating (Rayes et aI., 2009), which implies as yet unknown interfacial interactions 
in the coupling pathway, it is possible to surmise that the agonist sites at 
(a4p2)2a4 receptors may contribute similarly to receptor activation. Studies of 
the microscopic currents of the (a4p2ha4 nAChR should aid the understanding 
of the observed differences. 
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. The additional acetylcholine binding site 
at the a4( + )/ a4( -) interface of the 
(a4p2)2a4 nicotinic acetylcholine 
receptor contributes to desensitisation 
Chapter 4 
4.1 Introduction 
a4p2 nAChRs undergo acute and high-affinity desensitisation. Acute 
desensitisation refers to the loss in receptor response during a single exposure to 
high (-EC60 - EC lOo) concentrations of agonist, whereas high-affinity 
desensitisation is induced by chronic exposure to low or non-activating agonist 
concentrations (Steinbach, 1990; Giniatullin et aI., 2005; Gopalakrishnan et aI., 
1996; Paradiso & Steinbach, 2003; Lester, 2004). The molecular mechanisms 
producing acute or high-affinity desensitisation have not been fully identified. It 
is also unclear whether the two types of desensitisation are the result of a single 
process. Mutations within the second transmembrane domain of the a4 subunit 
(S248F and 776ins3) that affect both the apparent affinity to ACh and acute and 
chronic desensitisation (Bertrand et aI., 1998) suggest a single desensitisation 
pathway. In addition, studies with chimeric nAChRs have shown that the N-
terminal domain of the a4 subunit, along with the first three transmembrane 
domains and the N-terminal domain of the P2 subunit are involved in high-
affinity desensitisation (Corringer et aI., 1998; Kuryatov et aI., 2000). However, 
other single point mutations in the a4 subunit can cause changes in 
desensitisation without effect on agonist binding (Matsushima et aI., 2002). 
In this chapter, the individual contribution ofthe three agonist sites in (a4p2ha4 
nAChRs to high-affinity desensitisation were studied. The sites were individually 
mutated, and consequences of these mutations on ACh-induced activation and 
high-affinity desensitisation were assessed. It was found that the additional 
agonist site decreases sensitivity to activation and high-affinity desensitisation. 
Interestingly, the desensitisation studies reported here provide further evidence of 
functional non-equivalency between the agonist sites at the a4( + )/P2( -) and 
a4( +)/ a4( -) interfaces. 
4.2 Results 
4.2.1 Desensitisation of (u4P2)2U4 receptors 
The contribution of the ACh binding sites of (a4p2ha4 receptors to 
desensitisation was determined by measuring the fraction of activatable receptors 
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remaining after prolonged exposure to a range of ACh concentrations. As in the 
studies reported in the previous chapter, the studies were carried out using the 
concatenated version of (a4~2)2a4 nAChRs. 
Representative traces of the responses of ~2_a4_~2_a4_a4 receptors to short (2 
s) ACh test pulses at a concentration near the ECso ACh (lOO JlM) in the absence 
of and during the ACh prepulse application are shown in Fig. 4.1A. Exposure to 
ACh prepulses decreased the peak amplitude of the responses evoked by ECso 
ACh pulses in a concentration-dependent manner. Concentrations lower than 
0.01 JlM did not produce measurable effects on the responses to ACh test pulses . 
. Inhibition reached equilibrium within a few minutes following initiation of the 
prepulse applications and some recovery was observed when going back to 
control conditions. Plots of peak ACh EC50 current responses measured at 
equilibrium conditions as a function of the concentration of the ACh prcpulses 
produced monophasic sigmoidal inhibitory CRC (Fig. 4.1B). The estimated ICso 
was approximately 500-fold greater than the ECso for ACh-induced activation (p 
< 0.05; n = 8) (Table 4.1) and the Hill coefficient was less than 1. For 
comparison, the values for the ACh-induced functional inactivation of (a4~2)2a4 
receptors assembled from loose subunits are included in Table 4.1. 
Desensitisation of (1l4p2ha4 by ACh was measured using the same protocol 
described for p2_a4_p2_a4_a4 receptors. Fits to the data yielded ICso and Hill 
coefficient values that were comparable to those estimated for ~2_a4_~2_a4_a4 
receptors (Table 4.1). 
91 
A 
~ ••••••• !.~!~.~.~!.~~.~.~~ •••• ConlrOl 
Al~U. rr--;{1--r-Y-V--<vY-y-r-y 
MML 
w. 
~ ............... ~!~.~,I.?~:~9.' ....... Control 
MM\.. 
1O. 
r-v---v 
ConlrOl ................ ~~~.!~.~.~~~ ....... ConlrOl 
A<u.c·n~·····~ 
a .. \.. .. 
C 
Control 1'rq>u1!IC I ~M ACh Control "" .... V'~ .. : ..... : ..... ; .... : ..... ; ..... : ..... : -<. -v---v 
aM L. .. 
A(~JO'" nControln .................. ~!~.!.~~.~~"!' .... . 
! ' i 
.M", .. 
Control 
Chapter 4 
B 
1.2 
1.0 
~ 1(.,0.22100.08 111'.1 
&.0.8 
'" .. 
~0.6 :;: 
10.4 
~0.2 
0.0 +---.---.-....---r::--,,..... 
D 
-12 -10 ·8 -6 -4 ·2 
Log [ACh)M 
1.2 
ACh test Pulses 
.411M 
O.O+---.----,r--""T"""~ .... ~ 
·12 ·10 -8 -6 -4 ·2 
log [ACh) M 
Figure 4.1. Functional inhibition of p2_a4-.fJ2_a4_a4 nAChRs. (A) 
Typical traces of P2_u4_P2_u4_u4 nAChRs obtained by using the prolonged 
exposure to ACh protocol described in the Methods section. Impaled oocytes 
were challenged at regular intervals (90 s) by a 2 s pulse of 100 J.lM ACh, a 
concentration of ACh near the ECso. Responses evoked prior to prepulses show 
no desensitisation but prepulses (ACh prepulse, dashed lines) produce a 
concentration-dependent decrease of the responses evoked by 100 J.lM ACh. On 
termination of the prepulse some recovery was observed. (8) CRC for the 
desensitisation of P2_u4_P2_u4_u4 nAChR produced by the protocol shown in 
A. The peak current of the ECso ACh responses immediately before the end of 
. the period of prolonged exposure to ACh was normalised to the control ACh 
responses. The data were best fitted to the monophasic Hill equation described in 
Methods. The estimated ICso and Hill coefficient are summarized in Table 4.1. 
(C) Typical traces of P2_u4_P2_u4_u4 nAChRs stimulated by a 4 J.lM, 30 J.lM or 
300 J.lM ACh test pulses exposed to Ringer's solution containing 1 J.lM ACh. (D) 
CRC for the desensitisation of P2 _ u4 _P2 _ u4 _ u4 nAChR currents stimulated by a 
range of ACh test pUlses. The exposure protocol used to induce desensitisation 
was identical to the one shown in A, except that the ACh test pulses were 4 J.lM, 
10 J.l, 30 J.lM or 300 J.lM. The peak current of the ECso ACh responses 
immediately after the prepulses were normalised to the control ACh responses. 
The data were best fitted to the monophasic Hill equation described in Methods. 
The estimated ICso and Hill coefficient are summarised in Table 1. 
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Table 4.1. Summary of desensitisation and activation of a4p2 nAChRs 
by ACh. ECso or ICso values were determined by fitting respectively the 
activation or inhibition data to the equations given in Methods. (a4~2ha4 and 
(a4~2)2~2 receptors were expressed from individual subunits injected into 
oocytes as previously described (Moroni et aI., 2006). Desensitisation of 
concatenated ~2_a4J32_a4_a4 receptors was measured using ACh test pulses of 
4 J.lM ("), 10 IlM (AA), 30 IlM (AA"), 100 J.lM ("AA") or 300 J.lM (AA"AA). ICso and 
ECso/ICso values for (a4~2h~2 or ~2_a4_ ~2_a4_ ~2 receptors were statistically 
different (noted by *) from those estimated for the desensitisation of 
~2_a4_~2_a4_a4 receptors measured using ACh pulses of 100 J.lM, 10 J.lM, 30 
J.lM or 300 J.lM. ICso and ECso/ICso values estimated for the desensitisation of the 
responses elicited by 4 J.lM ACh at ~2_a4_~2_a4_a4 receptors were statistically 
different from the values estimated for the desensitisation of the responses 
evoked by higher concentrations of ACh at ~2_a4_~2_a4_a4 receptors (noted by 
+). Statistical comparisons were carried out as described in Methods. 
Receptor ECso(J.lM) nH ICso(J.lM) nH ECsol ICso 
0.032±0.007 + 0.57±0.06 3093+ 
O.29±0.08"" 0.54±O.03 341 
p2_a4_p2_a4_a4 99±12 1.l0±0.09 0.23±0.06~ 0.56±0.04 430 
0.22±0.04"""" 0.60±O.06 450 
0.27±0.04~ 0.52±O.09 367 
(a4p2ha4 101±21 O.95±O.O8 O.18±O.OI O.61±0.07 561 
P2_Cl4_p2_a4_p2 2.8±0.8· 1.05±0.09 0.058±O.00 I· 0.61±0.02 48.28· 
(a4p2hP2 2.2±0.3· 0.79±0.09 0.07I±O.001· O.54±O.01 31.03· 
To test if the concentration of the ACh test pulse affected the degree of 
functional inhibition induced by prolonged exposure to ACh, we measured 
desensitisation of ~2 _ a4 _~2 _ a4 _ a4 receptors using ACh test pulses of 4 J.lM, 10 
J.lM, 30 J.lM or 300 J.lM. ACh prepulses higher than 0.01 J.lM produced inhibition 
of all the ACh test pulses studied. Fig. 4.1 C shows representative traces of the 
inactivation of current responses evoked by the various ACh test pulses studied 
by an ACh prepulse of 1 J.lM. The inhibitory CRC produced by the inhibion data 
are shown in Fig. 4.1 D. The estimated ICso and Hill coefficient values for the 
desensitisation of currents evoked by ACh test pulses of 10 J.lM, 30 J.lM or 300 
J.lM were not different from each other or from the IC so and Hill coefficient 
values estimated from the inhibition of currents evoked by 100 J.lM ACh test 
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pulses (Table 4.1). In contrast, when the ACh test pulse was 4 J.1M, a 
concentration of agonist that elicited less than 10% of the maximal ACh 
response, the estimated IC50 value was about 9-fold lower (p < 0.05; n = 4) (Fig. 
4.1D; Table 4.1). A contributor to the observed concentration-dependent effects 
could be procedural. Desensitisation may not have reached equilibrium at low 
concentrations of ACh, or processes such as ion channel blockade by ACh may 
have contributed to the observed functional inhibition at high concentrations of 
ACh test pulses (Bertrand et aI., 1992; Chavez-Noriega et aI., 1997). This is 
unlikely for the following reasons. Firstly, if at low concentrations of ACh test 
pulses desensitisation had not completely attained steady-state conditions, the 
extent of desensitisation elicited may not yet be complete. Under these 
conditions, the inhibition CRC would have shifted to the right yielding higher 
IC50 values for desensitisation. Secondly, if at higher concentrations of ACh test 
pulses other inhibitory processes such as ion channel blockade by ACh added to 
the inhibitory process, sensitivity to desensitisation would have increased. 
There is evidence that both (u4P2)2U4 and (u4P2hP2 receptors may be expressed 
in the brain (Marks et aI., 1999; Gotti et aI., 2008; Marks et aI., 20 I 0; Rode et aI., 
2012). Therefore, the desensitisation of P2_u4_P2_u4_P2 nAChRs, the 
concatenated form of the (u4P2hP2 nAChR (Carbone et aI., 2009), was also 
measured. The (u4P2)2P2 nAChR displays lOO-fold higher sensitivity for 
activation by ACh than the (u4P2)2U4 isoform (Nelson et aI., 2003; Moroni et aI., 
2006; Carbone et aI., 2009). Typical recordings obtained for the inhibition of 
ECso (2 J.1M) ACh responses of P2_u4_P2_u4_P2 nAChRs using the prolonged 
exposure to low ACh concentrations protocol are shown in Fig. 4.2A. The data 
produced monophasic sigmoidal inhibition curves as shown for 
P2_u4_P2_u4_u4 receptors (Fig. 4.28). The ECso and Hill coefficient values 
estimated from the fit are shown in Table 4.1. The ICso value for 
P2_u4_P2_u4_P2 receptors (0.058 ± 0.001 J.1M) was comparable to that 
estimated for (u4P2)2P2 receptors (0.071 ± 0.001 J.1M) (Table 4.1). The ICso 
value obtained for P2_u4_P2_u4~2 was about 3.8-fold lower, in comparison to 
the IC50 values estimated for the desensitisation of the responses of 
P2_u4_P2_u4_u4 receptors stimulated by concentrations of ACh higher than 4 
flM. However, there was no statistical differences between the IC50 values 
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estimated for ~2 _ 0.4 J32 _0.4 _P2 receptors and for P2 _ 0.4 _P2 _ 0.4_0.4 receptors 
activated by ACh test pulses of 4 JlM. 
The window current of ligand-gated ion channels is the range of agonist 
concentrations at which receptors can be activated by agonists before 
desensitisation is complete (Steinbach, 1990). To provide an estimate of the 
window current for each a.4~2 receptor form, we replotted the desensitisation 
CRC obtained for ECso ACh test pulses and the activation concentration response 
curve of each receptor type on the same axes (Fig. 4.2B). The concentration 
range at which the activation and desensitisation curves overlap indicates the 
window current of receptors (Steinbach, 1990; Lester, 2004). Figs 4.2B and C 
show that for P2_a.4_P2_a.4_P2 receptors the window current extended from 
about 0.1 nM to 300 JlM ACh with the peak occurring at 0.1 JlM ACh. In 
contrast, for P2_a.4_P2_a.4_a.4 receptors stimulated by ECso ACh test pulses the 
window current was between 10 nM and 500 JlM ACh with the peak occurring at 
about 10 JlM ACh. At the peak of the window current only about 17% of the 
maximal response elicited by ACh at P2_a.4_P2_a.4_a.4 receptors was activated, 
whereas for P2 _ 0.4 _P2 _ 0.4 _P2 receptors the percentage of the maximal response 
stimulated was 24%. The EC501IC5o ratio for the two types of receptors differed 
by about 9-fold (p < 0.05; n = 4) (Table 4.1). Interestingly, the value of the 
EC50;ICso ratio for P2_a.4_P2_a.4_a.4 receptors varied depending on the 
concentration of the ACh test pulse used in the desensitisation experiments. 
When the ACh test pulse was 4 JlM the EC50;IC5o ratio was 7-fold lower than the 
ECsolICso values estimated for ~2_a.4_~2_a.4_a.4 receptors activated by higher 
concentrations of ACh test pulses (Figs., 4.2B and C;Table 4.1). Also, 
compared to test pulses of higher ACh concentrations, the peak of the window 
current obtained with 4 JlM ACh test pulses was approximately 7-fold lower (1.5 
JlM), and at this point only 10% of the maximal response to ACh was stimulated 
(Figs. 4.2B, C). 
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Figure 4.2. High-affinity desensitisation in concatenated (u4JJ2)2JJ2 and 
(a4JJ2)2a4 nA~hRs. (A) Representative traces obtained from P2_u4_P2_u4_ P2 
receptors using the desensitisation protocol described in Methods. Oocytes 
expressing p2_a4_p2_a4_p2 receptors were challenged at regular intervals (90 s) 
by a 2 s ACh test pulse of 2 /lM, a concentration of ACh near the ACh ECso at 
this receptor type. The control responses decreased in amplitude upon chronic 
exposure to low concentrations of ACh. (8) Activation and desensitisation CRC 
of p2_a4~2_a4_a4 or p2_a4~2_a4_p2 receptors. Activation and 
desensitisation curves obtained with ECso ACh test pulses are plotted on the 
same axis to reveal the window current for the a4p2 nAChR isoforms. The 
region where the activation and desensitisation concentration response curve 
overlap represents the window current of the receptors. We also include the data 
for the stimulation of p2_a4_p2_a4_a4 nAChRs with 4 /lM ACh (blue dots). 
Each activation and desensitisation data point represents the mean ± S.E.M of 4 -
6 independent experiments. Data were best fit to the monophasic Hill equation 
described in Methods (p < 0.00 I; n = 4-8). The estimated ECso, ICso and Hill 
coefficients values are summarised in Table J. (C) Detail of plot in B, showing 
the overlapping regions of the activation and desensitisation ACh CRe. 
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4.2.2 The ACh binding site at the u4(+)/u4(-) interface 
contributes to desensitisation 
Since agonist-induced desensitisation occurs following occupation of agonist 
sites (Steinbach 2000; Giniatullin et aI., 2005), impairment of the ACh binding 
site at the a4(+)/a4(-) interface by alanine substitution of a4W182 should affect 
desensitisation of ~2_a4_~2_a4_a4 receptors, if the additional ACh site 
contributed to it. To test the validity of this view, the ACh-induced 
desensitisation of ~2_ WI82Aa4_~2_ W182Aa4_ WI82Aa4 was first determined. As 
reported in the previous chapter, introducing a4W182A simultaneously into the 
three a4 subunits of ~2_a4_~2_a4_a4 receptors produces monophasic ACh 
sensitivity to activation by ACh and a seven-fold decrease in sensitivity to 
activation (Chapter 3; Mazzaferro et aI., 2011). Chronic exposure to low 
concentrations of ACh desensitised the current responses evoked by 700 J.lM 
ACh (a concentration near the ACh ECso of ~2_WI82Aa4J32_ W182Aa4_ W182Aa4; 
see Chapter 3 or Mazzaferro et aI., 2011). Compared to wild type, sensitivity to 
desensitisation was reduced significantly from 0.22 ± 0.04 J.lM to 60 ± 2.1 J.lM (p 
< 0.001; n = 6) (Fig. 4.3A) thus, impairment of agonist binding reduces 
sensitivity to desensitisation. As expected from this finding, the window current 
of ~2_ WI82Aa4_~2_ W182Aa4_ WI82Aa4 was shifted to the right (p < 0.001; n = 4) 
(Fig. 4.38). These results indicated that a4WI82A could be used to measure the 
contribution of individual agonist binding sites to desensitisation. 
It was shown in Chapter 3 that binding of ACh to the unaltered binding sites at 
the a4(+)/~2(-) subunit interfaces of p2_a4_p2_a4_ WI82Aa4 receptors gives rise 
to the higher sensitivity component of the activation concentration response 
curve, whilst the mutated site at the a4( + )/a4( -) interface contributes mostly to 
the low sensitivity component of the curve. Therefore, in order to provide 
estimates of desensitisation for intact and impaired agonist sites, the effects of 
prolonged exposure to ACh prepulses on the responses elicited by ACh test 
pulses of either ECso-1 (mostly intact agonist sites) ACh or ECSO-2 (intact agonist 
sites plus mutated agonist sites) ACh were measured. Representative current 
responses obtained for the p2_a4_p2_a4_ WI82Aa4 receptors using this protocol 
are shown in Fig. 4.3.A. The peak currents obtained with either of the ACh ECso 
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pulses were desensitised by ACh prepulses. For both ACh test pulses, 
desensitisation produced monophasic inhibition curves (p < 0.001; n = 5) (Fig. 
4.3B). However, the ICso values estimated from these curves were about 280-fold 
different (p < 0.05; n = 5) (Table 4.2). The mutated agonist site at the a4(+)/a4(-
} interface was less sensitive to desensitisation than the non-mutated agonist 
sites, which is consistent with the previous observation that impairment of ACh 
binding sites decreases sensitivity of a4~2 nAChRs to desensitisation (Fig. 
4.2A). Also, the ICso value estimated for the component with lower sensitivity to 
activation was about 41-fold greater compared to the ICso estimated for currents 
evoked by ECso ACh on wild type ~2_a4_~2_a4_a4 receptors. Interestingly, the 
estimated ICso at intact agonist sites (lCSO-I) was not statistically different from 
that estimated for ACh-induced desensitisation in ~2_a4~2_a4_~2 receptors 
(see Tables 4.1 and 4.2), or for desensitisation of the responses of 
~2_a4~2_a4_a4 receptors to 4 IlM ACh pulses. 
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Figure 4.3. Effect of W182A on the high-affinity desensitisation of 
P2 «4 ~2 «4 «4 rec~tors. (A) Wild type and mutant 
CP2_ wm A~4J32_WI 2Aa4_ 182Aa4 receptors) inhibition CRe. De en iti ation 
wa induced u ing a prolonged application of ACh test pulse protocol. The data 
were best fit to the monophasic Hill model described in Method. IC50 and Hill 
coefficient value are hown in Table 1 (wild type receptor ) or Table 2 (mutant 
receptor). (8) Plot of activation and inhibition CRC data plotted on the same 
axe .The area under the curve where the activation and desensitisation CRC 
overlap repre ent the window current of the receptor. 
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Table 4.2. Summary of ACh-induced desensitisation and activation of 
the three agonist sites of ~2_a4Jl2_a4_a4 receptors. EC50 or ICso values 
were detennined by fitting respectively the activation or inhibition data to the 
Hill equations given in Methods. ECso-1 and ICso-1 values correspond to the 
concentration response curve parameters estimated from the high sensitivity 
component of the curve, whilst ECSO-2 and ICso-2 are the parameters estimated 
from the low sensitivity component of the curve. Statistical differences between 
the values estimated for the agonist binding site at a4( + )/a4( -) and a4( + )/P2( -) 
interfaces were assessed as described in the Methods section. • denotes statistical 
comparisons between p2_a4_p2_a4_ WI82Aa4 and receptors with impaired 
a4(+)/p2(-) agonist sites. *, p < 0.05; .. , p < 0.001. + denotes statistical 
comparisons between mutant and wild type receptors. +, p < 0.05. 
Receptor ~2_W'.LAa4-P2_a4_a4 ~2_a4_~2_w'.LAa4_a4 ~2_a4_ ~2_a4_ WI.LAa4 
ECso.1 (~M) 1.8±0.02+ 1.20 ±0.03+ 28 ±2*'+ 
nH) 0.78±0.08 0.7I±O.06 0.74±0.09 
ICso.) (~M) 0.038±0.009+ 0.025±0.008+ 0.032±0.OO9+ 
nHin 0.54±0.01 0.48±O.08 0.5±0.02 
ECsolICso 47+ 48+ 875+ 
ECSO. 2 (~M) 630±71 640 ±65+ 3483±25*'++ 
nH2 1.3±0.5 1.4±0.7 1.8±1 
IC5o.2 (~M) 1.72±0.2+ 1.68 ±0.2+ 9±0.2*,+ 
nHin O.6±O.02 0.54±0.8 0.54±0.02 
ECsolICso 366 376 387 
In order to determine whether the ACh sites at a4(+)/p2(-) interfaces behave 
similarly to the additional site at the a4(+)/a4(-) interface in respect of sensitivity 
to desensitisation, we engineered mutant receptors P2_ WI48Aa4_p2_a4_a4 or P2_ 
a4J32_ W148Aa4_a 4 and detennined their sensitivity to desensitisation induced by 
ACh prepulses. As for mutant p2_a4J32_a4_ WI82Aa4 receptors, desensitisation 
associated with intact or mutant ACh sites was monitored by assaying the effects 
of ACh prepulses on currents evoked by either ACh ECso-1 or ACh ECSO-2 (Fig. 
4.4A, B). Introduction of a4Wl82A into any of the two agonist sites located at 
a4(+)/p2(-) interfaces altered wild type sensitivity to desensitisation induced by 
ACh. Patterns of desensitisation for intact or mutant agonist sites at 
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P2_ WI48AU4_P2_u4_u4 or P2_u4_P2_ W148AU4_u4 receptors were similar (Table 
4.2). Comparisons of desensitisation in the three mutant receptors showed that 
although ICso.1 values estimated for all three mutant receptors were not different 
from each other, ICso.2 values for mutant agonist sites located at u4( + )/~2( -) 
interfaces were approx. 7-fold lower than the ICso.2 value for mutant u4(+)/(-)u4 
agonist site (p < 0.05; n = 5 -7) (Table 4.2). 
A 
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Figure 4.4. Effect of impairing the ACh binding site at the u4(+)/u4(-) 
interface of P2_u4_P2_u4_u4 receptors on high-affinity desensitisation. (A) 
Representative traces showing the desensitisation of ACh currents evoked by 
ACh ECso-1 (non-mutated agonist sites) or ACh ECSO-2 (mutated u4(+)/u4(-) site), 
ACh prepulses were _ applied by adding ACh to the perfusing Ringer solution 
(dashed lines). (B) Desensitisation CRC of ACh ECso responses of mutated 
u4(+)/u4(-) ACh site or intact u4(+)/~2(-) sites. The peak currents evoked by 
ACh ECso-1 or ACh ECSO-2 measured at the end of the ACh prepulses, were 
normalised to control ACh currents (ACh currents evoked prior to application of 
prepulses). The data were best fitted to the monophasic Hill equation described 
in Methods (p < 0.001; n = 6). For comparison, the desensitisation concentration 
response curve for wild type is included ( dashed lines). 
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Figure 4.5. Mutant ACh agonist sites at a4(+)/p2(-) interfaces affect 
activation and high-affinity desensitisation of p2_a4~2_a4_a4 nAChRs. (A, 
B) Desen itisation CRC of ACh responses of mutated u4(+)/~2( -) and intact 
agonist ites in ~2_ WI82AU4_P2_u4_u4 or P2_u4_P2_ W182AU4_u4 receptors 
(W1 82u4 is indicated by a closed red circle). The peak currents evoked by ACh 
ECso-1 or ACh ECSO-2 measured at the end of ACh prepul e were normalised to 
control ACh currents (ACh currents evoked prior to application of prepulses). 
The data were best fit to the monopha ic Hill equation described in Method (p < 
0.002; n = 5). For compari son, the wild type desensitisation concentration 
re ponse curve was included (da hed line ). There i no significant difference in 
the activation or high-affinity de ensiti ation of P2_ WI 82AU4_P2_u4_u4 and 
P2_u4J32_WI 82AU4_u4 receptor . 
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4.3 Discussion 
All agonist sites In (a4p2)za4 receptors contribute to agonist-induced 
desensitisation. 
The desensitisation of a4p2 nAChRs is a complex process. Previous studies on 
a4p2 nAChRs of unknown stoichiometry have shown the existence of two 
desensitised states (Fenster et al., 1997; Buisson et al. 2000; Paradiso & 
Steinbach, 2011). Recovery from desensitisation is also biphasic, although a third 
desensitised state may also exist (Paradiso & Steinbach, 2003). High-affinity 
desensitisation and recovery from desensitisation of a4~2 nAChRs are both 
agonist-dependent, which is likely to reflect differential affinity of agonists for 
the desensitised states (Marks et al., 2010; Paradiso & Steinbach, 2003). The 
findings of this study add further complexity to the activation/desensitisation of 
a4p2 nAChRs by showing that the effects of a4W182A on desensitisation (and 
activation) are agonist site-specific. This strongly suggests that the agonist sites 
of (a4p2)za4 receptors have different sensitivity to both stimulation by ACh and 
high-affinity desensitisation. Moreover, the observation that impairment of any 
of the agonist sites by a4 W 182A produced biphasic sensitivity to activation and 
that a small fraction (less than 10%) of the maximal ACh response desensitised 
with higher sensitivity than greater response fractions suggests that two agonist 
sites, or perhaps one, when engaged by agonist, can lead to activation and then 
desensitisation with a sensitivity that is different from that observed with full 
occupancy. Thus, it appears that the agonist sites in (a4p2)za4 receptors are not 
functionally equivalent. 
Functional differences between the agonist sites in (a4p2)za4 nAChRs may arise 
from structural differences between the agonist sites and downstream pathways 
producing the coordinated motions triggered by agonist binding that lead to 
gating (Aucrbach, 2010). The primary face in the agonist site at a4(+)/a4(-) and 
a4( + )/P2( -) interfaces are identical but the complementary face is not. In the case 
of the agonist site at the a4(+)/a4(-) interface, the complementary face is 
contributed by the (-) face of the adjacent a4 subunit. Studies of GAB AA 
receptors, which are endowed with two structurally identical agonist sites, have 
shown that even structurally identical agonist sites may function non-
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equivalently (Baumann et aI., 2003). In the case of GABAA receptors, non-
equivalency may arise from differences in the subunits flanking each agonist site, 
which could produce agonist-site specific conformational transitions and hence 
agonist-site specific activation and/or desensitisation states (Baumann et aI., 
2003). However, previous studies of the muscle nAChR, which is the prototype 
protein for the pentameric ligand-gated ion channel family, have shown that even 
though the two agonist sites have different complementary subunits (0 or y/f.) 
and, thus, different structural properties, they are functionally comparable, with 
each having approximately the same affinity for ACh regardless of the 
conformational state (i.e., open or close) of the receptor (Jha & Auerbach, 2010). 
Incorporation of a4WI82A into any of the agonist binding sites decreased 
sensitivity of the site to both activation and desensitisation, but the effects were 
more striking on activation, consistent with the key role of a4WI82 in ACh 
binding (Corringer et aI., 1998; Mazzaferro et aI., 2011). The effect of a4WI82 
on desensitisation confirms earlier findings that high-affinity desensitisation is 
partly influenced by amino acid residues in the N-terminal domain of the a4 
subunit. Other regions that have also been implicated in high-affinity 
desensitisation are transmembrane domains M2 (Bertrand et a1. 1998;) M 1 and 
M3 (Kuryatov et aI., 2000). The mechanism connecting the open receptor states 
to the desensitised states are not fully understood (Auerbach, 2010). Recent 
studies on the a7 nAChR have suggested that desensitisation of nAChRs may be 
governed by the balance between agonist binding, coupling and gating (Zhang et 
aI., 2011). According to this proposal agonist binding induces conformational 
changes in the coupling region (N terminal loops 2 and 7 with M2-M3 linker 
from the transmembrane domain) that generate sufficient energy to overcome the 
gating energy barrier to open the channel. However, the coupling region tends to 
uncouple due to instability of the open state conformation, as compared to the 
closed state, triggering desensitisation (Zhang et aI., 20 11). This possibility is 
consistent with our finding that weakening agonist binding by incorporation of 
W 182A in P2 _ a4 _P2 _ a4 _ a4 receptors decreases sensitivity to desensitisation. 
Presumably, WI82A decreases coupling strength, which would in turn affect the 
critical balance between coupling and gating towards a decrease in sensitivity to 
desensitisation. 
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Considering the activation and desensitisation of (a4~2ha4 nAChRs m 
comparison to (a4~2)2~2 nAChRs, it seems that full agonist occupation m 
(a4~2ha4 nAChRs decreases sensitivity to both activation and desensitisation. 
Recent studies on a7 nAChRs assembled from «5-Chloro-2,4-
dimethoxyphenyl)-N-(5-methyl-3-isoxazolyl)-urea)-sensitive (PNU-120596) and 
PNU-120596-resistant a7 subunits have suggested that heteromeric receptor 
desensitisation is determined by the fastest desensitising subunit (Dacosta & 
Sine, 2013). Since our data suggest that engagement of two binding sites by 
agonist activates and desensitises (a4~2)2a4 nAChRs with sensitivities typical of 
{a4~2)2~2 nAChRs, it seems that for (a4~2)2a4 nAChRs occupation of the third 
agonist site modulates the function of the two other agonist sites by decreasing 
their sensitivity to high affinity desensitisation. This modulatory effect could be 
exerted at the gate or could be transmitted to the adjacent binding sites to affect 
agonist binding, and hence, the energy transitions leading to gating. Modulation 
of the function of two agonist sites by a third agonist site has been previously 
observed in homomeric 5-HT3-a7 chimeric receptors, although in this receptor 
construct full occupancy increases sensitivity to activation and possibly to 
desensitisation (Rayes et aI., 2009). 
It is difficult to propose a kinetic scheme that could represent adequatedly the 
activation and desensitisation of the (a4~2ha4 receptors because the data shown 
here cannot provide estimates of the affinity of each type of agonist site for the 
various states of the receptors, including closed, open and desensitised, or give 
insights on how these various states are connected. Single channel analysis of the 
activation and desensitisation of this receptor type should help to address this 
issue. Notwithstanding this lack of detail, the data strongly suggests that 
occupancy of two agonist sites is sufficient to activate and desensitise the 
(a4~2ha4 nAChR and that full occupation adds an additional active and 
desensited state. From the findings, these additional states are likely to be 
reached at concentrations of ACh that produce more than 10% stimulation of the 
maximal response, from which point receptor function appears to be 
predominantly shaped by the modulatory activity exerted by the third agonist site 
over the two other agonist sites. 
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Finally, studies of mouse native thalamic a4~2 nAChR receptors which show 
biphasic agonist CRC for stimulation of putative (a4p2)2a4 and (a4p2hP2 
nAChR function, have suggested that (a4~2ha4 and (a4~2hP2 receptors have 
similar sensitivity to high-affinity desensitisation, although the receptors differ in 
their window current due to differences in agonist sensitivity (Marks et aI., 
2010). We found that the receptors desensitise with different sensitivities. 
Although possible artifacts introduced by concatenation cannot be discarded, our 
findings may differ from those reported by Marks et aI., (2010) because native 
a4p2 nAChR function reflects stimulation of (a4~2ha4, (a4p2hP2 and 
(a4p2ha5 nAChRs (Marks et aI., 2010; Gotti et aI., 2008; Grady et aI., 2012). 
In summary the ACh site at the a4(+)/a4(-) interface confers distinct sensitivity 
to activation and slow desensitisation by ACh to (a4p2ha4 receptors which 
further supports our view that this site is responsible for the functional signatures 
of the (a4p2)2a4 nAChR. The additional agonist site is not functionally 
equivalent to the sites located at the a4( + )/P2(.) interfaces and this may be what 
determines the properties of this receptor type compared to the isoform 
(a4p2)2p2. The additional site not only contributes to global receptor activation 
and slow desensitisation but also appears to modulate the function of the agonist 
sites located at the a4( + )/P2( -) interfaces. Finally, slow desensitisation is likely to 
play an important role in modulating the duration and conducting states of the 
alternate a4p2 nAChRs and hence their effects in integrated neuronal behaviours. 
Indeed, the slow desensitisation profiles of the a4p2 nAChRs have important 
consequences for the window current of the alternate a4p2 receptors. The 
ECsolICso ratio for (a4~2ha4 receptors is much higher than that for (a4p2hP2 
receptors, which suggests that a4p2 nAChR activity through the (a4p2hP2 
isoform would be more prominent under conditions of prolonged exposure to 
low concentrations of ACh, as it occurs through volume transmission. 
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The ligand selectivity of the agonist site 
at the a4( + )/a4( -) interface of the 
(a4~2)2a4 nAChR revealed by cysteine 
substitution accessibility method 
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5.1 Introduction 
(a4p2)za4 and (a4p2)2p2 receptor isoforms respond with different sensitivity to 
nicotinic competitive compounds (Moroni et aI., 2006; Zwart et aI., 2008; 
Carbone et aI., 2009; Mazzaferro et aI., 2011) (for a summary of available data, 
see Table 1.1). In Chapter 3, it was shown that the additional agonist site that 
operates from the a4(+)/a4(-) interface determines the signature ACh sensitivity 
of (a4p2)2a4 receptors (see also, Mazzaferro et aI., 2011; Harpsoe et aI., 2011). 
The site is located at a position homologous to the ACh binding sites housed by 
a4( + )/P2( -) interfaces, and homologous amino acid residues of a4 and P2 
subunits form the agonist binding site pocket, which suggests that all agonist 
sites in (a4p2)2a4 receptors share similar functional properties. However, 
pharmacological studies that showed the potency and efficacy of agonists ACh, 
Cyt and Saz-A at (a4p2)za4 nAChRs lacking the a4(+)/a4(-) interface is 
(a4p2)2p2 nAChR-like (Chapter 3; Mazzaferro et aI., 2011), suggest different 
functional properties for the two types of agonist sites, which most likely 
accounts for the pharmacology of (a4p2)2a4 nAChRs (Moroni et aI., 2006; 
Carbone et aI., 2009). Therefore, if we are to fully understand the structural 
determinants and molecular mechanisms underlying the agonist sensitivity of 
(a4p2)2a4 receptors, it is necessary to determine the functional sensitivity of the 
additional site to nicotinic compounds. In work reported in this chapter, a free 
cysteine residue was introduced in the complementary face of the agonist site at 
the a4( + )/a4( -) face in order to apply the SCAM method to characterise for the 
first time the competitive ligand selectivity of the agonist site at the a4( + )/a4( -) 
interface. The rate of reaction, between the cysteine and MTSET, in the absence 
or presence of nicotinic ligands was measured to determine the ability of the 
ligands to recognise the site. It is demonstrated that the agonist site at a4( + )/a4( -) 
and a4( + )/P2( -) interfaces display di fferent properties for agonists and that this 
difference defines the overall agonist selectivity profile of the receptor, as 
compared to (a4p2)2p2 nAChRs. The findings suggest that the relative efficacy 
of agonists at (a4p2)2a4 receptors is defined by both their ability to recognise the 
agonist site at the a4( + )/a4( -) interface and by agonist-specific interactions with 
residues on the agonist binding pocket. The findings add another level of 
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complexity to the molecular mechanisms that define ligand efficacy in the 
pentameric ligand-gated ion channel family. 
5.2 Results 
5.2.1 Pharmacological characterization of P2_u4_P2_u4TI52C_u4 
receptors 
The nicotinic pharmacology of the agonist site at the a4(+)/a4(-) interface was 
examined by determining if a4p2-preferring ligands could impede the reaction 
between MTSET and a free cysteine residue (a4T152C) introduced by single 
point mutation into loop E of the agonist site at the a4(+)/a4(-) interface. a4T152 
occupies a position homologous to P2L146 in the agonist sites at a4(+)/p2(-) 
interfaces. Previous studies by Papke et aI., (2011) showed that neither P2L146C 
nor a4T152C have significant impact on the function and expression of a4p2 
nAChRs, and that both are accessible to modification by MTS reactions. Oocytes 
were injected with the mutant or wild type receptor cRNAs and were assayed for 
ACh and other nicotinic ligands responsiveness using two-electrode voltage 
clamp. 
ACh, Cyt, Var, TC-2559 and Saz-A elicited currents from oocytes expressing 
p2_a4_p2_a4T152C _a4 receptors, indicating that the T152C substitution was 
tolerated and yielded functional receptors (Fig. 5.1). The maximal macroscopic 
currents elicited by ACh, Cyt, Var, TC-2559 and Saz-A at p2_a4_p2_a4T152C_a4 
receptors were similar to wild type. Compared to wild type, a4T152C did not 
change the monophasic responses to ACh, Cyt, Var or TC2559 (Fig. 5.1, Table 
5.1). Compared to wild type, a4Tl52C had no effects on the potency or efficacy 
of agonist Cyt or competitive antagonist DhPE, but the potency of ACh 
decreased by 2.4-fold and the potency of Var and TC-2559 increased by 4-fold 
and 2-fold, respectively (Table 5.1). These effects are modest, which together 
with the lack of effect on functional expression and maximal macroscopic 
currents warranted the use of a4Tl52C for the ligand protection assays described 
below. 
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To test if the pattern of agonist responses found for P2_u4_P2_u4T152C_u4 
receptors was agonist-site specific, p2L146C was introduced on the homologous 
position on the agonist site on the u4( + )P2( -) interface farthest from the 
u4(+)/u4(-) interface (Fig. 5.3), and consequences of this substitution on the 
effects of ACh, Cyt Var or TC-2559 were studied. As shown in Fig. 5.1 and 
Table 5.1, ACh produced biphasic activation in p2L146C_u4J32_u4_u4 receptors 
(p < 0.0001; F 9.826), even though the confidence interval for estimated high-
sensitivity EC50 value was broad. The estimated EC50 value for the high 
sensitivity component (EC50-1) of the curve was 69 (2-2296) J.1M, whilst for the 
low sensitivity component (EC50-2) the value was 1600 (1180-2203) J.1M. It has 
been shown previously that impairment of any of the agonist sites in 
P2_u4_P2_u4_u4 receptors by alanine or cysteine substitution of conserved 
aromatic residues in loop B or C leads to biphasic ACh concentration responses 
comprising a high sensitivity component contributed mostly by intact agonist 
sites and a low-sensitivity component contributed by intact and impaired sites 
(Mazzaferro et aI., 2011). Unlike P2_u4_P2_u4TI52C_u4 receptors, 
p2L146C_u4J32_u4_u4 receptors displayed wild type sensitivity for Var but 
reduced sensitivity for Cyt and TC2559. Agonist relative efficacy was 
comparable at wild type and P2_u4_P2_u4T152C_u4 receptor, (Table 5.2). These 
findings indicate that the agonist sites at u4(+)/u4(-) and u4(+)/P2(-) sites have 
different sensitivity for agonists. 
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Figure. 5.]. Functional sensitivity of p2_a4_p2_a4T152C_a4 receptors to 
nicotinic ligands. All compounds tested produced monophasic concentration 
responses curves (A-I). For comparison, the ACh concentration-response curve 
at p2 L146 _ u4_P2_u4_u4 receptors is shown (F). p2 L146C_u4_ P2_ u4_ u4 receptors 
ACh produced a biphasic concentration response curve. Data points represent the 
mean of at least four independent experiments. The mean of the Imax ± SEM for 
4-10 experiments for each receptor were as follow: P2_u4_ P2_u4_u4, (ACh, 386 
± 77 nA), (Cyt, 241 ± 71 nA), (Var, 464 ± 123 nA), (TC-2559, 203 ± 32 nA); 
P2_u4_ p2_ u4TJ 52 _u4, (ACh, 532 ± 103 nA), (Cyt, 292 ± 70 nA), (Var, 373 
± J 12 nA), (TC-2559, 304 ± 87 nA); p2L146C_u4_P2_u4_u4, (ACh, 265 ± 42 nA) . 
Data were fitted by nonlinear regression as described in Chapter 2. 
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Table 5.1. Summary of agonists/antagonist effects on wild type and 
mutant p2_a4.Jl2_a4_a4 nAChRs. Data are the mean (Cl 95%) of 4 -10 
experiments ECso and ICso values were estimated from monophasic concentration 
response curves, whereas ECso land ECso 2 were estimated from biphasic 
concentration-response curves. All values are expressed in JlM. *Values are 
significantly different from wild type, p< 0.05 (Students I-test). 
~2_a4_~2_a4_a4 ~2_a4~2_a4 112c_a4 ~2L'4~_a4_~2_a4_a4 
EClO ECso ECso ECSO_I ECSO_2 
ACh 86 (57-116) 206 (75-337)· 69 (2-2296) 1600 ( 1180-2203) 
Cyt 7.3 (2.4-12) 11 (4.6-17) 19 (11-26)· 
Var 9.5 (S.4-13.6) 2.4 (1.5-3.3)· 8.7 (4-13) 
TC-2559 6 (3.7-8.5) 3 (1.6-4.5)· 12.7 (9.4-16)· 
Dhl3E 0.28 (0.24-0.33) ( lCso) 0.25 (0.07-0.43) ( ICso) 
Table 5.2. Relative efficacy of agonists at p2_a4_p2_a4TIS2C_a4, and 
p2_a4.Jl2_a4_H142Aa4 receptors compared with wild type 
p2_a4.Jl2_a4_a4 receptor. Data are the mean (Cl 95%) of 4-11 experiments. 
Significant differences were determined using one way ANOVA tests (**p < 
0.01, ***,p < 0.001). 
/32_a4_/32_a4_a4 /32_a4_/32_a4 "lL_a4 p2_a4~2_a4 114ll\_a4 
Relative Efficacy lmaxllACh_max I maxll ACh _ RlIX l ma.1I ACh _ ma. 
Cyt 0.19 (0.18-0.20) 0.21 (0.09-0.34) NO 
Var 0.29 (0.14-0.44) 0.22 (0.16-0.28) NO 
TC-2559 0.22 (0.16-0.27) 0.12 (0.07-0.17) 0.83 (0.76-0.90)··· 
SazA 0.11 (0.08-0.14) 0.10 (0.05-0.14) 0.55 (0.42-0.68)··· 
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5.2.2 MTSET effects on u4T152C 
To detennine the accessibility of the introduced cysteine to MTSET, 
p2_a4_p2_a4TlS2C_a4 receptors were exposed to ImM MTSET for 120 s (Fig. 
5.2). Application of 1 mM MTSET for 120 s had no effect on the ECso ACh 
responses of p2_a4_p2_a4_a4 receptors (Fig. 5.2; Table 5.3), showing that any 
effects observed in p2_a4.J32_a4TlS2C_a4 receptors were caused by MTSET 
reactions. MTSET modification ofp2_a4.J32_a4TlS2C_a4 receptors decreased the 
maximal responses of ACh by 43% (Fig. 5.2; Table 5.3). MTSET also reduced 
the maximal ACh responses of p2L146C_a4_p2_a4_a4 receptors, although its 
effects on this mutant receptor were more pronounced (71 %) (p < 0.03; n =6) 
. (Fig. 5.2; Table 5.3), further indicating functional differences between the 
agonist sites at a4(+)/a4(-) and a4(+)/p2(-) interfaces. Application of MTSET 
also significantly decreased the maximal responses of p2_a4_p2_a4TIS2C_a4 
receptors to Cyt and Var; the effects were similar for these agonists (-50% 
reduction), whereas the maximal current responses of TC-2559 were increased 
by 58% (p < 0.0001; n = 5) (Table 5.4). No further changes in agonist responses 
were observed with longer periods of MTSET exposure. Exposure to the 
reducing agent DTT (1 mM) for 2 min reversed the effects of MTSET for all 
agonist tested (Fig. 5.3B), demonstrating that the changes in the amplitude of the 
responses to agonists were due to MTSET reaction with a4T152C. 
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Figure 5.2. Effect of MTSET on the ACh responses of wild type and 
mutant P2_u4_P2_u4_u4 receptors. The percentage change in the responses 
elicited by ACh ECso concentrations on wild type and 5 x EC50 on the mutant 
~2_a4_~2_a4TI S2C_a4 and ~2L146C_a4_(32_a4_a4 receptors after 2 min 
applications of I mM MTSET is defined as [(1after MTS/ Iinitial)-I) x 100], 
where I indicates the current responses to agonists. The negative values represent 
an inhibition of the ACh responses after MTSET application. Data represent the 
mean from at least four independent experiments. 
Table 5.3. Effects of MTSET on ACh responses of wild type and mutant 
p2_a4JJ2_u4_u4 receptors. The percentage change in the responses elicited by 
5 x EC50 agonist concentrations on wild type and mutant (32_a4_(32_a4_a4 
receptors after a 2 min applications of I mM MTSET is defined as [(falter MTS/ 
Iinitial)-l) X 100], where I are the current responses to agonist. Negative values 
represent an inhibition of agonist responses after MTSET reaction. Data are the 
mean (95% Cl) for 4 -10 experiments. Significant differences were determined 
using one way ANOVA tests (**p < 0.01 , *** , p < 0.001). 
% Change of ACh responses MTSET reaction 
~2_a4J32_a4_a4 p2_a4_p2_a4, I)<L_a4 ~2 L I '~_a4_~2_a4_a4 
-0.13 (-8, +8) -43 (-56, -30)·· -71 (-87, -56)" · 
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Figure 5.3. Effects of MTSET on maximal nicotinic agonist currents. (A) 
Representative traces of the maximal responses elicited by ACh, Cyt, Var and 
TC-2559 at ~2_a.4J32_a.4TI52C_a.4 before and after MTSET reaction. MTSET 
reduce the maximal response of all agonist tested except that of TC-2559, which 
was increased. The effects of MTSET on the responses of all agonists were 
reversed after 2 min exposure to I mM DTT. The diagram immediately above 
the traces shows the steps of the MTSET application protocol used. (B) 
Histogram showing the percentage change in the amplitude of the agonist 
responses after MTSET application. The percentage change in the responses to 
agonists is defined as [(Iafter MTS/ Iinitial)-l) x 100]. Negative values represent 
an inhibition of the responses to agonists after MTSET reaction, whereas positive 
values represent an increase in the agonist responses after MTSET reaction . Data 
represent the mean of at least four independent experiments. 
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Table 5.4. Effects of MTSET on agonist responses of wild type and 
mutant p2_a4_p2_a4_a4 receptors. The percentage change in the responses 
elicited by 5 X ECso agonist concentrations on wild type and mutant 
p2_a4_p2_a4T1S2C_a4 receptors after a 2 min applications of 1 mM MTSET is 
defined as [(Iafter MTS/ Iinitial)-I) x 100]. Negative values represent an 
inhibition of agonist responses after MTSET reaction, whereas positive values 
represent an increase of the agonist responses after MTSET reaction. Data are the 
mean (95% Cl) for 4 -10 experiments. Significant differences were determined 
using one way ANOVA tests (* < 0.05, **p < 0.01, ***, P < 0.001). 
% Change of IAgonist after application 
of 1 mM MTSET for 120s 
p2_a4_p2_a4_a4 
ACh -0.13 (-8, +8) 
p2_a4_p2_a4' "lc_a4 
ACh -43.00 (-56, -30)** 
Cyt -51 (-69, -32)*** 
Var -43 (-64, -22)*** 
TC-2559 +58 (+29, +87)*** 
SazA NO. 
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5.2.3 MTSET reaction rates 
The rates at which MTSET modified the engineered a4I152C were determined 
by measuring the effect of sequential applications of 1 ~M MISEI on the 
responses elicited by the application of 5 s pulses of 5 x EC50 ACh. As these 
reactions were used as controls to assess the effects of a4~2 receptor agonists or 
the competitive antagonist Dh~H on rates of MTSET reaction, the responses of 
ACh used to measure the rates of MISEI reaction were stabilised in the 
presence of nicotinic ligand to ensure that any changes in the responses to ACh 
pulses observed during the protection assays were attributed to MISET reaction 
rather than to processes such as agonist-induced desensitisation or open channel 
. block. Under these conditions, the estimated control rates of MISEI reactions 
were not significantly different from each other (Table 5.5), indicating that the 
effects of MISEI were due to its reaction with a4I152C. Ihe maximum effect 
of 1 ~M MISEI (the plateau of the decay curves) for each of the control curves 
shown in Fig. 5.4 was comparable to that obtained following application of 1 
mM MISEI (Fig. 5.4, Table 5.4). Evidence for MISET modification of 
~2L146C _a4_~2_a4_a4 receptors was observed by using a lO-fold higher 
concentration of MISET and the ECso_2 ACh for the low sensitivity component 
of the ACh concentration response curve. Under these conditions, the control rate 
of MISEI reaction estimated for ~2L146C_a4_~2_a4_a4 receptors was 3-fold 
slower than the corresponding rate estimated for ~2_a4_p2_a4T1S2C_a4 receptors 
(Fig. 5.4G; Table 5.4). 
5.2.4 Effect of nicotinic Jigands on MTSET reaction rates 
To determine the nicotinic ligand selectivity of the agonist site at the a4( + )/a4( -) 
interface, the rate of modification of a4I152C by low concentrations of MISEI 
(1 ~M) was measured in the absence and presence of 5 X EC50 concentrations of 
either ACh, Cyt, Var, IC-2559, Saz-A or Dh~E. The MISEI reaction rates were 
markedly slower in the presence of ACh, Cyt or Var such that not even after 90 s 
of co-application the MTSEI reaction reached completion (Fig. 5.4; Table 5.5). 
Ihe rate of MISEI modification was also markedly slower in the presence of 
the antagonist Dh~E, indicating that the effects of the agonist used in the 
protection assay slowed down MISET reactions by impeding MISEI 
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modification of a4Tl52C rather than by indirect effects through agonist-induced 
conformational changes in the agonist binding site. In contrast, co-application of 
TC-2559 or Saz-A had no effects on the rate of MTSET modification (Fig. 5.4; 
Table 5.5), indicating that neither of these agonists can impede MTSET 
modifying a4T152C. 
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Figure 5.4. Rates of MTSET modification of p2_a4_p2_a4T152C_a4 
receptors in the presence and absence of nicotinic Iigands. Normalised ACh 
currents in the absence and presence of ACh (A), Cyt (B), Var (C), Saz-A (D), 
TC-2559 (E), DhPE (F) were plotted versus cumulative time of MTSET (1 JlM 
each 10 s) and fit with single exponential functions. Data were normali sed to 
ACh current measured at time 0 and are the mean ± SEM of at least 4 
inde£endent experiments. For comparison the rate of MTSET modification of 
~2L1 6c_a4_~2_a4_a4 receptors in the presence and absence of ACh is shown in 
(G). Note the difference in the decay of p2 L1 46C_a4_p2_a4_a4 (k l 0.032 S-I) and 
P2 a4 P2 a4TI 52C a4 receptors (kl 0.10 (0.061-0.14) S-I). The exponential 
de~ay dueto MTSET treatment was slower in the p2 L1 46C_a4_p2_a4_a4 than the 
p2_a4_p2_a4TI52C a4 receptor, even using a concentration of MTSET 10 times 
higher in the p2L f46C_a4_p2_a4_a4 receptor (cumulative time of MTSET (l0 
JlM each 10 s,». 
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Table 5.5. First (kl) and second (k2) order rate constants for reaction of 
MTSET with p2_a4J2_a4TI52C_a4 receptors in the absence and presence of 
nicotinic Iigands. Data are the mean (95% Cl) for 4 -10 experiments. Significant 
differences were detennined using Student's I-tests. (*p < 0.05). 
Control Protection Assay 
Ligands kl (5- 1) k2 (M-I S-I) kl (5- 1) k2 (M-Is-I) k2-<ODtro11k2-test 
ACh 0.10 (0.061-0.14) 100000 0.021 (0.0016-0.040)" 21000 4.8 
Cyt 0.22 (-0.11-0.56) 220000 0.0064(0.0029-0.0099)" 6400 34.4 
Var 0.16 (-0.027-0.34) 160000 0.027(0.0026-0.052)" 27000 5.9 
TC-2559 0.10 (-0.052-0.26) 100000 0.12( -0.037-0.28) 120000 0.83 
Saz-A 0.13 (0.12-0.14) 130000 0.15 (0.039-0.25) 150000 0.87 
Dh~E 0.087 (0.039-0.14) 87000 0.0037 (0.0015-0.0059)" 3700 23.5 
5.2.5 a4H142 excludes TC-2S59 and Saz-A from the agonist site 
at the a4(+)/a4(-) interface 
In an attempt to explain the nicotinic ligand selectivity of the agonist site at the 
a4( + )/a4( -) interface, docking calculations with the ligands on a structural 
homology model of the a4(+)/a4(-) interface were carried out. As anticipated 
from the findings of the protection assays, ACh, Cyt and Var were found to 
occupy the agonist site (Fig. 5.5). In contrast neither TC-2559 nor Saz-A were 
able to enter the binding site. 
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A 
ACh Vir Cyl 
B c D 
E F G 
a4(+)/a4(- ) binding site 
Figure 5.5. Docking of nicotinic ligands to 04(+)/04(-) and 04(+)/P2(-) 
interfaces in a (04p2)2n4 receptor homology model. (A) Stick representations 
of the ACh, Var and Cyt. Single docking of ACh, Cyt and Var, at the 04(+)/04(-) 
(B, C, D, respectively) and a4(+)/p2(-) (E, F, G, respectively) interfaces. (H) 
Superimposition of ACh, Cyt and Var docking to a4( + )/a4( -) interface of the 
(04P2)2U4 receptor homology model. 
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As previous radioligand binding studies have shown that both TC-2559 
(Bencherif et aI., 2000) and Saz-A (Xiao et aI., 2006) compete with high affinity 
for native or recombinant a4p2 nAChRs, the findings suggest these ligands 
stimulate (a4p2)2a4 receptors by engaging the agonist sites at a4( + )/P2( -) 
interfaces. Consistent with this possibility, TC-2559 and Saz-A were found to 
bind a structural homology model of the agonist site at the a4( + )/P2( -) interfaces 
(Fig. 5.6A, B). 
In a further attempt to understand the agonist site selectivity of TC-2559 and 
Saz-A a non-occupied a4(+)la4(-) agonist site was superimposed on a a4(+)/p2(-
) agonist site engaged by TC-2559 or Saz-A (Fig. 5.6A). In accord with Harpsl2le 
et aI., (2011), three differing residues in the complementary face of the two types 
of agonist sites were found. These are a4H142, a4Q150 and a4T152 on the 
a4(+)/a4(-) interface and P2V136, P2Fl44 and P2L146 on the a4(+)/p2(-) 
interface. Of these, P2V136 provides more favourable hydrophobic contacts with 
TC-2559 or Saz-A than a4H142, the residue on the equivalent position on the 
a4(+)/a4(-) interface, (Figs. 5.6A, B). It could be that a4H142 causes 
unfavourable polarlhydrophobic interactions with TC-2559 and Saz-A which 
hinder them from occupying the site. To test this possibility, alanine was 
substituted for a4H142 in the complementary face of the agonist site at the 
a4( + )/a4( -) interface, and the functional consequences of this substitution on the 
sensitivity of P2~4_p2_a4HI42A_a4 to TC-2559 and Saz-A were measured. If 
H142 impedes TC-2559 and Saz-A accessing the agonist site in the a4(+)/a4(-) 
interface, its replacement by alanine should allow occupancy, and hence, an 
increase in the efficacy of these two compounds at (a4p2)2a4 receptors. Figs. 
5.6D and E show that stimulation of P2_p4~2_a4HI42A_a4 by TC-2559 and Saz-
A produced maximal currents that were 6- and 12-fold greater than wild type, 
respectively (Fig. 5.6D, E). Additionally, the activation effects of these 
compounds were monophasic and more potent than wild type. 
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Figure 5.6. Superimposition of a4(+)/p2(-) bound to Saz-A and TC-2559 
and unbound a4(+)/a4(-) interfaces of a (a4p2)2a4 receptor homology model. 
Superimposition of structural homology models of non-occupied a4(+)/a4(-) 
interface with a4(+)/~2(-) interface engaged by Saz-A (A) or TC-2559 (B) shows 
that a4H142 is in lieu of~2V136 in the complementary face of the a4(+)/a4(-) 
interface. (In each view ~2V136 and a4H142 are shown as sticks. (C) 
Simultaneous superimposition of the dockings of TC-2559 and Saz-A shows that 
both agonists occupy the same region of the a4(+)/~2(-) binding site. Functional 
effects of Saz-A (D) and TC-2559 (E) on wild type and ~2_a4_~2_a4HI42A _a4 
receptors. Representative traces are shown next to CRC. Alanine substitution of 
H142 in the complementary face of the agonist site at the a4(+)/a4(-) interface 
increases markedly the efficacy and potency of TC-2559 and Saz-A, compared to 
wild-type. 
123 
Chapter 5 
5.3 Discussion 
This chapter combined the concatenated nAChR and SCAM approaches to 
address the question of whether or not the agonist sites on the (a4~2ha4 nAChR 
are functionally non-equivalent, and whether non-equivalency accounts for the 
signature efficacy of nicotinic agonists at (a4~2)2a4. For the homologous glycine 
receptor (Lape et al., 2009) and muscle nAChR (Mukhtasimova et al., 2009), 
both of which have functionally equivalent agonist sites, it has been proposed 
that agonist efficacy is defined by the ability of agonists to achieve flipped or 
priming states that immediately precede channel opening. This study shows that 
in the case of (a4~2ha4 nAChRs, which possess three operational and 
functionally non-equivalent agonist sites, agonist efficacy is also defined by the 
ability of agonists to recognise all three agonist sites. This finding thus adds 
another level of complexity to the mechanisms leading to ion channel gating in 
the family ofpLGIC 
The agonist sites at a4( + )/a4( -) and a4( + )/~2( -) interfaces display differing 
agonist selectivity. The agonist site at the a4(+)/a4(-) interface binds ACh, Cyt, 
Var but excludes TC-2559 and Saz-A. In contrast, the agonist sites at a4(+)/~2(-) 
interfaces have been previously shown to bind ACh, Cyt and Var (Tavares et al., 
2012) and, as suggested by several lines of experimental evidence, also bind TC-
2559 and Saz-A. First, TC-2559 and Saz-A partially activate ~2_a4J32_a4_a4 
receptors and treating ~2_~4_~2_a4Tl52C_a4 receptors with MTSET, which 
knocks out the agonist site at the a4(+)/a4(-) interface without apparently 
affecting a4( + )/~2( -) interfaces, did not abolish the agonist effects of these 
compounds. This is in accord with previous findings that have shown that the ion 
channel in (a4p2ha4 receptors can open efficiently when only the sites at 
a4( + )/~2( -) interfaces are occupied (Mazzaferro et al., 2011). Second, 
radioligand binding studies have shown that both TC-2559 (M Bencherif et al., 
2000) and Saz-A (Xiao et aI., 2006) compete with high affinity for native or 
recombinant a4~2 nAChRs, indicating that these agonists recognise the agonist 
sites at a4(+)/~2(-) interfaces. In the homologous muscle nAChR, there is 
evidence for differences between the two agonist sites in the resting closed state 
(Blount & Merlie, 1989; Sine et al., 1990; Edelstein et al., 1997; Prince & Sine, 
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1998) but for functional equivalency between the sites in the open and 
desensitised states (Martinez et aI., 2000; Tantama & Licht, 2009) or in the 
resting closed and open active confonnations (Jha & Auerbach, 2010). It has also 
been found that structurally identical agonist sites in another homologous 
protein, the GABAA receptor, interact with GABA, muscimol and bicuculline 
with subtly different selectivity (Baumann et aI., 2003). 
Functional differences between the sites were also revealed by agonists capable 
of entering both types of sites. A saturating concentration of MTSET reduced the 
efficacy of ACh by 43% in ~2_a4_~2_a4T152C_a4 but by 71% in 
~2L146C_a4_~2_a4_a4 receptors. a4T152C on the complementary face of the site 
at the a4(+)/a4(-) interface caused a slight decrease in sensitivity to ACh but 
~2L146C on the homologous position on the a4( + )/~2( -) interface produced 
biphasic sensitivity to activation by ACh. Whilst a4T152C had no significant 
effects on sensitivity to Cyt, ~2L146C reduced it by almost three-fold, and 
a4T152C increased sensitivity to Var by four-fold but ~2L146C had no effects. It 
was also found that the first rate of reaction (k)) estimated for MTSET 
modification of ~2_a4_~2_a4T152C _a4 receptors was faster than for modification 
of ~2L146C_a4J32_a4_a4 receptors, even though the concentration of MTSET 
used for modifying "a4T152C was lO-fold lower, thus indicating that ~2L146C on 
a4(+)/~2(-) interface is less accessible to MTSET than its homologue on the 
a4( +)/ a4( -) interface. 
Residues on the complementary face of the sites play a critical role in defining 
the ligand selectivity of the agonist sites in ~2_a4_~2_a4_a4 receptors. Because 
the principal face is fonned by a4 subunits at both types of agonist sites, binding 
interactions between agonist-binding residues and the agonists are expected to be 
similar for both types of agonist sites. In contrast, the complementary site is 
fonned by an a4 subunit at the site on the a4(+)/a4(-) interface and a ~2 subunit 
at the site on a4(+)/~2(-) interfaces. Accordingly, the complementary face 
contributes to define agonist efficacy by selecting the type of (a4~2ha4 agonists 
that can enter the site. Comparison of the maximum compounds length (MeL) 
and accessible surface area (ASA) of the nicotinic agonists studied suggests that 
the site at the a4( + )/a4( -) interface is readily occupied by small ligands such as 
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Cyt (MCL 5.6 A; - ASA 262.39) and Var (MCL 7.5 A; ASA 298.87). Larger 
compounds such as TC-2559 (MCL lOA A; ASA 353 .9) and Saz-A (MCL 14 A; 
413.6) cannot enter the site, thus reducing agonists efficacy (Fig 5.7). Taken 
together the findings suggest that a4H142 on the complementary face at the 
a4(+)/a4(-) interface acts as a gate-keeper occluding entry to agonists with a 
critical large/long size and that this is most likely due to steric rather than 
electrostatic effects. 
ACh 
Var 
TC-2559 
MCL= 6.2 
ASA= 290.4 Cyt 
MCL= 7.5 Saz-A 
ASA= 298.9 
MCL= 10.4 Dh~E 
ASA= 353.9 
MCL= 14 
ASA= 413 .6 
MCL= 6.7 
ASA= 409.4 
Figure,5.7. Maximum compound length (MCL) and accessible surface 
area (ASA) for ACh, Cyt, Var, TC-2559, Saz-A and DhpE. ASA values were 
calculated using the server at http://www.chemicalize.org/, whereas MCL (A) for 
each compound was measured in ligands after energy minimization using 
spartan '08 software. 
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The complementary face also contributes to defining the sensitivity of the 
agonists sites for ligands able to bind sites at the a4( + )/a4( -) and a4( + )/P2( -) 
interfaces, which intuitively indicates that agonist-specific interactions with 
residues on the complementary site are important for ligand efficacy. In accord 
with this possibility, it was observed that the extent agonists shielded the agonist 
site at the a4( + )/a4( -) interface from MTSET reactions depended on the nature of 
the protectant agonists. For example, Cyt protected more efficiently than ACh or 
Var. Furthermore, as noted above, cysteine substitutions on the complementary 
face of the two types of agonist sites, led to markedly different effects on the 
functional properties of ACh, depending on the subunit interface location of the 
agonist site. These findings are consistent with previous studies of a4p2 nAChRs 
that have shown that structurally diverse agonists activate nAChRs with agonist-
specific efficacy by engaging into intermolecular interactions with residues on 
the complementary face (Rohde et aI., 2012; Blum et aI., 2013). Also, in the 
muscle nAChR several residues on the complementary face have been suggested 
as critical determinants of differential competitive ligand selectivity between the 
two agonist sites of muscle nAChRs (Akk & Auerbach, 1999; Martinez et aI., 
2000; Karlin, 2002). Early studies have shown that both a and P subunits define 
sensitivity to activation by agonists in neuronal nAChRs (Luetje & Patrick, 1991; 
Chavez-Noriega et aI., 1997). It has also been shown that alanine or cysteine 
substitution of agonist binding aromatic residues on the principal face decreases 
ACh sensitivity regardless of the subunit interface location (Mazzaferro et aI., 
2011). These findings are consistent with the view that interactions with aromatic 
residues on the principal face are a pre-requisite for binding and define ligand 
affinity, whilst interactions with residues on the complementary face play a 
central role in defining ligand selectivity and efficacy (Rohde et aI., 2012). 
Regardless of the subunit interface location, obliteration of one agonist site by 
MTSET reactions produces receptors with two intact agonist sites that when 
occupied by ACh efficiently gate the intrinsic ion channel. Indeed, even agonists 
such as TC-2559 can gate the ion channel to produce measurable currents. If, as 
proposed by Mukhtasimova et aI., (2009), each binding site communicates with 
the ion channel gate independently of the other binding sites, ligand efficacy 
would then represent the summation of the signals arriving to the gate, which 
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could explain why engagement of three sites increases agonist efficacy. Studies 
of the AChBP bound with agonists or antagonists have suggested that channel 
opening and, possibly, ligand selectivity may occur through a conformation 
induced by the ligand. The agonist site is inherently flexible, allowing it to 
conform to the structural characteristics of the ligand (Hansen et al., 2005). One 
important conformational change upon agonist binding is a capping motion of 
loop C, which has been proposed to initiate a clockwork sequence of domain 
motions leading to gating (Mukhtasimova et al., 2005; Mukhtasimova et al., 
2009). This possibility is however not consistent with the observation that 
residues on the complementary face play an important role in defining agonist 
efficacy and with recent observations that structures of AChBP with partial 
agonist lobeline (Billen et al., 2012) and Var (Rucktooa et al., 2012) display full 
loop C closure. Indeed, the molecular pathway by which energy is transfer from 
the binding site to the ion pore is still an open question (Purohit & Auerbach, 
2013). 
Removal of the agonist site at the a4(+)/a4(-) interface by exchange of the N-
terminal domain of the auxiliary subunit a4 with a P2 subunit produces receptors 
that display (a4p2)2p2-like sensitivity to activation by ACh, Cyt or Saz-A 
(Mazzaferro et al., 2011). However, occupancy of three intact agonist sites 
produces more efficacious ion channel gating, as indicated by a significant 
increase in the amplitude of maximal ACh responses (Harps0e et al., 2011; 
Mazzaferro et al., 2011) and the maximal responses to Cyt and Var, compared to 
TC-2559 and Saz-A. In heteromeric receptors with only two agonist sites, single 
occupancy inefficiently opens the receptors (Auerbach, 2010). However, 
homomeric eys-Ioop ion channels, which are endowed with five structurally 
identical agonist sites, are activated efficiently by double occupancy, although 
triple occupancy is required for maximal gating (Beato et al., 2004; Solt et al., 
2007; Lape et al., 2008; Rayes et al., 2009). Thus, depending on agonist site 
selectivity (a4p2)2a4 receptors can activate efficiently through occupation of 
either two or three sites. Furthermore, although the affinity of each agonist site 
for ACh has not been determined, the differing effects of alanine substitution of 
a4W182 on ACh sensitivity on the two types of agonist sites, suggest that full 
agonists may activate the receptors through occupying just two agonist sites 
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producing functional effects more typical of (a4~2h~2 nAChRs. Hence, 
(a4~2ha4 nAChRs represents two receptors in one. 
An unexpected observation was that the efficacy of TC2559 and Saz-A at 
(a4p2)2a4 receptors is not (a4p2)2p2-like, even though these agonist bind the 
agonist sites at a4( + )/~2( -) interfaces. At (a4~2h~2 receptors, which have two 
operational agonist sites, one at each of the a4( + )/~2( -) interfaces, Saz-A behaves 
as a full agonist and TC-2559 as a super agonist (Moroni et aI., 2006; Zwart et 
aI., 2006; Carbone et aI., 2009). A possible explanation is that the a4(+)/a4(-) 
interface or the fifth subunit may allosterically influence the function of the 
agonist site at the adjacent a4( + )/P2( -) interface such that binding of agonist to 
a4(+)p2(-) interfaces differs from binding to a4(+)/p2(-) sites on (a4p2hP2 
receptors. In support of this possibility, a recent study that has compared the 
binding of agonist to the agonist sites on a4( + )/P2( -) interfaces in both (a4p2ha4 
and (a4p2hP2 receptors has suggested that ligands such as Cyt bind the agonist 
sites with different poses, depending on the receptor isoform (Tavares et aI., 
2009). 
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Final discussion and future work 
Chapter 6 
The aim of this study was to define the role of the a4( + )/a4( -) interface on the 
shaping of the stoichiometry-specific functional properties of the (a4p2)2a4 
nAChR. a4p2 nAChRs are the most abundant nAChR in the mammalian brain, 
and their role in brain behaviours and diseases is well documented (Cassels et aI., 
2005; Mantione et aI., 2012; Gotti et aI., 2009). It is well established that a4 and 
P2 subunits assemble into alternate receptors (a4p2)2a4 and (a4p2)zp2 that 
display lOO-fold difference in sensitivity to activation by ACh (Nelson et aI., 
2003; Moroni et aI., 2006; Carbone et aI., 2009). The alternate receptors also 
differ in sensitivity to a4p2-preferring ligands (Moroni et aI., 2006; Carbone et 
aI., 2009), unitary conductance (Nelson et aI., 2003), calcium permeability (Tapia 
et aI., 2007), sensitivity to modulation by Znz+ (Moroni et aI., 2008) and the 
allosteric compound NS9283 (Timmermann et aI., 2012). Both receptor forms 
consist of two identical a4p2 subunit pairs and a fifth auxiliary a4 or P2 subunit, 
all arranged around a central cation pore (Moroni et aI., 2006; Carbone et aI., 
Mazzaferro et aI., 2011). As mentioned elsewhere in this thesis, each a4p2 
subunit pair harbours a structural identical ACh binding site formed at the 
interface between the two adjacent subunits. The principal or (+) face of the 
binding site at a4( + )/P2( -) interfaces is contributed by the a4 subunit, whilst the 
P2 subunit contributes the complementary or (-) face (Mazzaferro et aI., 2011). 
Hence, structurally, the alternate a4p2 receptors are identical except for the 
auxiliary subunit, which is a4 in (a4p2)2a4 nAChRs and P2 in (a4p2hP2 
nAChRs. That the auxiliary subunit can be either a4 or P2 leads to stoichiometry-
specific interfaces. In the (a4p2)zp2 receptor there is a P2( + )/P2( -) interface, 
whereas in the (a4p2)za4 receptors there is a a4(+)/a4(-) interface (Fig. 3.1). At 
the commencement of this study, the auxiliary a4 subunit had been identified as 
key provider of structural determinants of functional signatures of (a4p2)za4 
nAChRs such as sensitivity to potentiation by Zn2+ (Moroni et aI., 2008) or Ca2+ 
permeability (Tapia et aI., 2007). Thus, the view that drove the studies reported 
in this thesis was that the a4(+)/a4(-) interface most likely additionally defines 
the response of (a4p2)2a4 nAChRs to agonists, and that the elucidation of how 
this interface influences the function of the (a4p2)2a4 nAChR should be 
prioritised, if we are to understand how, despite having identical agonist sites, the 
alternate a4p2 nAChRs display differing sensitivity to agonists. 
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The study of individual subunit interfaces is challenged by the high conservation 
of the subunits of the nAChR family, which in heterologous systems typically 
leads to one subunit substituting for any other leading to the expression of a vast 
assortment of possible pentameric arrangements. To circumvent this problem, 
this thesis used fully concatenated (a4~2)2a4 nAChRs. Concatenated (a4~2)2a4 
nAChRs had been previously shown to be stable and reproduce the functional 
properties of (a4~2)2a4 nAChRs assembled from loose a4 and ~2 subunits 
(Carbone et al., 2009). In terms of the development of experimental strategies 
with which to address the study of specific regions of pLGIC, an important 
achievement of this thesis has been to successfully combine the con catenated 
receptor technology with the SCAM method to address the role of the a4( + )/a4(-
) interface on the stoichiometry-specific properties of the (a4~2)2a4 receptor. By 
combining these two approaches, this thesis identified a third operational agonist 
site at the a4(+)/a4(-) interface whose functional properties differ from those of 
the classical agonist sites found on the a4(+)/~2(-) interfaces. To my knowledge, 
this is the first time that it has been shown that the agonist sites in a heteromeric 
pLGIC are both structurally and functionally different. Of course, the SCAM 
approach has been used previoulsy to address fundamental issues on the 
structure, function and dynamics of LGIC (for a comprehensive review see Baker 
et al., 2007 pages 439-452), however this is the first time that it has been 
combined with the concatenated receptor approach to study individual and 
identified subunits in a pLGIC. The tool, as shown by the achievements of this 
thesis, is powerful and can potentially illuminate the role of each subunit 
interface on the function of other concatenated pLGICs. Hopefully, the approach 
will lead to important insights in other members of the pLGIC family. 
Using the approaches discussed above, this study identified a third operational 
agonist site at the a4(+)/a4(-) interface of (a4p2)2a4 nAChRs (Chapter 3); 
Mazzaferro et al., 2011). The site is fully operational and plays a cardinal role in 
the shaping of the functional properties of the (a4p 2)2a4 nAChRs. The findings 
of Chapter 3 to 5 provided remarkable new insights into roles of the two types 
of ACh binding sites in both activation and desensitisation and revealed 
dominance of the site at the a4(+)/a4(-) interface. Some of the findings are 
highly surprising. For example, in the context of homomeric a7 nAChRs or 
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chimeric 5HT-3-a7, which have been shown to be maximally activated by 
occupation of three non-consecutive agonist binding sites (Rayes et aI., 2009; 
Dacosta & Sine, 2013), occupation of the three agonist sites of the (a4p2)2a4 
nAChR would be expected to increase sensitivity to activation and the 
desensitisation kinetics of this receptor would be expected to be determined by 
the fastest desensitising sites at the a4(+)/p2(-) interfaces. One possible 
explanation for these differences is that the a4(+)/a4(-) interface not only 
harbours an operational agonist site but also exerts a modulatory influence on the 
agonist sites at the a4( + )lP2( -) interfaces. Some of the findings of this thesis 
support this view. For example, the effects of the incorporation of a4W182A into 
the a4(+)/a4(-) interface on the function of the agonist sites at the a4(+)/p2(-) 
interfaces were different than the effects of the mutation incorporated into the 
a4( + )lP2( -) interfaces on the function of agonist site at the a4( + )la4( -) interface. 
Moreover, the effects of the agonists Saz-A and TC-2559, compared to their 
effects on (a4p2)2p2 nAChRs, could be explained if the a4(+)/a4(-) interface 
influenced the interaction of these agonists with the binding sites at the 
a4( + )/P2( -) interfaces or with the gating signals generated by these agonists. 
Besides the identification of an additional operational agonist site at the 
a4( + )/a4( -) interface, a key finding of this thesis is that full receptor occupancy 
increases maximal agonist responses. Given that occupation of the agonist sites 
at a4( + )/P2( -) interfaces produces efficacious gating, additional occupation of the 
site at the a4( + )/a4( -) interface increases the efficacy of the gating even if the 
agonist is a partial agonist. Another key finding that could have profound 
implications for drug discovery programs is that the agonist sites at the 
a4( + )/a4( -) and a4( + )/P2( -) interfaces have different agonist selectivity. It was 
found that large agonists are excluded from the agonist site at the a4(+)/a4(-) 
interface, leading to partial agonism, even for agonists that are full or super 
agonists at the (a4p2)2p2 receptor, the receptor isoform endowed with only two 
agonist sites, both located at the a4( + )/P2( -) interfaces. Examples of this type of 
agonist are TC-2559 and Saz-A. Agonists that bind the three sites display higher 
efficacy than ligands excluded fom the site at the a4( + )/a4( -) interface, 
regardless of their efficacy relative to the full agonist ACh. In the case of 
pLGICs with functionally equivalent agonist sites, agonist efficacy seems to be 
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detennined by the ability of agonists to achieve flipped (Lape et aI., 2009) states, 
which are shut states immediately preceding ion channel gating. In the context of 
current views on agonist efficacy at pLGIC (Lape et aI., 2009), the finding that 
relative agonist efficacy in (a4~2)2a4 is first detennined by the ability of agonists 
to bind all three sites adds another layer of complexity to the mechanisms by 
which agonists gate pLGIC. 
Because of the unavailability of single channel data, it is not possible to propose 
an adequate kinetic scheme for the activation/desensitisation cycle of the 
(a4~2)2a4 nAChR, and the possible existence of flipped or primed states 
provides additional difficulties. Although it was found that two agonist binding 
sites desensitise with higher sensitivity than three, it is not known whether the 
two desensitised states are connected. Similarly, it is not known whether the 
activation state achieved by engagement of two a4( + )/~2( -) binding sites by 
agonists not selected by the site at the a4( + )/a4( -) interface is the same as the 
active state achieved by occupation of two sites by agonists able to bind all three 
sites. It seems likely, however, that there are two pathways for the 
activation/desensitisation of the (a4~2)2a4 receptor (Fig. 6.1), with each pathway 
following a cyclic model similar to those proposed for the muscle nAChR by 
Cachelin & Colquhoun, (1989). The model proposed in Fig 6.1 shows that 
activation through pathway 1 (red), which leads to engagement of all three 
agonist sites by a full agonsit such as ACh, produces maximal activation 
(A3RO). whilst activation via pathway 2 (green), which involves occupation of 
the sites at a4( + )/~2{ -) interfaces by agonist excluded from the a4( + )/a4( -) site 
also leads to gating, albeit with reduced efficacy. Incorporation of a4W182A into 
any of the agonist sites produced biphasic concentration response curves showing 
that binding of two intact agonist sites produced effective receptor activation 
(Chapters 3 and 4), which, together with the finding that some agonists such as 
TC-2559 and Saz-A activate the receptor by binding only to the agonist sites at 
the a4( + )/~2( -) interfaces, suggest that state A2R may be common both 
pathways. 
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R----- A2R -------- A3R------ A3RO-------- A3RD 
A2RO 
A2RD 
Figure.6.1. A scheme for the activation and desensitisation of (a4p2)2a4 
nAChRs. The resting receptor is shown by R, a receptor with an open channel by 
0, an agonist molecule by A, desensitised state of a receptor occupied by two 
agonist sites by D, and the desensitised state of a receptor occupied by three 
agonists molecules by D. 
In summary, this study has allowed an insight into a complex receptor behaviour 
that was not anticipated from current views on the function of nAChRs. There is 
still much to learn about this receptor and most certainly new advances will be 
made by studying the concatenated receptors at the single channel level. Finally, 
the finding that (a4~2)za4 nAChRs can be effectively activated and desensitised 
through two pathways depending on the concentration of the agonist or the 
agonist site selectivity may have important consequences for our understanding 
and control of a4~2-signalling in brain pathologies. One of these pathways leads 
to active and desensitised receptors that resemble those of the isoform (a4~2)2~2 
nAChR, suggesting that at low concentrations of agonist, a4~2 signalling in 
neurones may be essentially of the high-sensitivity type, whilst (a4~2)za4 
nAChRs signalling may occur at higher concentrations of agonist and when 
(a4~2)2~2 nAChRs receptors are desensitised. 
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Future work 
1) Are the agonist sites at the u4( + )/P2( -) interfaces functionally equivalent? 
The work presented in this thesis suggests that the agonist sites at the 
u4(+)/P2(-) interfaces are functionally non-equivalent, even though they are 
structurally identical. This possibility is consistent with recent work by 
Unwin and Fujiyoshi (2012) that shows that the agonist sites at Torpedo 
nAChRs contribute asymmetrically to gating. Asymmetry in gating appears 
to occur because the auxiliary subunit adjacent to the air, interface is 
displaced outwardly upon agonist binding, suggesting the pseudosymmetric 
arrangement of subunits around the ion channel in heteromeric pLGICs as an 
important structural element of receptor function. Thus, because the position 
of the fifth subunit in (u4P2)2U4 nAChRs is similar to that of the PI subunit 
in the Torpedo nAChR, it would be of interest to determine whether the 
agonist sites at the u4( + )/P2( -) interfaces function asymmetrically. 
Specifically, the following aspect should be interesting to address: 
• Knocking out one u4(+)/P2(-) site at time using MTS reagents and 
mutagenesis in order to unveil if the two sites have the same or 
different function in the activation of the (u4P2)2U4 nAChR. 
• To determine whether, and how, the u4(+)/u4(-) site is connected 
allosterically to the u4( + )/P2( -) binding sites. 
2) Define the role of the non-binding P2(+)/u4(-) interfaces in (u4P2)2U4 
nAChR activation. 
In addition to the subunit interfaces that harbour the agonist sites, the (a4p2)2u4 
receptor is endowed with two p2(+)/a4(-) interface that up to now have been 
considered as non-binding interfaces. However the P2( + )/u4( -) interfaces host the 
inhibition binding site for Zn ++ (Moroni et aI., 2008) and the homologue 
interfaces P2(+)/u3(-) of the a3p2 nAChR bind the positive allosteric modulator 
morantel (Seo et aI., 2009). 
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Interestingly, agonist binding structural elements are conserved in ~2(+)/a4(-) 
interfaces, suggesting that they may bind ligands with some of the structural 
characteristics of nicotinergic ligands. This possibility could be tested by 
applying the SCAM approach and mutagenesis to the ~2( + )/a4( -) interfaces of 
the concatenated (a4p2)za4 nAChR. The findings of such studies should not only 
provide new molecular targets for drug discovery exercises but should also shed 
more light into the molecular and structural mechanisms underlying the function 
ofnAChRs. 
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